MolecularPathology.ca

larger smaller reset fixed-width fluid-width
 

 Trainees Publications

JC Cutz

1.  Wang Y, Xue H, Cutz JC, Bayani J, Mawji NR, Chen WG, Goetz LJ, Hayward SW, Sadar MD, Gilks CB, Gout PW, Squire JA, Cunha CR, Wang YZ. An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest. 2005 Nov;85(11); 1392-404.

2.  Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med. 2005 Jul 14;353(2):133-44. Erratum in: N Engl J Med 2006 Oct 19;355(16):1746.

3.  Cutz JC, Guan J, Bayani J, Yoshimoto M, Xue H, Sutcliffe M, English J, Flint J, LeRiche J, Yee J, Squire JA, Gout PW, Lam S, Wang YZ. Establishment in severe combined immunodificiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. Clin Cancer Res. 2006 Jul 1;12(13):4043-54.

4.  Zhu CQ, Cutz JC, Liu N, Lau D, Shepherd FA, Squire JA, Tsao MS. Amplification of telomerase (hTERT) gene is a poor prognostic market in non-small-cell lung cancer. Br J Cancer. 2006 May 22;94(10):1452-9.

5.  Yoshimoto M, Cutz JC, Nuin PA, Joshua AM, Bayani J, Evans AJ, Zielenska M, Squire JA.  Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias.  Cancer Genet Cytogenet.  2006 Sep; 169(2):128-37. 

6.  Doxsee DW, Gout PW, Kurita T, Lo M, Buckley AR, Want Y, Xue H, Kapr CM, Cutz JC, Cunha GC, Wang YZ. Sulfasalzine-induced cystine starvation:  Potential use for prostate cancer therapy.  Prostate.  2007 Feb 1;67(2):162-71

7.  Al-Romaih K, Somers GR, Bayani J, Hughes S, Prasad M, Cutz JC, Xue H, Zielenska M, Wang Y, Squire JA. Modulation by decitabine of gene expression and growth of osteosarcoma U2OS cells in vitro and in xenografts: Identification of apoptic genes as targets for demethylation.  Cancer Cell Int. 2007 Sep 10;7:14.

8.  Oza AM, Eisenhauer A, Elit L, Cutz J, Sakurada A, Tsao MS, Hoskins PJ, Biagi J, Ghatage P, Mazurka J, Provencher D, Dore J, Dancey J, Fyles A.  Phase II study of erlotinib (Tarceva, OSI774) in women with recurrent or metastatic endometrial cancer.  A trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND-148). J Clin Oncol. 2008 Sep 10;26(26):4319-25. Epub 2008 Jun 30.

9.  Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz J-C, Liu N, Zhang T, Marrano P, Whitehead M, Squire JA, Kamel-Reid S, Seymour L, Shepherd F, Tsao MS.  Role of KRAS and EGFR as biomarkers of response to erlotinib in National Institute of Canada Clinical Trial Group Study BR.  J Clinical Oncol 2008 Sep 10;26(26):4268-75. Epub 2008 Jul 14.

Joanna Ding

1. Chan FC, Telenius A, Healy S, Ben-Neriah S, Mottok A, Lim R, Drake M, Hu S, Ding J, Ha G, Scott DW, Kridel R, Bashashati A, Rogic S, Johnson N, Morin RD, Rimsza LM, Sehn L, Connors JM, Marra MA, Gascoyne RD, Shah SP, Steidl C. An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup. Blood. 2015 Feb 5;125(6):959-66. doi: 10.1182/blood-2013-06-507152. Epub 2014 Nov 13.

2. Morin RD, Mungall K, Pleasance E, Mungall AJ, Goya R, Huff RD, Scott DW, Ding J, Roth A, Chiu R, Corbett RD, Chan FC, Mendez-Lago M, Trinh DL, Bolger-Munro M, Taylor G, Hadj Khodabakhshi A, Ben-Neriah S, Pon J, Meissner B, Woolcock B, Farnoud N, Rogic S, Lim EL, Johnson NA, Shah S, Jones S, Steidl C, Holt R, Birol I, Moore R, Connors JM, Gascoyne RD, Marra MA. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood. 2013 Aug 15;122(7):1256-65. doi: 10.1182/blood-2013-02-483727. Epub 2013 May 22.

Jose Torrealba

1. Chen W, Zhou D, Torrealba JR, Waddell TK, Grant D, Zhang L. Donor lymphocyte infusion induces long-term donor-specific cardiac xenograft survival through activation of recipient double-negative regulatory T cells. J Immunol. 2005;175(5):3409-16.

Joerg Schwock

1. Schwock J, Geddie WR, Hedley DW. Analysis of hypoxia-inducible factor-1 alpha accumulation and cell cycle in geldanamycin-treated human cervical carcinoma cells by laser scanning cytometry. Cytometry A. 2005; 68:59-70.

2.  Bachtiary B, Boutros P, Pintilie M, Shi W, Bastianutto C, Li JH, Schwock J, Penn LZ, Jurisica I, Fyles AN, Liu FF.  Gene expression profiling in cervical cancer - an exploration of intra-tumor heterogeneity.  Clin Cancer Res.  2006 Oct 1;12(19):5632-30. 

3.  Pham NA, Morrison A, Schwock J, Aviel-Ronen S, Iakovlev V, Tsao MS, Ho J, Hedley DW.  Quantitative image analysis of immunohistochemical stains using a CMYK color model.  Diagnostic Pathology;  2007; 2:8(1-10)

4.  Schwock J, Jo JC, Luther E, Hedley DW, Geddie WR.  Measurement of signaling pathway activities in solid tumor fine-needle biopsies.  Diagnostic Molecular Pathology 2007 Sep ;16(3):130-40.

5.  Schwock J, Pham NA, Cao MP, Hedley DW.  Efficacy of Hsp90 inhibition for the induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.  Cancer Chemotherapy and Pharmacology 2008 Apr;61(4):669-81. Epub 2007 Jun 20.

6.  Pham NA, Schwock J, Iakovlev V, Pond GR, Hedley DW, Tsao MS.  Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis.  BMC Cancer 2008;6:8(1):43.

7. Pham NA, Magalhaes J, Do T, Schwock J, Dhani N, Cao P-J, Hill RP, Hedley DW.  Activation of Src and Src-associated signaling pathways in relation to hypoxia in human cancer xenograft models.  International Journal of Cancer.  2009 Jan 15;124(2):280-6.

8. Schwock J, Dhani N, Cao MP, Zheng J, Clarkson R, Radulovich N, Navab R, Horn LC, Hedley DW. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts. Cancer Res 2009 Jun 1;69(11):4750-9. Epub 2009 May 19.

9. Schwock J, Shani N, Hedley DW. Targeting focal adhesion kinase signalling in tumor growth and metastasis. Expert Opin Ther Targets 2010 Jan;14(1):77-94. Review.

10. Schwock J, Bradley G, Ho JC, Perez-Ordonez B, Hedley DW, Irish JC, Geddie WR. SNAI1 expression and the mesenchymal phenotype: an immunohistochemical study performed on 46 cases of oral squamous cell carcinoma. BMC Clin Pathol 2010 Feb 5;10:1.

11. Lara-Guerra H, Chung CT, Schwock J, Pintilie M, Hwang DM, Leighl NB, Waddell TK, Tsao MS. Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer. Lung Cancer 2012 May;76(2):235-41.

12. Chaundary N, Pintilie M, Schwock J, Dhani N, Clarke B, Milosevic M, Fyles A, Hill RP. Characterization of the tumor-microenvironment in patient-derived cervix xenograft (OCICx). Cancers (Basel). 2012 Aug 29;4(3):821-45.

13. Schwock J, Geddie WR. Diagnosis of B-cell non-Hodgkin lymphomas with small-intermediate-sized cells in cytopathology. Pathology Res Int. 2012;2012: 164934.

14. Dodbiba L, teichman J, Fleet A, Thai H, Sun B, Panchal D, Patel D, Tse A, Chen Z, Faluyi OO, Renouf DJ, Girgis H, Bandarchi B, Schwock J, Xu W, Bristow RG, Tsao MS, Darling GE, Ailles LE, El-Zimaity H, Liu G. Primary esophageal and gastro-esophageal junction cancer xenograft models: clinicopathological features and engraftment. Lab Invest. 2013 Apr;93(4):397-407.

15. Laurie SA, Goss GD, Shepherd FA, Reaume MN, Nicholas G, Philip L, Wang L, Schwock J, Hirsh V, Oza A, Tsao MS, Wright JJ, Leighl NB. A phase II trial of saracatinib, an inhibitor of src kinase, in previously-treated advanced non-small-cell lung cancer: The Princess Margaret Hospital Phase 11 consortium. Clin Lung Cancer 2014 Jan;15(1):52-7.

16. Dhani NC, Serra S, Pintilie M, Schwock J, Xu J, Gallinger S, Hill RP, Hedley DW. Analysis of the intra and intertumoral heterogeneity of hypoxia in pancreatic cancer patients receiving the nitroimidazole tracer pimonidazole. Br J Cancer. 2015 Sep 15;113(6):864-71. Epub 2015 Sep 1.

Sarit Aviel-Ronen

1.  Duran I, Kortmansky J, Siggh D, Hirte H, Kocha W, Goss G, Le L, Oza A, Nicklee T, Ho J, Birle D, Pind GR, Arboine D, Dancey J, Aviel-Ronen S, Tsao MS, Siu LL.  A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas.  Br J Cancer.  2006 Nov 6;95(():1148-54. 

2.  Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS. K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer. 2006 Jul;8(1):30-8. Review. 

3.  Aviel-Ronen S, Zhu CQ, Coe BP, Liu N, Watson SK, Lam WL, Tsao MS.  Large fragment Bst DNA polymerase for whole genome amplification of DNA from formalin-fixed paraffin-embedded tissues. BMC Genomics 2006 Dec 12;7:312.

4.  Seve P, Lai R, Ding K, Winston T, Butts C, Mackey J, Dumontet C, Dabbagh K, Aviel-Ronen S, Seymour L, Whitehead M, Tsao MS, Shepherd FA, Reiman T.  Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10.  Clin Cancer Res. 2007 Feb 1;13(3):994-9.

5.  Pham NA, Morrison A, Schwock J, Aviel-Ronen S, Iakovlev V. Tsao MS, Jo J, Hedley DW.  Quantitative image analysis of immunohistochemical stains using a CMYK color model.  Diagnostic Pathology 2007;2:8(1-10).

6.  Tsao MS, Aviel-Ronen S, Ding K, Lau D, Liu N, Sakurada A, Whitehead M, Zhu CQ, Livingston R, Johnson DH, RIgas J, Seymour L, Winton T, Shepherd FA.  Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.  J Clin Oncol.  2007 Nov 20;25(33):5240-7.

7.  Aviel-Ronen S, Coe BP, Lau SK, da Cunha Santos G, Zhu CQ, Jurisica I, Lam WL, Tsao MS.  Genomic markers for malignant progression in pulmonary adenocarcinoma with bronchioloalveolar features.  Proc Natl Acad Sci USA.  2008 Jul 22;105(29):10155-60. 

8.  Aviel-Ronen S, Lau SK, Pintilie M, Lau D, Liu N, Tsao MS, Jothy S.  Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma.  Mod Pathol 2008 (7):817-25.

9.  Buys TP, Aviel-Ronen S, Waddell TK, Lam WL, Tsao MS.  Defining genomic alteration boundaries for a combined small cell and non-small cell lung carcinoma.  J Thorac Oncol 2009 4(2):227-39. 

10. Tsao MS, Sakurada A, Ding K, Aviel-Ronen S, Ludkovski O, Liu N, Le Maitre A, Gandare D, Johnson DH, Rigas JR, Seymour L, Shepherd FA. Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer. J Thorac Oncol. 2011 Jan;6(1):139-47.

11. Coe BP, Thu KL, Aviel-Ronen S, Vucic EA, Gazdar AF, Lam S, Tsao MS. Lam WL. Genomic deregulation of the E2F/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer. PLoS One. 2013 Aug 15;8(8):e71670.

Sandra Fischer

1. Ezzat S, Mader R, Fischer SE, Yu S, Ackerley C, Asa SL. An essential role for the hematopoietic transcription factor ikaros in hypothalamic-pituitary mediated somatic growth. Proc Natl Acad Sci, 2006, 103(7):2214-9.

2. Ezzat S, Yu S, Fischer SE, Asa SL. Tumor-derived ikaros 6 isoform acetylates the Bcl-XL to upregulate an anti-apoptotic signal in pituitary cells.  Mol. Endocrinol 2006, 20(11)2976-2986.

3.  Fischer SE, Asa SL.  Familial pituitary adenomas and loss of function of AIP.  Adv Anat Pathol 2006 14(1):58.

4.  Kiehl R, Fischer SE, Ezzat S, Asa SL. Mice lacking the hematopoietic transcription factor Ikaros display behavioural alterations of an anti depressive phenotype.  Exp Neurol. 2008 May;211(1):107-14.

5. Fischer SE, Kulasingam V, Diamandis EP, Ezzat S, Asa SL. Thyroid cancer biomarker discovery using two-dimensional liquid chromatography- tandem mass spectrometry.

6.  Fischer SE, Asa SL.  Application of immunohistochemistry to thyroid neoplasms.  Arch Pathol Lab Med. 2008 Mar;132(3):359-72.  Review. 

7. Fischer SE, Asa SL. Chapter 18: Adrenal Gland. Differential Diagnosis in Surgical Pathology Eds. Gattuso, Reddy, David, Spitz, Haber. Elsevier Ltd, Edinburgh, UK. 2nd ed, 2010.

Pedro Farinha

1. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel R, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC. Confirmation of the molecular classification of diffuse large B cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.

2. Banham AH, Connors JM, Brown PJ, Ott G, Sreenivasan G, Farinha P, Gascoyne RD. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B cell lymphoma. Clin Can Res 2005;11: 1065-1072.

3. Farinha P, Gascoyne RD. Helicobacter pylori and MALT lymphoma. Gastroenterology 2005;128(6):1579-605.

4. Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, Klasa R, Voss N, Connors J, Gascoyne RD. Analysis of multiple biomarkers shows that lymphoma- Associated Macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005;106:2169-2174.

5. Farinha P, Gascoyne RD. Molecular Pathogenesis of Mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005; 23:6370-6378.

6. Farinha P, Gascoyne RD. Advances in pathology and molecular diagnosis of non Hodgkin lymphomas. Physicians Education Resource Minireviews, 2005.

7. Joao C, Farinha P, Silva MG, Martins C, Crespo M, Cabeçadas J. MALT1 gene rearrangement is uncommon in primary breast MALT lymphomas. Histopathology 2007; 50:217-224.

8. Rimsza LM, Farinha P, Fuchs DA, Masoudi H, Connors JM, Gascoyne RD.HLA-DR protein status predicts survival in patients with diffuse large B cell lymphoma (DLBCL) treated onthe MACOP-B chemotherapy regimen. Leuk Lymphoma. 2007 Mar;48(3):542-6.

9. Korenberg MJ, Farinha P, Gascoyne RD. Predicting survival in follicular lymphoma using tissue microarrays. Methods Mol Biol. 2007;377:255-68.

10. Natkunam Y, Farinha P, His ED, Hans CP, Tibshirani R, Sehn LH, Connors JM, Gratzinger R, Rosado M, Zhao S, Pohlman B, Wonchawart N, Bast M, Avigdor A, Schiby G, Nagler A, Byrne GE, Levy R, Gascoyne RD, Lossos IS. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol. 2008 Jan 20;26(3):447-54.

11. Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, Chan J, Rosenwald A, Gascoyne RD, Staudt LM. Cooperative signalling through the STAT3 and NF-kB pathways in subtypes of diffuse large B cell lymphoma. Blood. 2008 Apr 1;111(7):3701-13.

12. Cerchietti LC, Polo JM, Da Silva GF, Farinha P, Shaknovich R, Gascoyne RD, Dowdy SF, Melnick A. Sequential Transcription Factor Targeting for Diffuse Large B-Cell Lymphomas. Cancer Res. 2008 May 1;68(9):3361-9.

13. Pugh TJ, Delaney AD, Farnoud N, Flibotte S, Griffith M, Li HI, Qian H, Farinha P, Gascoyne RD, Marra MA. Impact of whole genome amplification on analysis of copy number variants. Nucleic Acids Res. 2008 Aug; 36(13):e80. Epub 2008 Jun 17.

14. Ci W, Polo JM, Cerchietti L, Shaknovich R, Wang L, Yang SN, Ye K, Farinha P, Horsman DE, Gascoyne RD, Elemento O, Melnick A. The BCL6 transcriptional program features repression of multiple oncogenes in primary B-cells and is deregulated in DLBCL. Blood 2009; 113: 5536-5548.

15. Savage KJ, Johnson NA, Ben-Nerian S, Connors JM, Sehn LH, Farinha P, Horsman DE, Gascoyne RD. MYC gene re-arrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17): 3533-7.

16. Shustik J, Han G, Farinha P, Johnson N, Connors JM, Sehn L, Gascoyne RD and Steidl C. Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. 2010 Jan; 95(1):96-101. Epub 2009 Oct 1.

17. Gratzinger D, Advani R, Zhao S, Talreja N, Tibshirani RJ, Shyam R, Horning S, Sehn LH, Farinha P, Briones J, Lossos IS, Gascoyne RD, Natkunam Y. Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochistochemistry (R-CHOP). Br J Haematol 2010 Jan;148(2):235-44.

18. Farinha P , Al-Tourah, Jill K, Connors JM, Shumansky K, Spinelli JJ, Gascoyne RD. The Architectural Pattern of FOXP3+ T Cells Is an Independent Predictor of Survival in Patients with Follicular Lymphoma (FL). Blood. 2010 Jan 14; 115(2):289-95. Epub 2009 Nov 9.

19. Evens AM, Sehn LH, Farinha P, Nelson BP, Raji A, Lu Y, Brakman A, Parimi V, Winter JN, Schumacker PT, Gascoyne RD, Gordon LI. Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2010 Feb 20;28(6):1017-24. Epub 2010 Jan 4.

20. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010 Mar 11;362(10):875-85.

21. Steidl C, Telenius A, Shah SP, Farinha P, Barclay L, Boyle M, Connors JM, Horsman DE, Gascoyne RD. Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. Blood 2010 Jul 22;116(3):418-27. doi: 10.1182/blood-2009-12-257345. Epub 2010 Mar 25.

22. Relander T, Johnson NA, Farinha P, Connors JM, Sehn LH, Gascoyne RD. Prognostic Factors in Follicular Lymphoma. J Clin Oncol 2010 Jun 10;28(17):2902-13. doi: 10.1200/JCO.2009.26.1693. Epub 2010 Apr 12.

23. Farinha P, Kyle A, Minchinton A, Connors JM, Karsan A, Gascoyne RD. Vascularization predicts overall survival and risk of transformation in follicular lymphoma. Haematologica 2010 Dec;95(12):2157-60. doi: 10.3324/haematol.2009.021766. Epub 2010 Aug 16.

24. Marafioti T, Rodig SJ, Kutok JL, Paterson JC, Nitta H, Zhang W, Shipp MA, Grogan T, Montes- Moreno S, Johnson NA, Ben-Neriah S, Farinha P, Piris MA, Pileri SA, Gascoyne R. The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker to identify c-MYC+ lymphomas. Haematologica 2010 Dec;95(12):2056-62. doi: 10.3324/haematol.2010.025767. Epub 2010 Sep 7.

25. Goswami RS, Atenafu EG, Xuan Y, Waldron L, Reis PP, Sun T, Datti A, Xu W, Kuruvilla J, Good DJ, Lai R, Church AJ, Lam WS, Baetz T, Lebrun DP, Sehn LH, Farinha P, Jurisica I, Bailey DJ, Gascoyne RD, Crump M, Kamel-Reid S. MicroRNA signature obtained from the comparison of aggressive with indolent non-hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma. J Clin Oncol. 2013 Aug 10;31(23):2903-11.

26. Rodig SJ, Kutok JL, Paterson JC, Nitta H, Zhang W, Chapuy B, Tumwine LK, Montes-Moreno S, Agostinelli C, Johnson NA, Ben-Neriah S, Farinha P, Shipp MA, Piris MA, Grogan TM, Pileri SA, Gascoyne RD, Marafioti T. The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas. Haematologica. 2010 Dec;95(12):2056-62. doi: 10.3324/haematol.2010.025767. Epub 2010 Sep 7.

27. Steidl C, Farinha P, Gascoyne RD. Macrophages predict treatment outcome in Hodgkin's lymphoma. Haematologica. 2011 Feb;96(2):186-9. doi: 10.3324/haematol.2010.033316.

28. Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, Johnson NA, Zhao Y, Telenius A, Neriah SB, McPherson A, Meissner B, Okoye UC, Diepstra A, van den Berg A, Sun M, Leung G, Jones SJ, Connors JM, Huntsman DG, Savage KJ, Rimsza LM, Horsman DE, Staudt LM, Steidl U, Marra MA, Gascoyne RD. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011 Mar 17;471(7338):377-81. doi: 10.1038/nature09754. Epub 2011 Mar 2.

29. Steidl C, Diepstra A, Lee T, Chan FC, Farinha P, Tan K, Telenius A, Barclay L, Shah SP, Connors JM, van den Berg A, Gascoyne RD. Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. Blood. 2012 Oct 25;120(17):3530-40. doi: 10.1182/blood-2012-06-439570. Epub 2012 Sep 5.

30. Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. Scott DW, Chan FC, Hong F, Rogic S, Tan KL, Meissner B, Ben-Neriah S, Boyle M, Kridel R, Telenius A, Woolcock BW, Farinha P, Fisher RI, Rimsza LM, Bartlett NL, Cheson BD, Shepherd LE, Advani RH, Connors JM, Kahl BS, Gordon LI, Horning SJ, Steidl C, Gascoyne RD. J Clin Oncol. 2013 Feb 20;31(6):692-700. doi: 10.1200/JCO.2012.43.4589. Epub 2012 Nov 26

31. Goswami RS, Atenafu EG, Xuan Y, Waldron L, Reis PP, Sun T, Datti A, Xu W, Kuruvilla J, Good DJ, Lai R, Church AJ, Lam WS, Baetz T, Lebrun DP, Sehn LH, Farinha P, Jurisica I, Bailey DJ, Gascoyne RD, Crump M, Kamel-Reid S. MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma. J Clin Oncol. 2013 Aug 10;31(23):2903-11.

32. Lencastre A, Cabete J, João A, Farinha P, Ferreira G, Lestre S. Blastic plasmacytoid dendritic cell neoplasm. An Bras Dermatol. 2013 Nov-Dec;88(6 Suppl 1):158-61. doi: 10.1590/abd1806-4841.20132388.

33. Kridel R, Xerri L, Gelas-Dore B, Tan K, Feugier P, Vawda A, Canioni D, Farinha P, Boussetta S, Moccia AA, Brice P, Chavez EA, Kyle AH, Scott DW, Sanders AD, Fabiani B, Slack GW, Minchinton AI, Haioun C, Connors JM, Sehn LH, Steidl C, Gascoyne RD, Salles G. The prognostic impact of CD163-positive macrophages in follicular lymphoma: A study from the BC Cancer Agency and the Lymphoma Study Association. Clin Cancer Res. 2015 Aug 1;21(15):3428-35. Epub 2015 Apr 13.

34. Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, Kridel R, Barry GS, Hother C, Abrisqueta P, Boyle M, Meissner B, Telenius A, Savage KJ, Sehn LH, Slack GW, Steidl C, Staudt LM, Connors JM, Rimsza LM, Gascoyne RD. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol. 2015 Sep 10;33(26):2848-56. Epub 2015 Aug 3.

35. Kridel R, Mottok A, Farinha P, Ben-Neriah S, Ennishi D, Zheng Y, Chavez EA, Shulha HP, Tan K, Chan FC, Boyle M, Meissner B, Telenius A, Sehn LH, Marra MA, Shah SP, Steidl C, Connors JM, Scott DW, Gascoyne RD. Cell of origin of transformed follicular lymphoma. Blood. 2015 Oct 29;126(18):2118-27. Epub 2015 Aug 25.

36. Mottok A, Woolcock B, Chan FC, Tong KM, Chong L, Farinha P, Telenius A, Chavez E, Ramchandani S, Drake M, Boyle M, Ben-Neriah S, Scott DW, Rimsza LM, Siebert R, Gascoyne RD, Steidl C. Genomic alterations in CIITA are frequent in primary mediastinal large b call lymphomas and are associated with diminished MHC class II expression. Cell Rep. 2015 Nov 17;13(7):1418-1431. Epub 2015 Nov 5.

37. Chapuy B, Cheng H, Watahiki A, Ducar MD, Tan Y, Chen L, Roemer MG, Ouyang J, Christie AL, Zhang L, Gusenleitner D, Abo RP, Farinha P, von Bonin F, Thorner AR, Sun HH, Gascoyne RD, Pinkus GS, van Hummelen P, Wulf GG, Aster JC, Weinstock DM, Monti S, Rodig SJ, Wang Y, Shipp MA. Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. Blood. 2016 May 5;127(18):2203-13. Epub 2016 Jan 15.

38. Savage KJ, Slack GW, Mottok A, Sehn LH, Villa D, Kansara R, Kridel R, Steidl C, Ennishi D, Tan KL, Ben-Neriah S, Johnson NA, Connors JM, Farinha P, Scott DW, Gascoyne RD. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood. 2016 May 5;127(18):2182-8. Epub 2016 Feb 1.

39. Kendrick S, Rimsza LM, Scott DW, Slack GW, Farinha P, Tan KL, Persky D, Puvvada S, Connors JM, Sehn L, Gascoyne RD, Schmelz M. Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma. Virchows Arch. 2017 Jan;470(1):113-117. Epub 2016 Nov 25.

40. Kridel R, Chan FC, Mottok A, Boyle M, Farinha P, Tan K, Meissner B, Bashashati A, McPherson A, Roth A, Shumansky K, Yap D, Ben-Neriah S, Rosner J, Smith MA, Nielsen C, Giné E, Telenius A, Ennishi D, Mungall A, Moore R, Morin RD, Johnson NA, Sehn LH, Tousseyn T, Dogan A, Connors JM, Scott DW, Steidl C, Marra MA, Gascoyne RD, Shah SP. Histological transformation and progression in follicular lymphoma: A clonal evolution study. PLoS Med. 2016 Dec 13;13(12):e1002197.

41. Ennishi D, Mottok A, Ben-Neriah S, Shulha HP, Farinha P, Chan FC, Meissner B, Boyle M, Hother C, Kridel R, Lai D, Saberi S, Bashashati A, Shah SP, Morin RD, Marra MA, Savage KJ, Sehn LH, Steidl C, Connors JM, Gascoyne RD, Scott DW. Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. Blood. 2017 May 18;129(20):2760-2770. Epub 2017 Mar 28.

42. Mottok A, Jurinovic V, Farinha P, Rosenwald A, Leich E, Ott G, Horn H, Klapper W, Boesl M, Hiddemann W, Steidl C, Connors JM, Sehn LH, Gascoyne RD, Hoster E, Weigert O, Kridel R. FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy. FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy. Blood. 2018 Jan 11;131(2):226-235. Epub 2017 Nov 9.

43. Scott DW, King RL, Staiger AM, Ben-Neriah S, Jiang A, Horn H, Mottok A, Farinha P, Slack GW, Ennishi D, Schmitz N, Pfreundschuh M, Nowakowski GS, Kahl BS, Connors JM, Gascoyne RD, Ott G, Macon WR, Rosenwald A. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large b-cell lymphoma morphology. Blood. 2018 May 3;131(18):2060-2064. Epub 2018 Feb 23.

44. Villa D, Sehn LH, Aquino-Parsons C, Tonseth P, Scott DW, Gerrie AS, Wilson D, Bénard F, Gascoyne RD, Slack GW, Farinha P, Morris J, Pickles T, Connors JM, Savage KJ. Interim PET-directed therapy in limited stage Hodgkin lymphoma initially treated with ABVD. Haematologica. 2018 Jul 12.

Gilda da Cunha Santos

1.  Tsao MS, Sakurada A, Cutz JC, Zhu C-Q, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, Santos Gda C, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA. Molecular and clinical predictors of response of survival in patients treated with Erlotinib in National Cancer Institute of Canada clinical trials group trial BR.21. N Engl J Med. 2005 353:133-144.

2.  Santos GC, Zielenska M, Prasad M, Squire JA.  Chromosome 6p amplification and cancer progression.  J Clincal Pathol.  2006 Jan;60(1);1-7

3.  Agulnik M, Santos Gda C, Hedley D, Nicklee T, Reis PP, Jo J, Pond GR, Chen H, Chen S, Shyr Y, Winquist E, Soulieres D, Chen EX, Squire JA, Marrano P, Kamel-Reid S, Dancey J, Siut LL, Tsao MS.  Pharmacodynamic studies of erlotinib in tumor and skin tissue samples of patients with recurrent or metastatic suqmous cell carcinoma of the head and neck.  J Clin Oncol.  2007 Jun;25(16):2184-90.

4.  Aviel-Ronen S, Coe BP, Lau SK, da Cunha Santos G, Zhu CQ, Jurisica I, Lam WL, Tsao MS.  Genomic markers for malignant progression in pulmonary adenocarcinoma with bronchioloalveolar features.  Proc Natl Acad Sci USA.  2008 Jul 22;105(29):10155-60. 

5. Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, Zhang T, Marrano P, Whitehead M, Squire JA, Kamel-Reid S, Seymour L, Shepherd FA, Tsao MS; National Cancer Institute of Canada Clinical Trials Group Study BR.21. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institue of Canada Clincal Trials Group Study BR.21. J Clin Oncol. 2008 Sep 10;26(26):4268-75. doi: 10.1200/JCO.2007.14.8924. Epub 2008 Jul 14.

6. Chung CT, Santos Gda C, Hwang DM, Ludkovski O, Pintilie M, Squire JA, Tsao MS. FISH assay development for detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol 2010 Jul;63(7):630-4.

7. da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Annu Rev Pathol 2011;6:49-69. doi: 10.1146/annurev-pathol-011110-130206. Review. PMID:20887192

8. da Cunha Santos G, Dhani N, Tu D, Chin K, Ludkovski O, Kamel-Reid S, Squire J, Parulekar W, Moore MJ, Tsao MS. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA 3. Cancer 2010 Dec 15;116(24):5599-607. doi: 10.1002/cncr.25393. Epub 2010 Sep 7.

Ashish Rajput

1.  Wiseman S.M, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Filipenko D, Huntsman D, Gilks B. Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. American Journal of Surgery May 2006:191(5):581-7.

2.  Wisemen SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Bugis S, Filipenko D, Huntsman D, Gilks B.  Anaplastic thyroid carcinoma:  expression profile of targets for therapy offers new insights for disease treatment. Ann Sug Oncol 2007 Feb;12(2):719-29. Epub 2006 Nov 10.

3.  Rajput A, Miller MA, De Luca A, Boyd N, Leung S, Hurtado-Coll A, Fazli L, Jones E, Palmer J, Gleave M, Cox M, Huntsman D.  Frequency of the TMPRSS2-ERG gene fusion is increased in moderate to poorly differntiatted prostate cancers.  Editorialized Jouranl of Clinical Pathology 2007 Nov;60(11):1238-43.  Epub 2007 Jan 26.

4.  Wisemen SM, Griffith OL, Deen S, Rajput A, Masoudi H, Gilks B, Goldstein L, Gown A, Jones SJ.  Identification of molecular markers altered during transformatin of differentiated into anaplastic thyroid carcinoma.  Arch Surg Aug 2007; 142(8):717-29.

5.  Ursini-Siegel J, Rajput AB, Lu H, Sanguin-Gardreau V, Zuo D, Papavasiliou V, Lavoie C, Turbin J, Cianflone K, Huntsman DG, Muller WJ.  Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development. Mol Cell Biol Sep 2007; 27(18):6361-71.

6.  Rajput AB, Miller MA, De Luca A, Boyd N, Leung S, Hurtado-Coll A, Fazli L, Jones E, Palmer J, Gleave M, Cox M, Huntsman D.  Frequency of the TMPRSS2-ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.  Journal of Clinical Pathology (Editiorialized) Nov 2007; 60(11):1238-43.

7.  Edwards LA, Woo J, Huxham LA, Verreault M, Dragowska WH, Chiu G, Rajput A, Kyle AH, Kalra J, Yapp D, Yan H, Minchinton AI, Huntsman D, Daynard Tm Waterhouse DN, Thiessen B, Dedhar S, Bally MB.  Suppression of VEGF secretin and changes in glioblastoma multiforme microenvironment by inhibition of Integrin-linked kinase (ILK).  Mol Cancer Ther 2008 Jan; 7(1):59-70.

8.  Rajput AB, Turbin DA, Cheang MC, Voduc DK, Leung S, Gelmon KA, GIlks CB, Huntsman DG.  Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4444 cases.  Breast Cancer Res Treat 2008 Jan; 107(2): 249-57. 

9.  Fitzgerald LM, Agalliu I, Johnson K, Miller MA, Kwon EM, Hurtado-Coll A, Fazli L, Rajput AB, Gleave ME, Cox ME, Ostrander EA, Stanford JL, Huntsman DG.  Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes:  results from a population-based study of prostate cancer.  BMC Cancer 2008 Aug 11;8(1):230. 

10.  Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D.  Ovarian carcinoma subtypes are different diseases:  implications for biomarker studies.  PLoS Med. 2008 Dec 2;5(12):e232.

11.  Liu S, Chia SK, Mehl E, Leung S, Rajput A, Cheang MC, Nielsen TO. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients.  Breast Cancer Res Treat 2010 Jan;119(1):53-61. Epub 2009 Feb 10.

Vladimir Iakovlev

1.  Iakovlev V, Goswami RS, Vecchiarelli J, Arneson NCR, Done SJ. Quantitative detection of circulating epithelial cells by Q-RT-PCR.  Breast Cancer Research and Treatment, 2007;107:145-54.

2.  Pham NA, Morrison A, Schwock J, Aviel-Ronen S, Iakovlev V, Tsao MS, Ho J, Hedley D.  Quantitative image analysis of immunohistochemical stains using a CMYK color model.  Diagnostic Pathology. 2007;2:8(1:10).

3.  Wang C, Navab R, Iakovlev V, Tsao M-S, McCready D, Done SJ.  Abelseon-interactor protein 1 (ABI-1/E3b1) positively regulates breast cancer cell proliferation, migration and invasion.  Molecular Cancer Research, 2007;5:1031-9.

4.  Iakovlev V, Pintilie M, Morrison A, Fyles A, Hill R, Hedley D.  Effects of distributional heterogeneity on the analysis of tumor hypoxia based on Carbonic Anhydrase IX.  Laboratory Investigation, 2007;87:1206-17.

5.  Pham NA, Schwock J, Iakovlev V, Pond GR, Hedley DW, Tsao MS.  Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis.  BMC Cancer 2008;6:8(1):43. 

6.  Iakovlev VV, Arneson NCR, Wong V, Leung S, Iakovleva G, Wang C, Warren K, Pintilie M, Done SJ.  Genomic differences between pure duct carcinoma in situ (DCIS) of the breast and DCIS associated wtih invasive disease:  a calibrated aCGH study.  Clinical Cancer Research 2008 Jul 15;14(14):4446-54. 

7.  Pintilie M, Iakovlev V, Fyles A, Hedley D, Milosevic M, Hill R.  Heterogeneity and power in clinical biomarker studies. Journal of Clinical Oncology 2009 Mar 20;27(9):1517-21. Epub 2009 Feb 9. Erratum in: J Clinc Oncol 2009 Jun 1;27(16):2742.

8. Wang C, Iakovlev V V, Wong V, Leung S, Warren K, Iakovleva G, Arneson NC, Pintilie M, Miller N,Youngson B, McCready Dr, Done SJ. Genomic alterations in primary breast cancers compared with their sentinel and more distal lymph node metastases: an aCGH study. Genes Chromosomes Cancer 2009 Dec;48(12):1091-101.

9. Cawthorn TR, Moreno JC, Dharsee M, Tran-Thanh D, Ackloo S, Zhu PH, Sardana G, Chen J, Kupchak P, Jacks LM, Miller NA, Youngson BJ, Iakovlev V , Guidos CJ, Vallis KA, Evans KR,McCready D, Leong WL, Done SJ. Proteomic analyses reveal high expression of decorin and endoplasmin (HSP90B1) are associated with breast cancer metastasis and decreased survival. PLoS One. 2012;7(2):e30992. Epub 2012 Feb 20.

10. Arneson N, Moreno J, Iakovlev V, Ghazani A, Warren K, McCready D, Jurisica I, Done SJ. Comparison of whle genome amplification methods for analysis of DNA extracted from microdissected early breast lesions in formalin-fixed paraffin-embedded tissue. ISRN Oncol. 2012;2012-710692. Epub 2012 Mar 14.

11. Iakovlev V, Siegel ER, Tsao MS, Haun RS. Expression of kallikrein-related peptidase 7 predicts poor prognosis in patients with unresectable pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1135-42. Epub 2012 May 9.

Nathalie Johnson

1. Malumbres R, Chen J, Tibshirani R, Johnson NA, Sehn LH, Nathunam Y, Briones J, Advani R, Connors JM, Byrne GE, Levy R, Gascoyne RD, Lossos IS.  Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated wtih R-CHOP.  Blood.  2008 Jun 15;11(12):5509-14.

2. Johnson NA, Gascoyne RD.  Gene expression signatures in follicular lymphoma:  are they ready for the clinic?  Haematolologica.  2008 Jul;93(7):982-7.

3. O'Shea D, O'Riain C, Taylor C, Waters R, Carlotti E, Macdougall F, Gribben J, Rosenwald A, Ott G, Rimsza LM, Smeland EB, Johnson N, Campo E, Greiner TC, Chan WC, Gascoyne RD, Wright G, Staudt LM, Lister TA, Fitzgibbon J.  The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and a poorer overall survival.  Blood.  2008 Oct 15;112(8):3126-9.

4. Rimsza LM, Leblanc ML, Unger JM, Miller TP, Grogan TM, Persky DO, Martel RR, Sabalos CM, Seligmann B, Braziel RM, Campo E, Rosenwald A, Connors JM, Sehn LH, Johnson N, Gascoyne RD.  Gene expression predicts overall survival in paraffin embedded tissues of dissuse large B cell lymphoma treated with R-CHOP.  Blood. 2008 Oct 15;112(8):3425-33.

5. Johnson NA, Boyle M, Bashashati A, Leach S, Brooks-Wilson A, Sehn L, Chhanabhai M, Brinkman RR, Connors JM, Weng AP, Gascoyne RD.  Diffuse large B cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood 2009 Apr 16;113(16):3773-80. Epub 2008 Nov 24.

6. Johnson NA, Al-Tourah A, Brown CJ, Connors JM, Gascoyne RD, Horsman DE.  Prognostic significance of secondary cytogenetic alterations in follicular lymphomas.  Genes Chromosomes Cancer. 2008 Dec;47(12):1038-49.

7. O'Riain C, O'Shea D, Yang Y, Le Dieu R, Gribben JG, Afari J, Fleischmann C, Mein CA, Crook T, Smith P, Kelly G, Rosenwald A, Ott G, Campo E, Rimsza LM, Smeland EB, Chan WC, Johnson N, Gascoyne RD, Reimer S, Braziel RM, Wright GW, Staudt LM, Lister TA, Fitzgibbon J. Array-based DNA methylation profiling in follicular lymphoma and benign lymph nodes. Leukemia 2009. Oct;23(10):1858-66. doi: 10.1038/leu.2009.114. Epub 2009 Jul 9.

8. Cheung KJ, Shah SP, Steidl C, Johnson N, Relander T, Telenius A, Lai B, Murphy KP, Lam W, Al-Tourah AJ, Connors JM, Ng RT, Gascoyne RD, Horsman DE.  Genome-wide profiling of follicular lymphoma by array comparative genomic hybridizatin reveals prognostically significant DNA copy number imbalances.  Blood. 2009 Jan 1;113(1):137-48.  Epub 2008 Aug 14

9. Johnson NA, Leach S, Woolcock B, de Leew R, Bashashati A, Sehn L, Connors JM, Brooks-Wilson A, Gascoyne RD.  CD20 mutations involving the rituximbab epitope in diffuse large B cell lymphomas are rate and are not a significant cause of R-CHOP failure.  Haematologica 2009 Mar;94(3):423-7. Epub 2009 Feb 11.

10. O'Shea D, O'Riain C, Wrench D, Yang Y, Gribben J, Rosenwald A, Ott G, Rimsza LM, Holte H, Cazier J-B, Johnson N, Campo E, Chan WC, Gascoyne RD. Young BD, Staudt LM, Lister TA, Fitzgibbon J.
Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. Blood 2009 Mar 5;113(16):3773-80. Epub 2009 Jan 13.

11. Shah SP, Cheung KJ Jr, Johnson NA, Alain G, Gascoyne RD, Horsman De, NgRT, Murphy KP. Model based clustering of aCGH data. Bioinformatics. 2009; Jun15;25(12):i30-8.

12. Johnson NA, Savage KJ, Ludkovski O, Ben-Neriah S, Woods R, Steidl C, Dyer MJ, Siebert R, Kuruvilla J, Klasa R, Connors JM, Gascoyne RD, Horsman DE. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009 Sep 10;114(11):2273-9. Epub 2009 Jul 13.

13. Shustik J, Han G, Farinha P, Johnson NA, Connors JM, Sehn LH, Gascoyne RD, Steidl C et al. Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. Haematologica 2010 Jan;95(1):96-101. Epub 2009 Oct 1.

14. Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, Horsman DE, Gascoyne RD. MYC gene re-arrangements are associated with a poor prognosis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009 Oct 22;114(17):3533-7. Epub 2009 Aug 24.

15. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM. Chronic active B-cell receptor signalling in diffuse large B-cell lymphoma. Nature 2010 Jan 7;463(7277):88-92.

16. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, Paul JE, Boyle M, Woodcock BW, Kuchenbauer F, Yap D, Humphries RK, Griffith OL, Shah S, Zhu H, Kimbara M, Shashkin P, Charlot JF, Tcherpakov M, Corbett R, Tam A, Varhol R, Smailus D, Moksa M, Zhao Y, Delaney A, Qian H, Birol I, Shein J, Moore R, Holt R, Horsman DE, Connors JM, Jones S, Aparicio S, Hirst M, Gascoyne RD, Marra MA. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010 Feb;42(2);181-5. Epub 2010 Jan 17.

17. Relander T, Johnson NA, Farinha P, Connors JM, Sehn LH, Gascoyne RD. Prognostic factors in follicular lymphoma. J Clin Oncol 2010 Jun 10;28(17):2902-12. Epub 2010 Apr 12.

18. Cheung KJ, Delaney A, Ben-Neriah S, Schein J, Lee T, Shah SP, Cheung D, Johnson NA, Mungall AJ, Telenius A, Lai B, Boyle M, Connors JM, Gascoyne RD, Marra MA, Horsman DE. High resolution analysis of follicular lymphoma genomes reveales somatic recurrent sites of copy-neutral loss of heterozygosity and copy number alterations that target single genes. Genes Chromosomes Cancer 2010 Aug;49(8):669-81.

19. Shaknovich R, Geng H, Johnson NA, Tsikitas L, Cerchietti L, Greally JM, Gascoyne RD, Elemento O, Melnick A. DNA methylation signatures define molecular subtypes of diffuse large B cell lymphoma. Blood 2010 2010 Nov 18;116(20):e81-9. Epub 2010 Jul 7.

20. Williams PM, Li R, Johnson NA, Wright G, Heath JD, Gascoyne RD. A novel method of amplification of FFPET-derived RNA enables accurate disease classification with microarrays. J Mol Diagn 2010 Sep;12(5):680-6. Epub 2010 Aug 5.

21. Rodig SJ, Kutok JL, Paterson JC, Zhang W, Chapuy B, Tumwine LK, Montes-Moreno S, Agostinelli C, Johnson NA, Ben-Neriah S, Farinha P, SHpp MA, Piris MA, Grogan TM, Pileri SA, Gascoyne RD, Marafioti T. The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker to identify c-MYC translocated lymphomas. Haematologica 2010 Dec;95(12):2056-62. Epub 2010 Sep 7.

22. Cheung KJ, Johnson NA, Affleck JG, Severson T, Steidl C, Ben-Neriah S, Schein J, Morin RD, Moore R, Shah SP, QIan H, Paul JE, Telenius A, Relander T, Lam W, Savage K, Connors JM, Brown C, Marra MA, Gascoyne RD, Horsman DE. Acquired TNFRSF14 mutations in follicular llymphoma are associated with worse prognosis. Cancer Res 2010 Nov 15;70(22):9166-74. Epub 2010 Sep 30.

23. Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, Johnson NA, Zhao Y, Telenius A, Neriah SB, McPherson A, Meissner B, Okoye UC, Diepstra A, van den Berg A, Sun M, Leung G, Jones SJ, Connors JM, Huntsman DG, Savage KJ, Rimsza LM, Horsman DE, Staudt LM, Steidl U, Marra MA, Gascoyne RD. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011 Mar 17;471(7338):377-81. Epub 2011 Mar 2.

24. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, Jackman S, Krzywinski M, Scott DW, Trinh DL, Tamura-Wells J, Li S, Firme MR, Rogic S, Griffith M, Chan S Yakovenko O, Meyer IM, Zhao EY, Smailus D, Moksa M, Chittaranjan S, Rimsza L, Brooks-Wilson A, Spinelli JJ, Ben-Neriah S, Meissner B, Woolcock B, Boyle M, McDonald H, Tam A, Zhao Y Delaney A, Zeng T, Tse K, Butterfield Y, BIrol I, Holt R, Schein J, Horsman DE, Moore R, Jones SJ, Connors JM, Hirst M, Gascoyne RD. Marra MA Matire 2011 Jul 27;476(7360):298-303. doi: 10.1038/nature10351.

25. Iqbal J, Meyer PN, Smith LM, Johnson NA, Vose JM, Geiner TC, Connors JM, Staudt LM, Rimsza L, Jaffe E, Rosenwald A, Ott G, Delabie J, Campo E, Braziel RM, Cook JR, Tubbs RR, Gascoyne RD, Armitage JO, Weisenburger DD, Chan WC. Clin Cancer Res 2011 Dec 15;17(24)”7785-95. Epub 2011 Sep 20.

26. Singh RR, Ben-Neriah S, Johnson NA, Connors JM, Gascoyne RD Horsman DE. Identification of a novel non-immunoglobulin/MYC translocation t(8;12)(q24;p12) involving the LRMP gene in a primary B-cell lymphoma. A case report. Leuk Res 2012 Jan;36(1):e22-4. Epub 2011 Oct 11.

27. Schuetz JM, Johnson NA, Morin RD, Scott DW, Tan K, Ben-Nierah S, Boyle M, Slack GW, Marra MA, Connors JM, Brooks-Wilson AR, Gascoyne RD. BCL2 mutations in diffuse large B-cell lymphoma. Leukemia 2012 Jun;26(6):1383-90. doi: 10.1038/leu.2011.378. Epub 2011 Dec 22.

28. Bashashati A, Johnson NA, Khodabakhshi AH Whiteside MD, Zare H, Scott DW, Lo K, Gottaro R Brinkman FS, Connors JM, Slack GW, Gascoyne RD, Weng AP, Brinkman RR. B cells with high side scatter parameter by flow cytometry correlate with inferior survival in diffuse large B-cell lymphoma. AM J Clin Pathol 2012 May;137(5):805-14.

29. Johnson NA, Slack GW, Savage KJ Connors JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C Sehn LH, Chan WC, Iqbal J, Meyer PN, Lenz G, Wright G, Rimsza LM, Valentino C, Brunhoeber P, Grogan TM, Braziel RM, Cook JR, Tubbs RR, Weisenburger DD, Campo E, Rosenwald A, Ott G, Delabie J, Holcroft C, Jaffe ES, Staudt LM, Goscoyne RD. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with Rituximab Plus Cyclophospamide, Doxorubicin, Vicristine, and Prednisone. J Clin Oncol 2012 Oct 1;30(28):3452-0. Epub 2012 Jul 30.

30. Khodabakhshi AH, Morin RD, Fejes AP, Mungall AJ, Mungall KL, Bolger-Munro M, Johnson NA , Connors JM, Gascoyne RD, Marra MA, Birol I, Jones SJ. Recurrent targets of aberrant somatic hypermutation in lymphoma. Oncotarget 2012 Nov;3(11):1308-19.

31. De S, Shaknovich R, Riester M, Elemento O, Geng H, Kormaksson M, Jiang Y, Woolcock B, Johnson NA, Polo JM, Cerchietti L, Gascoyne RD, Melnick A, Michor F. Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. PLoS Genet. 2013;9(1):e1003137. doi: 10.1371/journal.pgen.1003137. Epub 2013 Jan 10.

32. Valentino C, Kendrick S, Johnson NA, Gascoyne R, Chan WC, Weisenburger D, Braziel R, Cook JR, Tubbs R, Campo E, Rosenwald A, Ott G, Delabie J, Jaffe E, Zhang W, Brunhoeber P, Nitta H, Grogan T, Rimsza L. Colorimetric in situ hybridization identifies MYC gene signal clusters correlating with increased copy number, mRNA, and protein in diffuse large B-cell lymphoma. Am J Clin Pathol. 2013 Feb;139(2):242-54. doi: 10.1309/AJCP2Z0TAGMUYJEB

33. Morin RD, Mungall K, Pleasance E, Mungall AJ, Goya R, Huff RD, Scott DW, Ding J, Roth A, Chiu R, Corbett RD, Chan FC, Mendez-Lago M, Trinh DL, Bolger-Munro M, Taylor G, Hadj Khodabakhshi A, Ben-Neriah S, Pon J, Meissner B, Woolcock B, Farnoud N, Rogic S, Lim EL, Johnson NA, Shah S, Jones S, Steidl C, Holt R, Birol I, Moore R, Connors JM, Gascoyne RD, Marra MA. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood. 2013 Aug 15;122(7):1256-65. doi: 10.1182/blood-2013-02-483727. Epub 2013 May 22.

34. Chambwe N, Kormaksson M, Geng H, De S, Michor F, Johnson NA, Morin RD, Scott DW, Godley LA, Gascoyne RD, Melnick A, Campagne F, Shaknovich R.Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes Blood. 2014 Mar 13;123(11):1699-708. doi: 10.1182/blood-2013-07-509885. Epub Jan 2.

35. Chan FC, Telenius A, Healy S, Ben-Neriah S, Mottok A, Lim R, Drake M, Hu S, Ding J, Ha G, Scott DW, Kridel R, Bashashati A, Rogic S, Johnson NA, Morin RD, Rimsza LM, Sehn L, Connors JM, Marra MA, Gascoyne RD, Shah SP, Steidl C. An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup. Blood. 2015 Feb 5;125(6):959-66. Epub 2014 Nov 13.

36. Lim EL, Trinh DL, Scott DW, Chu A, Krzywinski M, Zhao Y, Robertson AG, Mungall AJ, Schein J, Boyle M, Mottok A, Ennishi D, Johnson NA, Steidl C, Connors JM, Morin RD, Gascoyne RD, Marra MA. Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients. Genome Biol. 2015 Jan 29;16:18.

37. Savage KJ, Slack GW, Mottok A, Sehn LH, Villa D, Kansara R, Kridel R, Steidl C, Ennishi D, Tan KL, Ben-Neriah S, Johnson NA, Connors JM, Farinha P, Scott DW, Gascoyne RD. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood. 2016 May 5;127(18):2182-8. Epub 2016 Feb 1.

38. Kridel R, Chan FC, Mottok A, Boyle M, Farinha P, Tan K, Meissner B, Bashashati A, McPherson A, Roth A, Shumansky K, Yap D, Ben-Neriah S, Rosner J, Smith MA, Nielsen C, Giné E, Telenius A, Ennishi D, Mungall A, Moore R, Morin RD, Johnson NA, Sehn LH, Tousseyn T, Dogan A, Connors JM, Scott DW, Steidl C, Marra MA, Gascoyne RD, Shah SP. Histological transformation and progression in follicular lymphoma: A clonal evolution study. PLoS Med. 2016 Dec 13;13(12):e1002197.

Sonja Steigen

1. Steigen SE, Straume B, Turbin D, Chan AK, Leung S, Nielsen TO, Lindal S. Clinicopathologic factors and nuclear morphometry as independent prognosticators in KIT positive gastrointestinal stromal tumors. J Histochm Cytochem 2008 Feb;56(2):139-45.  Epub 2007 Oct 15.

2.  Steigen SE, Bjerkehagen B, Haugland HK, Nordrum IS, Loberg EM, Isaksen V, Eide TJ, Nielsen TO.   Diagnostic and prognostic markers for gastrointestinal stromal tumors in Norway.  Mod Pathol 2008 Jan;21(1):46-53. Epub 2007 Oct 5. 

3.  Steigen SE, Schaeffer DF, West RB, Nielsen TO.  Expression of Insulin-like growth factor 2 in mesenchymal neoplasms.  Modern Pathology. Modern Pathol 2009 Jul;22(7):914-21. Epub May 1.

Blaise Clarke

1. Alkushi A, Clarke BA, Akbari M, Makretsov N, Lim P, Miller D, Magliocco A, Coldman A, van de Rijin M, Huntsman D, Parker R, Gilks CB. Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis in immunostaining data. Mod Pathol 2007 Nov;20(11):1156-65.

2. Gilks CB, Ionescu DN, Kalloger Se, Kobel M, Irving J, Clarke B, Santos J, Le N, Noravan V, SwenertonK; on behalf of the Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency, Vancouver BC. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol. 2008 Aug;39(8):1239-1251. Epub 2008 Jul 7.

3. Clarke B, Tinker AV, Lee C, Subramanian S, van de Rijin M, Turbin D, Kalloger S, Cadungog MG, Huntsman D, Coukos G, Gilks CB. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associateion with stage, tumor type, and BRCA1 loss. Mod Pathol 2009 Mar;22(3):393-402. Epub 2008 Dec 5.

4. Shah SP, Kobel M, Senz J, Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A, Mehl E, Kalloger SE, Sun M, Giuliany R, Yorida E, Jones S, Varhol R, Swenerton KD, Miller D, Clement PB, Crane C, Madore J, Provencher D, Leung P, DeFaxio A, Khattra J, Turashvili G, Zhao Y, Zeng T, Glover JN, Vanderhyden B, Zhao C, Parkinson CA, Jimenez-Linan M, Bowtell DD, Mes-Masson AM, Brenton JD, Aparicio SA, Boyd N, Hirst M, Gilks CB, Marra M, Huntsman DG. Mutation of FOXL2 in granulose-cell tumors of the ovary. N Engl J Med 2009 Jun 25;360(26):27-29. Epub 2009 Jun 10.

5. Mulligan Am, Plotkin A, Rouzbahman M, Soslow RA, GIlks CB, Clarke BA. Endometrial giant cell carcinoma: a case series and review of the spectrum of endometrial neoplasms containing giant cells. Am J Surg Pathol 2010 Aug;34(8):1132-8. Review.

6. Lu FI, Gilks CB, Mulligan AM, Ryan P, Allo G, Sy K, Shaw PA, Pollett A, Clarke BA. Prevalence of loss of expression of DNA mismatch repair proteins in primary epithelial ovarian tumors. Int J Gynecol Pathol. 2012 Nov;31(6):524-31.

7. Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012 Oct 3;10:205.

8. Sieh W, Köbel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Høgdall E, Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke BA, Menon U, Gilks CB, Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkens LR, Carney ME, Thompson PJ, Matsuno RK, Kjær SK, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, García-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bshara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittemore AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol. 2013 Aug;14(9):853-62. doi: 10.1016/S1470-2045(13)70253-5. Epub 2013 Jul 9.

9. Diaz-Padilla I, Hirte H, Oza AM, Clarke BA, Cohen B, Reedjik M, Zhang T, Kamel-Reid S, Ivy SP, Hotte SJ, Razak AA, Chen EX, Brana I, Wizemann M, Wang L, Siu LL, Bedard PL. A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. Invest New Drugs. 2013 Oct;31(5):1182-91. doi: 10.1007/s10637-013-0001-5. Epub 2013 Jul 17.

10. How C, Hui AB, Alajez NM, Shi W, Boutros PC, Clarke BA, Yan R, Pintilie M, Fyles A, Hedley DW, Hill RP, Milosevic M, Liu FF. MicroRNA-196b regulates the homeobox B7-vascular endothelial growth factor axis in cervical cancer. PLoS One. 2013 Jul 4;8(7):e67846.

11. Mackay HJ, Eisenhauer EA, Kamel-Reid S, Tsao M, Clarke B, Karakasis K, Werner HM, Trovik J, Akslen LA, Salvesen HB, Tu D, Oza AM. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. Cancer. 2014 Feb 15;120(4):603-10

12. Downes MR, Allo G, McCluggage WG, Sy K, Ferguson SE, Aronson M, Pollett A, Gallinger S, Bilbily E, Shaw P, Clarke BA. "Review of Findings in Prophylactic Gynaecologic Specimens in Lynch Syndrome with Literature Review and Recommendations for Grossing" Histopathology. 2014 Feb 4.

13. Ramos P, Karnezis AN, Craig DW, Sekulic A, Russell ML, Hendricks WP, Corneveaux JJ, Barrett MT, Shumansky K, Yang Y, Shah SP, Prentice LM, Marra MA, Kiefer J, Zismann VL, McEachron TA, Salhia B, Prat J, D'Angelo E, Clarke BA, Pressey JG, Farley JH, Anthony SP, Roden RB, Cunliffe HE, Huntsman DG, Trent JM. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat Genet. 2014 May;46(5):427-9.

14. Wiegand KC, Sy K, Kalloger SE, Li-Chang H, Woods R, Kumar A, Streutker CJ, Hafezi-Bakhtiari S, Zhou C, Lim HJ, Huntsman DG, Clarke BA, Schaeffer DF. ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts. Hum Pathol. 2014 Jun;45(6):1258-68. Epub 2014 Feb 20.

15. Köbel M, Madore J, Ramus SJ, Clarke BA, Pharoah PD, Deen S, Bowtell DD, Odunsi K, Menon U, Morrison C, Lele S, Bshara W, Sucheston L, Beckmann MW, Hein A, Thiel FC, Hartmann A, Wachter DL, Anglesio MS, Høgdall E, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Fogarty ZC, Vierkant RA, Liu S, Cho S, Nelson G, Ghatage P, Gentry-Maharaj A, Gayther SA, Benjamin E, Widschwendter M, Intermaggio MP, Rosen B, Bernardini MQ, Mackay H, Oza A, Shaw P, Jimenez-Linan M, Driver KE, Alsop J, Mack M, Koziak JM, Steed H, Ewanowich C, DeFazio A, Chenevix-Trench G, Fereday S, Gao B, Johnatty SE, George J, Galletta L; AOCS Study Group, Goode EL, Kjær SK, Huntsman DG, Fasching PA, Moysich KB, Brenton JD, Kelemen LE. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An ovarian tumour tissue analysis consortium study. Br J Cancer. 2014 Dec 9;111(12):2297-307. Epub 2014 Oct 30.

16. Tone AA, McConechy MK, Yang W, Ding J, Yip S, Kong E, Wong KK, Gershenson DM, Mackay H, Shah S, Gilks B, Tinker AV, Clarke BA, McAlpine JN, Huntsman D. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas. BMC Cancer. 2014 Dec 18;14:982.

17. McConechy MK, Hoang LN, Chui MH, Senz J, Yang W, Rozenberg N, Mackenzie R, McAlpine JN, Huntsman DG, Clarke BA, Gilks CB, Lee CH. In-depth molecular profiling of the biphasic components of uterine carcinosarcomas. J Pathol Clin Res. 2015 Apr 9;1(3):173-85.

18. Clarke BA, Witkowski L, Ton Nu TN, Shaw PA, Gilks CB, Huntsman D, Karnezis AN, Sebire N, Lamovec J, Roth LM, Stewart CJ, Hasselblatt M, Foulkes WD, McCluggage WG. Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small-cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics. Histopathology. 2016 Nov;69(5):727-738. Epub 2016 Jul 28.

Abderrahman Ouban

1.  Rezania D, Ouban A, Marcet J, Kelley S, Coppola D.  CMV colitis mimicking recurrent inflammatory bowel disease:  report of three cases.  American Surgeon 2007 Jan;73(1):58-61.

2.  Dos Reis PP, Bharadwaj RR, Machado J, Ouban A, Kamel-Reid S. Claudin 1 overexpression increases invasion and is associated with aggressive histological features in oral squamous cell carcinoma. Journal of Cancer 2008 Dec1; 113(11):3169-80

3.  Coppola D, Ouban A, Gilbert-Barness E. Expression of the insulin-like growth factor receptor 1 during human embryogenesis. Fetal Pediatric Pathology. 2009;28(2):47-54.

4.  Ouban A, Ahmed AA. Claudin 1 in human cancer; a review. Histology Histopathology. 2010 Jan;25(1):83-90. Review.

Rashmi Goswami

1.  Iakovlev VV, Goswami RS, Vecchiarelli J, Arneson NCR, Done SJ.  Quantitative detection of circulating epithelial cells by Q-RT-PCR.  Breast Cancer Research and Treatment 2008 Jan;107(1):145-54. Epub 2007 Mar 9

2. Reis PP, Bharadwaj RR, Machado J, Macmillan C, Pintilie M, Sukhai MA, Galloni NN, Freeman J, Clark J, Brown D, Gilbert R, Ouban A, Goswami RS, Grenman R, Perez-Ordonez B, Gullane P, Irish J, Kamel-Reid S. Claudin 1 overexpression increases invasion and is associated with aggressive histological features in oral squamous cell carcinoma. Cancer 2008 Dec 1;113(11):3169-80.

3. Goswami RS, Sukhai MA, Thomas M, Reis PP, Kamel-Reid S. Application of microarray technology to acute myelogenous leukemia. Cancer Inform 2009;7:13-28.

4. Goswami RS, Waldron L, Machado J, Cervigne NK, Xu W, dos Reis PP, Jurisica I, Bailey DJ, Crump M, Kamel-Reid S. Optimization and analysis of a quantitative real-time PCR-based technique to determine microRNA expression in formalin-fixed paraffin-embedded samples. MBC Biotechnol 2010 Jul 23; 10(1):47. [Epub ahead of print].

5. Barker EV, Cervigne NK, Reis PP, Goswami RS, Xu W, Weinreb I, Irish JC, Kamel-Reid S. microRNA evluatinof unknown primary lesions in the head and neck. Mol Cancer 2009 Dec 23;8:127.

6. Reis PP, Waldron L, Goswami RS, Xu W, Xuan Y, Perez-Ordonez B, Gullane P, Irish J, Jurisica I, Kamel-Reid S. mRNA transcript quantification in archival samples using multiplexed, color-coded probes. BMC Biotechnol 2011 May 9;11:46.

7. Goswami RS, Atenafu EG, Xuan Y, Waldron L, Reis PP, Sun T, Datti A, Xu W, Kuruvilla J, Good DJ, Lai R, Church AJ, Lam WS, Baetz T, Lebrun DP, Sehn LH, Farinha P, Jurisica I, Bailey DJ, Gascoyne RD, Crump M, Kamel-Reid S. MicroRNA signature obtained from the comparison of aggressive with indolent non-hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma. J Clin Oncol. 2013 Aug 10;31(23):2903-11.

8. Cervigne NK, Machado J, Goswami RS, Sadikovic B, Bradley G, Perez-Ordonez B, Galloni NN, Gilbert R, Gullane P, Irish JC, Jurisica I, Reis PP, Kamel-Reid S. Recurrent genomic alterations in sequential progressive leukoplakia and oral cancer: drivers of oral tumorigenesis? Hum Mol Genet 2014 May 15;23(10):2618-28.

9. Goswami RS. PCR techniques in next-generation sequencing. Methods Mol Biol. 2016;1392:143-51.

Stefano Serra

1. DiGiovanni R, Serra S, Ezzat S, Asa SL.  AIP mutations are not identified in patients with sporadic pituitary adenomas.  Endoc Pathol 2007;18:76-8.

2.  Salahshor S, Naidoo R, Serra S, Shih W, Tsao MS, Chetty R, Woodgett JR.  Frequent accumulation of nuclear E-cadherin and alterations in the Wnt signaling pathway in esophageal squamous cell carcinomas.  Mod Pathol. 2008 Mar;21(3):271-81.

3.  Chetty R, Serra S, Asa SL.  Loss of membrane localization and aberrant nuclear E-cadherin expression correlates with invasion in pancreatic endocrine tumors. Am J Surg Pathol. 2008 Mar;32(3):413-9.

4.  Serra S, Asa SL.  Controversies in thyroid pathology:  The diagnosis of follicular neoplasms.  Endocr Pathol. 2008 Fall 19(3):156-65. Review.

5. Serra S, Asa SL, Bamberger AM, Wagener C, Chetty R. CEACAM1 expression in pancreatic endocrine tumors. Appl Immunohistochm Mol Morphol 2009;17:286-93.

6. Jain R, Fischer S, Serra S, Chetty R. The use of cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas gastrointestinal tract and liver. Appl Immunohistochem Mol Morphol 2010 Jan;18(1):9-15. Review.

7. Cheng S, Serra S, Mercado M,Ezzat S, Asa SL. A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior. Clinc Cancer Res 2011 Apr15;17(8):2385-94. Epub 2011 Mar 9.

8. Guo M, Liu W, Serra S, Asa SL, Ezzat S. FGR2 isoforms support epithelial-stromal interactions in thyroid cancer progression. Cancer Res 2012 Apr 15;72(8):2017-27. Epub 2012 Feb 17.

9. Serra S, Zheng L, Hassan M, Phan AT, Woodhouse LJ, Yao JC, Ezzat S, Asa SL. The FGR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy. Cancer Res 2012 Nov15;72(22):5683-91. doi: 10.1158/0008-5472 CAN-12-2012. Epub 2012 Sep 17.

10. Araujo PB, Cheng S, Mete O, Serra S, Morin E, Asa SL, Ezzat S. Evaluation of the WHO 2010 grading and AJCC/UICC staging systems in prognostic behaviour of intestinal neuroendocine tumors. PLoS One. 2013 Apr 19;8(4):e61538. Print 2013.

11. Francis JM, Kiezun A, Ramos AH, Serra S, Pedamallu CS, Qian ZR, Banck MS, Kanwar R, Kulkarni AA, Karpathakis A, Manzo V, Contractor T, Philips J, Nickerson E, Pho N, Hooshmand SM, Brais LK, Lawrence MS, Pugh T, McKenna A, Sivachenko A, Cibulskis K, Carter SL, Ojesina AI, Freeman S, Jones RT, Voet D, Saksena G, Auclair D, Onofrio R, Shefler E, Sougnez C, Grimsby J, Green L, Lennon N, Meyer T, Caplin M, Chung DC, Beutler AS, Ogino S, Thirlwell C, Shivdasani R, Asa SL, Harris CR, Getz G, Kulke M, Meyerson M. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet. 2013 Dec;45(12):1483-6. Epub 2013 Nov 3.

12. Morin E, Cheng S, Mete O, Serra S, Araujo PB, Temple S, Cleary S, Gallinger S, Greig PD, McGilvray I, Wei A, Asa SL, Ezzat S. Hormone profiling, WHO 2010 grading, and AJCC/UICC staging in pancreatic neuroendocrine tumor behaviour. Cancer Med. 2013 Oct;2(5):701-11. Epub 2013 Aug 6.

13. Wei W, Liu W, Serra S, Asa SL, Ezzat S. The breast cancer susceptibility FGFR2 provides an alternate mode of HER2 activation. Oncogene. 2015 Feb 2

14. Karpathakis A, Dibra H, Pipinikas C, Feber A, Morris T, Francis J, Oukrif D, Mandair D, Pericleous M, Mohmaduvesh M, Serra S, Ogunbiyi O, Novelli M, Luong T, Asa SL, Kulke M, Toumpanakis C, Meyer T, Caplin M, Meyerson M, Beck S, Thirlwell C. Prognostic impact of novel molecular subtypes of small intestinal neuroendocrine tumor. Clin Cancer Res. 2016 Jan 1;22(1):250-8. Epub 2015 Jul 13.

15. Yang Z, Zhang L, Serra S, Law C, Wei A, Stockley TL, Ezzat S, Asa SL. Establishment of characterizatio of a human neuroendocrine tumor xenograft. Endocr Pathol. 2016 Jun;27(2):97-103

16. Karpathakis A, Dibra H, Pipinikas C, Feber A, Morris T, Francis J, Oukrif D, Mandair D, Pericleous M, Mohmaduvesh M, Serra S, Ogunbiyi O, Novelli M, Luong T, Asa SL, Kulke M, Toumpanakis C, Meyer T, Caplin M, Beck S, Thirlwell C. Progressive epigenetic dysregulation in neuroendocrine tumour liver metastases. Endocr Relat Cancer. 2017 Feb;24(2):L21-L25. Epub 2017 Jan 3.

Joao Magalhaes

1. Pham NA, Magalhaes J, Do T, Schwock J, Dhani N, Cao PJ, Hill RP, Hedley DW. Activation of Src and Src-associated signaling pathways in relation to hypoxia in human cancer xenograft models. International Journal of Cancer 2009 Jan 15;124(2):280-6.

2. You B, Brade A, Magalhaes J, Siu LL, Oza A, Lovell S, Wang L, Hedley DW, Nicasio LV, Chen EX. A dose-escalation phase I trail of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies. Invest New Drugs 2011 Oct;29(5):996-1003 [Epub ahead of print].

Gulisa Turashvili

1. Eirew P, Stingl J, Raouf A, Turashvili G, Aparicio S, Emerman JT, Eaves CJ. A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability. Nat Med 2008;14:1384-1389.

2. Jensen KC, Schaeffer DF, Cheang M, Montgomery K, West RB, Gilks CB, Ross D, Turashvili G, Schnitt S, van de Rijn M. Characterization of a novel anti-fatty acid synthase (FASN) antiserum in breast tissue. Mod Pathol 2008;21:1413-1420.

3. Turashvili G, Hayes M, Gilks B, Watson P, Aparicio S. Are columnar cell lesions the earliest histologically detectable non-obligate precursor of breast cancer? Virchows Arch 2008;452:589-598.

4. Dumont N, Crawford YG, Sigaroudinia M, Nagrani SS, Wilson MB, Buehring GC, Turashvili G, Aparicio S, Gauthier ML, Fordyce CA, McDermott KM, Tlsty TD. Human mammary cancer progression model recapitulates methylation events associated with breast premalignancy. Breast Cancer Res 2009;11(6):R87.

5. Shah SP, Kobel M, Senz J, Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A, Mehl E, Kalloger SE, Sun M, Giuliany R, Yorida E, Jones S, Varhol R, Swenerton KD, Miller D, Clement PB, Crane C, Madore J, Provencher D, Leung P, DeFazio A, Khattra J, Turashvili G, Zhao Y, Zeng T, Glover JN, Vanderhyden B, Zhao C, Parkinson CA, Jimenez-Linan M, Bowtell DD, Mes-Masson AM, Brenton JD, Aparicio SA, Boyd N, Hirst M, Gilks CB, Marra M, Huntsman DG. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med 2009;360:2719-2729.

6. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A, Gelmon K, Guliany R, Senz J, Steidl C, Holt RA, Jones S, Sun M, Leung G, Moore R, Severson T, Taylor GA, Teschendorff AE, Tse K, Turashvili G, Varhol R, Warren RL, Watson P, Zhao YJ, Caldas C, Huntsman D, Hirst M, Marra MA, Aparicio S. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009;461:809-U867.

7. Turashvili G, Leung S, Turbin D, Montgomery K, Gilks B, West R, Carrier M, Huntsman D, Aparicio S. Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis. BMC Cancer 2009;May 29:9-165.

8. Turashvili G, McKinney S, Martin L, Gelmon KA, Watson P, Boyd N, Aparicio S. Columnar cell lesions, mammographic density and breast cancer risk. Breast Cancer Res Treat 2009;115:561-571.

9. Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, Baglietto L, Severi G, Giles GG, McLean CA, Callagy G, Green AR, Ellis I, Gelmon K, Turashvili G, Leung S, Aparicio S, Huntsman D, Caldas C, Pharoah P. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer. 2010;103(5):668-75.

10. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJM, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih I-M, Mes-Masson A-M, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG. ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas. N Engl J Med. 2010 Oct 14;363(16):1532-43.

11. Turashvili G, McKinney S, Goktepe O, Leung S, Huntsman D, Gelmon K, Los G, Rejto P, Aparicio S. P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer. Mod Pathol 2011 Jan;24(1):64-81.

12. Prentice LM d'Anglemont de Tassigny X, McKinney S, Ruiz de Algara T, Yap D, Turashvili G, Poon S, Sutcliffe M, Allard P, Burleigh A, Fee J, Huntsman DG, Colledge WH, Aparicio SA. The testosterone-dependent and independent transcriptional networks in the hypothalamus of Gpr54 and Kiss1 knockout male mice are not fully equivalent. BMC Genomics 2011 Apr 28;12:209.

13. Lee-Hoeflich ST, Pham TQ, Dowbenko D, Munroe X, Lee J, Li L, Zhou W, Haverty PM, Pujara K, Stinson J, Chan SM, Eastham-Anderson J, Pandita A, Seshagiri S, Hoeflich KP, Turashvili G, Gelmon KA, Aparicio SA, Davis DP, Sliwkowski MX, Stern HM. PPM1H is a p27 phosphatase implicated in trastuzumab resistance. Cancer Discov. 2011 Sep;1(4):326-37. doi: 10.1158/2159-8290.CD-11-0062. Epub 2011 Jul 20.

14. Yap DB, Walker DC, Prentice LM, McKinney S, Turashvili G, Mooslehner-Allen K, de Algara TR, Fee J, de Tassigny Xd, Colledge WH, Aparicio S. Mll5 is required for normal spermatogenesis. PLoS One. 2011;6(11):e27127. doi: 10.1371/journal.pone.0027127. Epub 2011 Nov 1.

15. Turashvili G, Yang W, McKinney S, Kalloger S, Gale N, Ng Y, Chow K, Bell L, Lorette J, Carrier M, Luk M, Aparicio S, Huntsman D, Yip S. Nucleic acid quantity and quality from paraffin blocks: defining optimal fixation, processing and DNA/RNA extraction techniques. Exp Mol Pathol 2012 Feb;92(1):33-43.

16. Roth A, Ding J, Morin R, Crisan A, Ha G, Giuliany R, Bashashati A, Hirst M, Turashvili G Oloumi A, Marra MA, Aparicio S, Shah SP. JointSNVMix: a probabilistic model for accurate detection of somatic mutations in normal/tumour paired next-generation sequencing data. Bioinformatics 2012 Apr 1;28(7):907-13.

17. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, Bashashati A, Prentice LM, Khattra J, Burleight A, Yap D, Bernard V, McPherson A, Shumansky K, Crisan A, Giuliany R, Heravi-Moussavi A, Rosner J, Lai D, Birol I, Varhol R, Tam A, Dhalla N, Zeng T, Ma K, Chan SK, Griffith M, Moradian A, Cheng SW, Morin GB, Watson P, Germon K, Chia S, Chin SF, Curtis C, Rueda OM, Pharoah PD, Damaraju S, Mackey J, Hoon K, Harking T, Tadigotla V, Sigaroudinia M, Gascard P, Tlsty T, Costello JF, Meyer IM, Eaves Cj, Wasserman WW, Jones S, Huntsman D, Hirst M, Caldas C, Marra MA, Aparicio S. Nature 2012 Apr 4;486(7403):395-9. doi: 10.1038/nature10933.

18. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S; METABRIC Group, Langerod A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Borresen-Dale AL, Brenton JD, Tavare S, Caldas C, Aparicio S. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nture 2012 Apr 18;486(7403):346-52.

19. Ha G, Roth A, Lai D, Bashashati A, Ding J, Goya R, Giuliany R, Rosner J, Oloumi A, Shumansky K, Chin SF, Turashvili G, Hirst M, Caldas C, Marra MA, Aparicio S, Shah SP. Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer. Genome Res 2012 Oct;22(10):1995-2007. doi: 10.1101/gr:137570.112.

20. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge Dc, Nik-Zainal S, Martin S, Varela I, Bignell GR, Yates LR, Papaemmanuil E, Beare D, Butler A, Cheverton A, Gamble J, Hinton J, Jia M, Jayakumar A, Jones D, Latimer C, Lau KW, McLaren S, McBride DJ, Menzies A, Mudie L, Raine K, Rad R, Chapman MS, Teague J, Easton D, Langerod A; Oslo Breast Cancer Consortium (OSBREAC), Lee MT,Shen CY, Tee BT, Huimin BW, Broeks A, Vargas AC, Turashvili G, Martens J, Fatima A, Miron P, Chin SF, Thomas G, Boyault S,Mariani O, Lakhani SR, van de Vijver M, van't Veer L, Foekens J, Desmedt C, Sotiriou C, Tuff A, Caldas C, Reis-Filho JS, Aparicio SA, Salomon AV, Borrensen-Dale AL, Richardson AL, Campbell PJ, Futreal PA, Stratton MR. Nature 2012 May 16;486(7403):400-4. doi: 10.1038/nature11017.

21. Yuan Y, Failmezger H, Rueda OM, Ali HR, Gräf S, Chin SF, Schwarz RF, Curtis C, Dunning MJ, Bardwell H, Johnson N, Doyle S, Turashvili G, Provenzano E, Aparicio S, Caldas C, Markowetz F. Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling. Sci Transl Med. 2012 Oct 24;4(157):157ra143. doi: 10.1126/scitranslmed.3004330. Erratum in: Sci Transl Med. 2012 Oct 24;4(157):161er6.

22. Dvinge H, Git A, Gräf S, Salmon-Divon M, Curtis C, Sottoriva A, Zhao Y, Hirst M, Armisen J, Miska EA, Chin SF, Provenzano E, Turashvili G, Green A, Ellis I, Aparicio S, Caldas C. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature. 2013 May 16;497(7449):378-82. doi: 10.1038/nature12108. Epub 2013 May 5.

23. Fam HK, Walton C, Mitra SA, Chowdhury M, Osborne N, Choi K, Sun G, Wong PC, O'Sullivan MJ, Turashvili G, Aparicio S, Triche TJ, Bond M, Pallen CJ, Boerkoel CF. TDP1 and PARP1 deficiency are cytotoxic to rhabdomyosarcoma cells. Mol Cancer Res. 2013 Oct;11(10):1179-92. doi: 10.1158/1541-7786.MCR-12-0575. Epub 2013 Aug 2.

24. Vollan HK, Rueda OM, Chin SF, Curtis C, Turashvili G, Shah S, Lingjærde OC, Yuan Y, Ng CK, Dunning MJ, Dicks E, Provenzano E, Sammut S, McKinney S, Ellis IO, Pinder S, Purushotham A, Murphy LC, Kristensen VN; METABRIC Group, Brenton JD, Pharoah PD, Børresen-Dale AL, Aparicio S, Caldas C. A tumor DNA complex abrration index is an independent predictor of survival in breast and ovarian cancer. Mol Oncol. 2015 Jan;9(1):115-27

25. Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ, Tsui DW, Liu B, Dawson SJ, Abraham J, Northen H, Peden JF, Mukherjee A, Turashvili G, Green AR, McKinney S, Oloumi A, Shah S, Rosenfeld N, Murphy L, Bentley DR, Ellis IO, Purushotham A, Pinder SE, Børresen-Dale AL, Earl HM, Pharoah PD, Ross MT, Aparicio S, Caldas C. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptiomic landscapes. Nat Commun. 2016 May 10;7:11479.

26. Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ, Tsui DW, Liu B, Dawson SJ, Abraham J, Northen H, Peden JF, Mukherjee A, Turashvili G, Green AR, McKinney S, Oloumi A, Shah S, Rosenfeld N, Murphy L, Bentley DR, Ellis IO, Purushotham A, Pinder SE, Børresen-Dale AL, Earl HM, Pharoah PD, Ross MT, Aparicio S, Caldas C. Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcritomic landscapes. Nat Commun. 2016 Jun 6;7:11908.

27. Mukherjee A, Russell R, Chin SF, Liu B, Rueda OM, Ali HR, Turashvili G, Mahler-Araujo B, Ellis IO, Aparicio S, Caldas C, Provenzano E. Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort. NPJ Breast Cancer. 2018 Mar 7;4:5

Bizhan Bandarchi

1. Lo, P-C, Chen J, Stefflova K, Navab R, Bandarchi B, Gand L, Tsao M-S, Mullins S, Cheng JD, Zheng G. Photodynamic molecular beacon triggered by fibroblast activation protein on cancer-associated fibroblasts for diagnosis and treatment of epithelial cancers. Journal of Medicinal Chemistry, 2009 January 22;52(2):358-68.

2. Navab R, Bandarchi B, Tsao M-S. Chapter of cancer associated fibroblasts in lung cancer. In: Arenberg D, Gdit: Lung Cancer Metastasis: Novel biological mechanisms and impact on clinical practice. ISBN: 978-1-4419-0771-4.

3. Navab R, Liu J, Seiden-Long I, Shih W, Li M. Bandarchi B, Chen Y, Lau D, Zu Y-F, Cescon D, Zhu CQ, Ibrahimov E, Ohanessian D, Tsao M-S. Co-overexpression of Met and HGF promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells. Neoplasia 2009 December; 11(12):1292-1300.

4. Quintela-Fandino M, Le Tourneau C, Duran I, Chen EX, Wang L, Tsao M, Bandarchi-Chamkhaleh B, Pham NA, Do T, MacLean M, Nayyar R, Tusche MW, Metser U, Wright JJ, Mak TW, Siu LL. Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation form an expansion cohort. Mol Cancer Ther. 2010 Mar;9(3):751-60. Epub 2010 Mar 2.

5. Navab R, Strumpf D, Bandarchi B, Zhu CQ, Pintilie M, Ramnarine VR, Ibrahimov E, Radulovich N, Leung L, Barczyk M, Panchal D, To C, Yun JJ, Der S, Shepherd FA, Jurisica I, Tsao MS. Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc Natl Acad Sci USA 2011 Apr 26;108(17):7160-5. Epub 2011 Apr 7

6. Hai J, Zhu CQ, Bandarchi B, Wang YH, Navab R, Shepherd FA, Jurisica I, Tsao MS. L1 cell adhesion molecule promotes tumorigenicity and metastatis potential in non-small cell lung cancer. Clin Cancer Res 2012 Apr 1;18(&):1914-24. Epub 2012 Feb 3.

7. Leung L, Radulovich N, Zhu CQ, Organ S, Bandarchi B, Pintilie M, To C, Panchal D, Tsao MS. PLoS One. 2012;7(10):e46677. doi: 10.1371/journal.pone.0046677. Epub 2012 Oct 4.

8. John T, Yanagawa N, Kohler D, Craddock KJ, Bandarchi-Chamkhaleh B, Pintilie M, Sykes J, To C, Li M, Panchal D, Chen W, Shepherd FA, Tsao MS. Characterization of lymphomas developing in immunodeficient mice implanted with primary human non-small cell lung cancer. Thorac Oncol. 2012 Jul;7(7):1101-8

9. Mamaghani S, Simpson CD, Cao PM, Cheung M, Chow S, Bandarchi B, Schimmer AD, Hedley DW. Glycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to TRAIL-induced apoptosis. PLos One 2012;7(7):e41102.

10. Dodbiba L, Teichman J, Fleet A, Thai H, Sun B, Panchal D, Patel D, Tse A, Chen Z, Faluyi O, Renouf D, Girgis H, Bandarchi B, Schwock J, Xu W, Bristow R, Tsao M-S, Darling G, Ailles L, El-Zimaity H, Liu G. Primary esophageal and gastro-esophageal junction cancer xenograft models: clinicopathoogical features and engraftment. Laboratory Investigation 2013 93;397-407.

11. Shepherd FA, Domerg C, Hainaut P, Jänne PA, Pignon JP, Graziano S, Douillard JY, Brambilla E, Le Chevalier T, Seymour L, Bourredjem A, Teuff GL, Pirker R, Filipits M, Rosell R, Kratzke R, Bandarchi B, Ma X, Capelletti M Soria JC, Tsao MS. Polled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subbype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. Journal of Clinical Oncology 2013 Jun 10;31(17):2173-81.

12. Allo G, Bandarchi B, Yanagawa N, Wang A, Shih W, Xu J, Dalby M, Nitta H, To C, Liu N, Sykes J, Tsao MS. EGFR mutation-specific immunohistochemical antibodies in lung adenocarcinoma. Histopathology 2013 Nov 20. doi: 10.1111/his. 12331 [Epub ahead of print].

13. Dodbiba L, Teichman J, Fleet A, Thai H, Sun B, Panchal D, Patel D, Tse A, Chen Z, Faluyi OO, Renouf DJ, Girgis H, Bandarchi B, Schwock J, Xu W, Bristow RG, Tsao MS, Darling GE, Ailles LE, El-Zimaity H, Liu G. Primary exophageal and gastro-esophageal junction cancer xenograft models: clinicopathological features and engraftment. Lab Invest. 2013 Apr;93(4):397-407..

14. Allo G, Bandarchi B, Yanagawa N, Wang A, Shih W, Xu J, Dalby M, Nitta H, To C, Liu N, Sykes J, Tsao MS. Epidermal growth factor receptor mutation-specific immunohistochemical antibodies in lung adenocarcinoma. Histopathology 2014 May;64(6):826-39. doi: 10.1111/his. 12331. Epub 2014 Jan 29.

15. Dodbiba L, Teichman J, Fleet A, Thai H, Starmans MH, Navab R, Chen Z, Girgis H, Eng L, Espin-Garcia O, Shen X, Bandarchi B, Schwock J, Tsao MS, El-Zimaity H, Der SD, Xu W, Bristow RG, Darling GE, Boutros PC, Ailles LE, Liu G. Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers. PLoS One. 2015

16. Navab R, Strumpf D, To C, Pasko E, Kim KS, Park CJ, Hai J, Liu J, Jonkman J, Barczyk M, Bandarchi B, Wang YH, Venkat K, Ibrahimov E, Pham NA, Ng C, Radulovich N, Zhu CQ, Pintilie M, Wang D, Lu A, Jurisica I, Walker GC, Gullberg D, Tsao MS. Integrin α11β1 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer. Oncogene. 2016 Apr 14;35(15):1899-908. Epub 2015 Jul 6.

17. Kim BR, Van de Laar E, Cabanero M, Tarumi S, Hasenoeder S, Wang D, Virtanen C, Suzuki T, Bandarchi B, Sakashita S, Pham NA, Lee S, Keshavjee S, Waddell TK, Tsao MS, Moghal N. SOX2 and PI3K cooperate to induce and stabilize a squamous-committed stem cell injury state during lung squamous cell carcinoma pathogenesis. PLoS Biol. 2016 Nov 23;14(11):e1002581.

Danh Tran-Thanh

1. Tran-Thanh D, Buttars S, Wen Y, Wilson C, Done SJ. Cyclooxygenase-2 inhibition for the prophylaxis and treatment of preinvasive breast cancer in a her-2/neu mouse model. Cancer Prev Res (Phila) 2010 Feb;3(2):202-11.

2. Tran-Thanh D, Done SJ. The role of stromal factors in breast tumorigenicity. Am J Pathol 2010 Mar;176(3):1072-4.

3. Sridhar SS, Hotte SJ, Chin JL, Hudes GR, Gregg R, Trachtenberg J, Wang L, Tran-Thanh D, Pham NA, Tsao MS, Hedley D, Dancey JE, Moore MJ. A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am J Clin Oncol 2010 Dec:33(6):609-13.

4. Tran-Thanh D, Arneson NC, Pintillie M, Deliallisi A, Warren KS, Bane A, Done SJ. Amplification of the prolactin receptor gene in mammary lobular neoplasia. Breast Cancer Res Treat 2011 Jul;128(1):31-40.

5. Wang C, Tran-Thanh D, Moreno JC, Cawthorn TR, Jacks LM, Wang DY, McCready DR, Done SJ. Expression of Abl interactor 1 and its prognostic significance in breast cancer: A tissue-array-based investigation. Breast Cancer Res Treat 2011 Sep;129(2):373-86.

6. Ouellet V, Mourskaia A, Tiedemann K, Fong J,Tran-Thanh D, Amir E, Clemons M, Perbal B, Komorova S, Siegel PM. CCN3 impairs osteoblast and stimulates osteoclast differentiation to favour breast cancer metastasis to bone. Am J Pathol. 2011 May;178(5):2377-88.

7. Cawthorn TR, Moreno JC, Dharsee M, Tran-Thanh D, Ackloo S, Zhu PH, Sardana G, Chen J, Kupchak P, Jacks LM, Miller NA, Youngson BJ, Iakovlev V, Guidos CJ, Vallis KA, Evans KR, McCready D, Leong WL, Done SJ. Proteomic analyses reveal high expressin of decorin and endoplasmin (HSP90B10 are associated with breast cancer metastasis and decreased survival. PLoS One 2012;7(2):e30992.

8. Xu C, Tran-Thanh D, Ma C, May K, Jung J, Vecchiarelli J, Done SJ. Mitochondrial D310 mutations in the early development of breast cancer. Br J Cancer 2012 Apr 24;106(9):1506-11,

9. Renouf DJ, Tang PA, Hedley D,Chen E, Kamel-Reid S, Tsao MS, Tan-Thanh D, Gill S, Dhani N, Au HJ, Wang L, Moore MJ. A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer. Eur J Can cer 2014 Jul;50(11):1909-15.

10. Cutz JC, Craddock KJ, Torlakovic E, Brandao G, Carter RF, Bigras G, Deschenes J, Izevbaye I, Xu Z, Greer W, Yatabe Y, Ionescu D, Karsan A, Jung S, Fraser RS, BLumenkrantz M, Lavoie J, Fortin F, Bojarski A, Cote GB, van den Berghe JA, Rashid-Kolvear F, Trotter M, Sekhon HS, Albadine R, Tran-Thanh D, Gorska I, Knoll JH, Xu J, Blencowe B, Iafrate AJ, Hwang DM, Pintilie M, Gaspo R, Couture C, Tsao MS. Canadian anaplastic lymphoma kinase study: a model for multicenter standardization and optimization of ALK testing in lung cancer. J Thorac Oncol 2014 Sep;9(9):1255-83.

11. Xu C, Tran-Thanh D, Ma C, May K, Jung J, Vecchiarelli J, Done SJ. Mitochondrial D310 mutations in the early development of breast cancer Br J Cancer 2012 Apr 24;106(9):1506-11.

12. Trop I, LeBlanc SM, David J, Lalonde L, Tran-Thanh D, Labelle M, El Khoury MM. Molecular classification of infiltrating breast cancer: toward personalized therapy. Radiographics 2014 Sep-Oct;34(5):1178-95.

13. El Khoury M, Tran-Thanh D, Terrone D, David J, Lalonde L, Trop I. Case 201: glomus tumor of the breast. Radiology 2015 Jan;270(1):302-6.

14. Abdalla M, Tran-Thanh D, Moreno J, Iakovlev V, Nair R, Kanwar N, Abdalla M, Lee JPY, Kwan JYY, Cawthorn TR, Warren K, Arneson N, Wang DY, Fox NS, Youngson BJ, Miller NA, Easson AM, McCready D, Leong WL, Boutros PC, Done SJ. Mapping genomic and transcriptomic alterations spatially in epithelial cells adjacent to human breast carcinoma. Nat Commun. 2017 Nov 1;8(1):1245.

Marina Pacheco

1. Jagdis A, Rubin BP, Tubbs RR, Pacheco M, Nielsen TO. Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcoma. Am J Surg Pathol 2009 Dec;33(12):1743-51.

2. Cheng H, Clarkson PW, Gao D, Pacheco M, Wang Y, Nielsen TO. Therapeutic antibodies targeting CSF1 impede macrophage recruitment in a xenograft model of tenosynovial giant cell tumor. Sarcoma 2010:174528. Epub 2010 Oct 13.

3. McPherson A, Hormozdiari F, Zaed A, Giuliany R, Ha G, Sun MG, Griffith M, Heravi Moussavi A, Senz J, Melnyk M, Pacheco M, Marra MA, Hirst M, Nielsen TO, Sahinalp SC, Huntsman D, Shah SP. deFuse: an algorithm for gene fusion discovery in tumor RDA-Seq data. Plos Comput Biol. 2011 May;7(5):e1001138.

4. Pacheco M, Nielsen TO. Histone deacetylase 1 and 2 in mesenchymal tumors. Mod Pathol 2012 Feb;25(2):222-30.

5. Su L, Sampaio AV, Jones KB, Pacheco M, Goytain A, Lin S, Poulin N, Yi L, Rossi FM, Kast J, Capecchi MR, Underhill TM, Nielsen TO. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer Cell 2012 Mar 20;21(3):333-47.

Naoki Yanagawa

1. Wei Y, Tong J, Taylor P, Strumpf D, Ignatchenko V, Pham NA, Yanagawa N, Liu G, Jurisica I, Shepherd FA, Tsao MS, Kislinger T, Moran MF. Primary tumor xenografts of human lung adeno and squamous cell carcinoma express distinct proteomic signatures. J Proteome Res. 2011 Jan 7;10(1):161-74.

2. John T, Kohler D, Pintilie M, Yanagawa N, Pham N-A, Li M, Panchal D, Hui F, Meng F, Shepherd FA, Tsao M-S. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early stage non-small cell lung cancer. Clinical Cancer Research 2011 Jan1;17(1):134-41.

3. Allen TD, Zhu CQ, Jones KD, Yanagawa N, Tsao M-S, J. Bishop M. Interaction between MYC and MCL1 in the genesis and outcome of non-small lung cancer. Cancer Research 2011 Mar 15;71(6):2212-21.

4. Yanagawa N, Leduc C, Kohler D, Saieg M, John T, Sykes J, Yoshimoto M, Pintilie M, Squire J, Shepherd FA, Tsao MS. Loss of phosphate and tensin homolog (PTEN) protein expression is an independent prognostic marker in lung adenocarconoma. Journal of Thoracic Oncology 2012 Oct;7(10):1513-1521.

5. Yanagawa N, Wang A, Kohler D, da Cunha Santos G, Sykes J, XU J, Pintilie M, Tsao MS. Human papilloma virus (HPV) genome is rare and P16 immunostaining is not a marker for its presence in North American non-small cell lung carcinoma patients. Lung Cancer 2013 Mar;79(3):215-20

6. John T, Yanagawa N, Kohler D, Craddock KJ, Bandarchi-Chamkhaleh B, Pintilie M, Sykes J, To C, Li M. Panchal D, Chen W, Shepherd FA, Tsao MS. Characterization of lymphomas developing in innunodeficient mice implanted with primary human non-small cell lung cancer. J Thorac Oncol 2012 7(7)1101-8.

7. Allo G, Bandarchi B, Yanagawa N, Wang A, Shih W, Xu J, Dalby M, Nitta H, To C, Liu N, Sykes J, Tsao MS. EGFR mutation-specific immunohistochemical antibodies in lung adenocarcinoma. Histopathology 2014 May;64(6):826-39. doi: 10.1111/his.12331. Epub 2014 Jan 29.

8. Li L, Wei Y, To C, Zhu CQ, Tong J, Pham NA, Taylor P, Ignatchenko V, Ignatchenko A, Zhang W, Wang D, Yanagawa N, Li M, Pintilie M, Liu G, Muthuswamy L, Shepherd FA, Tsao MS, Kislinger T, Moran MF. Integrated Omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact. Nat Commun 2014; Nov 28;5:5469.

9. Stewart EL, Mascaux C, Pham NA, Sakashita S, Sykes J, Kim L, Yanagawa N, Allo G, Ishizawa K, Wang D, Zhu CQ, Li M, Ng C, Liu N, Pintilie M, Martin P, John T, Jurisica I, Leighl NB, Neel BG, Waddell TK, Shpherd FA, Liu G, Tsao MS. Clinical utility of patient-derived xenografts to determine biomarkers of prognosis and map resistance pathways in EGFR-mutant lung adenocarcinoma. J Clin Oncol 2015 Aug 1;33(22):2472-80. Epub 2015 Jun 29.

10. Wang D, Pham NA, Tong J, Sakashita S, Allo G, Kim L, Yanagawa N, Raghavan V, Wei Y, To C, Trinh QM, Starmans MH, Chan-Seng-Yue MA, Chadwick D, Li L, Zhu CQ, Liu N, Li M, Lee S, Ignatchenko V, Strumpf D, Taylor P, Moghal N, Liu G, Boutros PC, Kislinger T, Pintilie M, Jurisica I, Shepherd FA, McPherson JD, Muthuswamy L, Moran MF, Tsao MS. Molecular heterogenetity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors. Int J Cancer. 2017 Feb 1;140(3):662-673. Epub 2016 Nov 7.

Lucia Kim

1. Kim L, Tsao MS. Tumor tissue sampling for lung cancer management in the era of personalized therapy: what is good enough for molecular testing? Eur Resp J 2014;44:754-764.

2. Stewart EL, Mascaux C, Pham NA, Sakashita S, Sykes J, Kim L, Yanagawa N, Allo G, Ishizawa K, Wang D, Zhu CQ, Li M, Ng C, Liu N, Pintilie M, Martin P, John T, Jurisica I, Leighl NB, Neel BG, Waddell TK, Shepherd FA, Liu G, Tsao MS. Clinical utility of patient-derived xenografts to determine biomarkers of prognosis and map resistance pathways in EGFR-mutant lung adenocarcinoma. J Clin Oncol 2015 Aug 1;33(22):2472-80.

3. Martin P, Stewart E, Pham NA, Mascaux C, Panchal D, Li M, Kim L, Sakashita S, Wang D, Sykes J, Friess T, Shepherd FA, Liu G, Tsao MS. Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model. Clin Lung Cancer 2016 Jan 22 pii: S1525-7304(16)00005-X. doi: 10.1016/j.cllc.2016.01.002. [Epub ahead of print].

4. Sacher AG, Le LW, Lara-Guerra H, Waddell TK, Sakashita S, Chen Z, Kim L, Zhang T, Kamel-Reid S, Salvarrey A, Darling G, Yasufuku K, Keshavjee S, De Perrot M, Shepherd FA, Liu G, Tsao M, Leighl NB. A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer. Oncotarget. 2016 Mar 25. doi: 10.18632/oncotarget.8350. [Epub ahead of print]

5. Wang D, Pham NA, Tong J, Sakashita S, Allo G, Kim L, Yanagawa N, Raghavan V, Wei Y, To C, Trinh QM, Starmans MH, Chan-Seng-Yue MA, Chadwick D, Li L, Zhu CQ, Liu N, Li M, Lee S, Ignatchenko V, Strumpf D, Taylor P, Moghal N, Liu G, Boutros PC, Kislinger T, Pintilie M, Jurisica I, Shepherd FA, McPherson JD, Muthuswamy L, Moran MF, Tsao MS. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors. Int J Cancer. 2017 Feb 1;140(3):662-673.

6. Kim L, Saieg M, Di Maio M, Gallo C, Butts C, Ciardiello F, Feld R, Cheng D, Gebbia V, Burgio MA, Alam Y, Signoriello S, Rossi A, Leighl N, Maione P, Morabito A, Liu G, Tsao MS, Perrone F, Gridelli C. Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients. Oncotarget. 2017 Feb 25;8(34):57528-57536.

7. Leighl NB, Tsao MS, Liu G, Tu D, Ho C, Shepherd FA, Murray N, Goffin JR, Nicholas G, Sakashita S, Chen Z, Kim L, Powers J, Seymour L, Goss G, Bradbury PA. A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND. 196. Oncotarget. 2017 Jun 28;8(41):69651-69662.

8. Brana I, Pham NA, Kim L, Sakashita S, Li M, Ng C, Wang Y, Loparco P, Sierra R, Wang L, Clarke BA, Neel BG, Siu LL, Tsao MS. Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts. Oncotarget. 2017 Jul 8;8(49):84659-84670.

Derek Kohler

1. John T, Kohler D, Pintilie M, Yanagawa N, Pham N, Li M, Panchal D, Hui F, Meng F, Shpherd FA, Tsao M. The ability to form primary tumor xenografts is predictive if increased risk of disease recurrence in early stage non-small cell lung cancer. Clin Cancer Res. 2011 Jan 1;17(1):134-41.

2. John T, Yanagawa N, Kohler D, Craddock KJ, Bandarchi-Chamkhaleh B, Pintilie M, Sykes J, To C, Li M, Panchal D, Chen W, Shepherd FA, Tsao MS. Characterization of lymphomas developing in immunodeficient mice implanted with primary human non-small cell lung cancer. Thorac Oncol. 2012 Jul;7(7):1101-8.

3. Yanagawa N, Leduc C, Kohler D, Saieg M, John T, Sykes J, Yoshimoto M, Pintilie M, Squire J, Shepherd FA, Tsao MS. Loss of phosphate and tensin homolog (PTEN) protein expression is an independent prognostic marker in lung adenocarcinoma. Journal of Thoracic Oncology 2012 Oct;7(10):1513-1521.

4. Yanagawa N, Wang A, Kohler D, da Cunha Santos G, Sykes J, Xu J, Pintilie M, Tsao MS. Human papilloma virus (HPV) genome is rare and P16 immunostaining is not a marker for its presence in North American non-small cell lung carcinoma patients. Lung Cancer 2013 Mar;79(3):215-20.

Osama M. Al-Agha

1. Wiegand KC, Sohrab, Shah P, Al-Agha OM, Zhao Y, Tse K, Zeng T, Janine Senz, B.Sc., McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJM, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA,, Shih, Mes-Masson A-M, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG. ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas. NEJM September 2010 Oct 14;363(16):1532-43.

2. Al-Agha OM, Huwait HF, Chow C, Yang W, Senz J, Kalloger SE, Huntsman DG, Young RH, Gilks CB. FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary. Am J Surg Pathol. 2011 Apr;35(4):484-94. doi:10.1097/PAS.0b013e31820a406c.

3. Wlegand KC, Lee AF, Al-Agha OM, Chow C, Kalloger SE, Scott DW, Steidl C, Wisemen SM, Gascoyne RD, Gilks B, Huntsman DG. Loss of BAF250a (AR11A) is frequent in high-grade endometrial carcinoma. J Pathol 2011 Jul;224(3):328-33.

Clarissa Araujo Cassol

1. Cassol CA, Guo M, Ezzat S, Asa SL. GNAq mutations are not identified in papillary thyroid carcinomas and hyperfunctioning thyroid nodules. Endocr Pathol 2010. Dec;21(4):250-2.

2. Cassol CA, Noria D, Asa SL. Ectopic thyroid tissue within the gall bladder: Case report and brief review of the literature. Endocr Pathol 2010. Dec 21(4):263-5.

3. Cassol CA, Asa SL. Molecular Pathology of Thyroid. Diagnostic Histopathology 2011;17(3):124-139.

4. Wei W, Lu W, Cassol C, Zheng W, Asa SL, Ezzat S. The Breast Cancer. The breast cancer susceptibility gene product fibroblast growth factor receptor 2 serves as a scaffold for regulation of NF-κB signaling. Mol Cell Biol. 2012 Nov;32(22):4662-73. doi: 10.1128/MCB.00935-12. Epub 2012 Sep 17.

5. Erovic BM, Kim D, Cassol C, Goldstein DP, Irish JC, Asa SL, Mete O. Prognostic and predictive markers in medullary thyroid carcinoma. Endocr Pathol. 2012 Dec;23(4):232-42. doi: 10.1007/s12022-012-9225-8.

6. Chui MH, Cassol CA, Asa SL, Mete O. Follicular epithelial dysplasia of the thyroid: morphological and immunohistochemical characterization of a putative preneoplastic lesion to papillary thyroid carcinoma in chronic lymphocytic thyroiditis. Virchows Arch. 2013 May;462(5):557-63. doi: 10.1007/s00428-013-1397-1. Epub 2013 Mar 27.

7. Cassol CA, Winer D, Liu W, Guo M, Ezzat S, Asa SL. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas. Mod Pathol. 2014 Jan 3. doi: 10.1038/modpathol.2013.233. [Epub ahead of print].

8. Cassol CA, Winer D,Liu W, Guo M, Exxat S, Asa SL. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas. Mod Pathology 2014 Aug;27(8):1050-62.

9. Wei W, Liu W, Cassol CA, Zheng W, Asa SL, Ezzat S. Retraction for Wei et al., “The breast cancer susceptibility gene product fibroblast growth factor receptor 2 serves as a scaffold for regulation of NF-κB Signaling Mol Cell Biol. 2018 Jul 30;38(16). Print 2018 Aug 15.

Juan Moreno

1. Wang C, Tran-Thanh D, Moreno JC, Cawthorn TR, Jacks LM, Wang DY, McCready DR, Done SJ. Expression of Abl interactor 1 and its prognostic significance in breast cancer: A tissue-array- based investigation. Breast Cancer Res Treat 2011 Sep;129(2):373-86. doi: 10.1007/s10549-010-1241-0. Epub 2010 Nov 3.

2. Cawthorn TR, Moreno JC, Dharsee M, Tran-Thanh Danh, Ackloo S, Zhu PH, Sardana G, Chen J, Kupchak P, Jacks LM, Leong W, McCready D, Evans KR, Miller NA, Youngson BJ, Iakovlev V, Done SJ. Proteomic analyses reveal high expression of decorin and endoplasmin (HSP90B10 are associated with breast cancer metastasis and decreased survival. PLosOne 2012;7(2):e30992. Epub 2012 Feb 20.

3. Arneson N, Moreno J, Iakovlev V, Ghazani A, Warren K, McCready D, Jurisica I. Comparison of whole genome amplification methods for analysis of DNA extracted from microdissected early breast lesions in formalin fixed paraffin embedded tissue. ISRN Oncol 2012;2012:710692.

4. Chio II, Sasaki M, Ghazarian D, Moreno J, Done S, Ueda T, Inoue S, Chang YL, Chen NJ, Mak TW. TRADD contributes to tumour suppression by regulating ULF-dependent p19Arf ubiquitylation. Nat Cell Biol. 2012 May 6;14(6):625-33. doi: 10.1038/ncb2496.

5. Quail D, Zhang G, Walsh L, Broughton H, Moreno J, Lewis J, Done S, Hess DA, Postovit L-M. Empbyonic protein nodal promotes breast cancer vascularizatin. Cancer Res 2012 Aug 1;72(15):3851-3863.

6. Harris IS, Blaser H, Moreno J, Treloar AE, Gorrini C, Sasaki M, Mason JM, Knobbe CB, Rufini A, Hallé M, Elia AJ, Wakeham A, Tremblay ML, Melino G, Done S, Mak TW. PTPN12 promotes resistance to oxidative stress and supports tumorigenesis by regulating FOXO signaling. Oncogene. 2014 Feb 20;33(8):1047-54. doi: 10.1038/onc.2013.24. Epub 2013 Feb 25.

7. Abdalla M, Tran-Thanh D, Moreno J, Iakovlev V, Nair R, Kanwar N, Abdalla M, Lee JPY, Kwan JYY, Cawthorn TR, Warren K, Arneson N, Wang DY, Fox NS, Youngson BJ, Miller NA, Easson AM, McCready D, Leong WL, Boutros PC, Done SJ. Mapping genomic and transcriptomic alterations spatially in epithelial cells adjacent to human breast carcinoma. Nat Commun. 2017 Nov 1;8(1):1245.

Suk Jin Choi

1. Wood B, Sikdar S, Choi SJ, Virk S, Alhejaily A, Baetz T, LeBrun D. Abundant expression of interleukin-21 receptor in follicular lymphoma cells is associated with more aggressive disease. Leuk Lymphoma 2013 Jun;54(6):1212-20. doi: 10.3109/10428194.2012.742522. Epub 2012 Nov 23.

Mauro Saieg

1. da Cunha Santos G, Saieg MA, Geddie W, Leigh N. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities. Cancer Cytopathol 2011 Apr 25;119(2):80-91.

2. da Cunha Santos G, Ko HM, Saieg MA, Boerner SL, Lai SW, Bailey D, Geddie WR. Cytomorphological findings of B-cell lymphomas with concurrent IGH/BCL2 and MYC rearrangements (dual-translocation lymphomas). Cancer Cytopathol 2011 Jul;23(8):459-67.

3. Saieg MA, Geddie WR, Boerner SL, Ni Liu, Tsao M, Zhang T, Kamel-Reid S, da Cunha Santos G. The use of FTA® cards for preserving unfixed cytological material for high-throughput molecular analysis. Cancer Cytopathol 2012 Jan 25;120(3):206-14.

4. Da Cunha Santos G, Lai S, Saieg MA, Boerner S, Hwang D, Pintilie M, Tsao M, Geddie W. Cyto-histologic agreement in pathologic subtyping of non-small cell lung carcinoma: Review of 602 fine needle aspirates with follow-up surgical specimens over a nine year period and analysis of factors underlying failure to subtype. Lung Cancer 2012 Sept;77(3):501-6.

5. da Cunha Santos G, Ko H, Saieg MA, Geddie W. The petals and thorns of rose: Rapid on-site assessment. Cancer Cytopathol 2013 Jan;121(1)4-8. 6. Gridelli C, Ciardiello F, Gallo C, Feld R, Butts C, Gebbia V, Maione P, Morgillo F, Genestreti G, Favaretto A, Leighl N, Wierzbicki R, Cinieri A, Cantile F, Tsao M, Saieg MA, Da Cunha Santos G, Piccirillo M, Di Maio M, Morabito A, Perrone F. First-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small cell lung cancer. The TORCH randomized trial. J Clin Oncol. 2012 Aug 20;30(24):3002-11. doi: 10.1200/JCO.2011.41.2056. Epub 2012 Jul 9.

6. Yanagawa N, Leduc C, Kohler D, Saieg M, John T, Sykes J, Yoshimoto M, Pintilie M, Squire J, Shepherd FA, Tsao MS. Loss of phosphate and tensin homolog (PTEN) protein expression is an independent prognostic marker in lung adenocarcinoma. Journal of Thoracic Oncology 2012 Oct;7(10):1513-1521.

7. Tong LC, Ko HM, Saieg MA, Boerner S, Geddie WR, da Cunha Santos G. Subclassification of lymphoproliferative disorders in serous effusions: A 10-year experience. Cancer Cytopathol 2013 May;121(5):261-70.

8. Di Maio M, Leighl NB, Gallo C, Feld R, Ciardiello F, Butts C, Maione P, Gebbia V, Morgillo F, Wierzbicki R, Favaretto A, Alam Y, Cinieri S, Siena S, Bianco R, Riccardi F, Spatafora M, Ravaioli A, Felletti R, Fregoni V, Genestreti G, Rossi A, Mancuso G, Fasano M, Morabito A, Tsao MS, Signoriello S, Perrone F, Gridelli C; TORCH Investigators. Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/germcitabine chemotherapy in advanced non-small-cell lung cancer. J Thorac Oncol. 2012 Dec;7(12):1830-44.

9. da Cunha Santos G, Ko HM, Saieg MA, Boerner SL, Lai SW, Bailey D, Geddie WR. Cytomorphologic findings of B-cell lymphoma with concurrent IGH/BCL2 and MYC rearrangements (dual-translocation lymphomas). Cancer of Cytopathology 2013 Jan;121(1)4-8.

10. Saieg MA, Geddie WR, Boerner SL, Bailey D, Crump M, da Cunha Santos G. EZH2 and CD79B mutational status over time in B-cell non-Hodgkin lymphomas detected by high-throughput sequencing using minimal samples. Cancer Cytopathol. 2013 Jul;121(7):377-86

11. Da Cunha Santos G, Saieg MA, Geddie WR, Kamel-Reid S. Cytological preparations for molecular pathology: Letter to the editor regarding Ancillary techniques on direct-smear aspirate slides: A significant evolution for cytopathology techniques. Cancer Cytopathol 2013 May;121(5):275.

12. Garady C, Saieg MA, Ko HM, Geddie WR, Boerner SL, da Cunha Santos G. Epstein-Barr virus encoded RNA detected by in situ hybridization using cytological preparations. Cytopathology 2014 Apr;25(2):101-7. doi: 10.1111/cyt.12073. Epub 2013 Jun 3.

13. Da Cunha Santos G, Saieg MA, Tsao MS. Training in molecular cytopathology. Cytopathology 2013 Jun;24(3):205-7.

14. Saieg MA, Geddie W, Boerner S, Bailey D, Crump M, da cunha Santos G. EZH2 and CD79B mutational status over time in B-cell non-Hodgkin lymphomas detected by high-throughput sequencing using minimal samples. Cancer Cytopathology 2013 Jul;121(7):377-86.

15. da Cunha Santos G, Saieg MA, Geddie WR, Kamel-Reid S. Cytological preparations for molecular pathology: Letter to the editor regarding “Ancillary techniques on direct-smear aspirate slides: a significant evolution for cytopathology techniques. Cancer Cytopathol. 2013 May;121(5):275. doi: 10.1002/cncy.21296. Epub 2013 Apr 23

16. Da cunha Santos G, Schroder M, Baoqian Zhu J, Saieg MA, Geddie W, Boerner S, McDonald S. Minimizing delays in DNA retrieval from smears for molecular cytopathology using the “freezer method” for glass coverslip removal. Cancer Cytopathology 2013 June 25 121(7)377-386.

17. Gridelli C, Ciardiello F, Gallo C, Feld R, Butts C, Gebbia V, Maione P, Morgillo F, Genestreti G, Favaretto A, Leighl N, Wierzbicki R, Clinieri A, Cantile F, Tsao M, Saieg MA, da Cunha Santos G, Piccirillo M, Di Maio M, Morabito A, Perrone F. First-line erlotinib followed by second-line cisplatin/germcitabine chemotherapy in advanced non-small cell lung cancer. The TORCH randomized trial. Journal of Clinical Oncology 2012 Aug 20;30(24);3002-11.

18. da Cunha Santos G, Schroder M, Baoqian ZJ, Saieg MA, Gedie W, Boerner S, McDonald S. Minimizing delays in DNA retrieval from smears for molecular cytopathology using the “freezer method” for glass coverslip removal. Cytopathology 2013 Sep;121(9):533.

19. da Cunha Santos G, Saieg MA, Ko H, Geddie W, Boerne S, Craddock K, Crump M, Bailey D. Multiplex sequencing for EXH2, CD798 and MYD88 mutations using archival cytospin preparations from b-cell non-Hodgkin lymphoma aspirates previously tested for MYC rearrangement and IGH/BCL2 translocatin. Cancer Cytopathology 2015 Jul;123(7)413-20.

20. Da Cunha Santos G, Wyeth T, Reid A, Saieg MA, Pitcher B, Pintilie M, Kamel-Reid S, Tsao MS. A proposal for cellularity assessment for EGFR mutational analysis with a correlation with DNA yield and evaluation of the number of sections obtained from cell blocks for immunohistochemistry in non-small cell lung carcinoma. J Clin Pathol 2016 Jul;69(7)607-11.

21. da Cunha Santos G, Wieth T, Reid A, Saieg MA, Pitcher B, Pintilie M, Kamel-Reid S, Tsao M. A proposal for cellularity assessment for EGFR mutational analysis with a correlation with DNA yield and evaluation of the number of sections obtained from cell blocks for immunohistochemistry in non-small cell lung carcinoma. Journal of Clinical Pathology 2016 Jan 5.

22. Ko HM, Saieg MA, da Cunha Santos G, Kamel-Reid S, Boerner SL, Geddie WR. Use of cytological samples of metastatic melanoma for ancillary studies. Cytopathology. 2017 Jun;28(3):221-227. Epub 2017 Feb 20.

23. da Cunha Santos G, Saieg MA Preanalytic specimen triage: Smears, cell blocks, cytospin preparations, transport media, and cytobanking. Cancer Cytopathol. 2017 Jun;125(S6):455-464.

24. da Cunha Santos G, Saieg MA, Troncone G, Zeppa P. Cytological preparations for molecular analysis: A review of technical procedures, advantages and limitations for referring samples for testing. Cytopathology. 2018 Apr;29(2):125-132

Charles Leduc

1. Yanagawa N, Leduc C, Kohler D, Saieg M, John T, Sykes J, Yoshimoto M, Pintilie M, Squire J, Shepherd FA, Tsao MS. Loss of phosphate and tensin homolog (PTEN) protein expression is an independent prognostic marker in lung adenocarcinoma. Journal of Thoracic Oncology 2012 Oct;7(10):1513-1521.

2. Nagaria TS, Williams JL, Leduc C, Squire JA, Greer PA, Sangrar W. Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems. Neoplasia. 2013 Aug;15(8):939-51.

3. Leduc C, Pacheco-Bladino I, Squire J, Farmer P, Good D, LeBrun D. Composite mantle cell and primary cutaneous anaplastic large cell lymphoma: case and review of the literature. American Journal of Dermatopathology; Am J Dermatopathol. 2015 Mar;37(3):232-6

David Scott

1. Sehn LH, Scott DW, Chbanabhai M, Berry B, Ruskova A, Berkahn L, Connors JM, Gascoyne RD. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2011Apr 10;29(11):1452-7. Epub 2011 Mar 7.

2. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbert RD, Johnson NA, Severson TM, Chiu R, Field M, Jackman S, Krzywinski M, Scott DW, Trinh DL, Tamura-Wells J, Li S, Firme MR, Rogic S, Griffith M, Chan S, Yakovenko O, Meyer IM, Zhao EY, Smailus D, Moksa M, Chittarangan S, Rimsza L, Brooks-Wilson A, Spinelli JJ, Ben-Neriah S, Meissner B, Woolcock B, Boyle M, McDonald H, Tam A, Zhao Y, Delaney A, Zeng T, Tse K, Butterfield Y, Birol I, Holt R, Schein J, Horsman DE, Moore R, Jones SJ, Connors JM, Hirst M, Gascoyne RD, Marra MA. Frequent mutation of histo-modifying genes in non-Hodgkin lymphoma. Nature 2011 Jul 27;476(7360):298-303.

3. WIegand KC, Lee AF, Al-Agha OM, Chow C, Kalloger SE, Scott DW, Steidl C, Wisemen SM, Gasocyne RD, Gilks B, Huntsman DG. Loss of BAF250a (ARI1A) is frequent in high-grade endometrial carcinomas. J Pathol 2011 Jul;224(3):328-33. doi: 10.1002/path.2911. Epub 2011 May 18.

4. Schueltz JM, Johnson NNA, Morin RD, Scott DW, Tan K, en-Neriah S, Boyle M, Slack GW, Marra MA, Connors JM, Brooks-Wilson AR, Gascoyne RD. BCL2 mutations in diffuse large B-cell lumphoma. Leukemia Advance online publication. January 13, 2012; doi: 10.1038.

5. Bashashati A, Johnson NA, Khodabakhshi AH, Whiteside MD, Zare H, Scott DW, Lo K, Gottardo R, Brinkman FSL, Connors JM, Slack GW, Gascoyne RD, Weng AP, Brinkman RR. B-cells with high side scatter parameter by flow cytometry correlate with inferior survival in diffuse large B cell lymphoma. Am J Clin Path 2012; 137:805-814.

6. Gascoyne RD, Scott DW, Steidl C. Molecular pathology of Hodgkin's lymphoma: prognostic implications. Hematology Association 20126:165-174.

7. Scott DW, Mungall KL, en-Neriah S, Rogic S, Morin RD, Slack GW, Tan KL, Cahn FC, Lim RS, Connors JM, Marra MA, Mungall Aj, Steidl C, Gascoyne RD. TBL1XR1/TP63 – A novel recurrent gene fusion in B-cell non-Hodgkin lymphoma. Blood 2012; 119:4949-4952.

8. Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Sehn LH, Chan WC, Iqbal J, Meyer PN, Penz G, Wright G, Rimza LM, Valentino C, Brunhoeber P, Grogan TM, Braziel RM, Cook JR, Tubbs RR, Weisenburger DD, Campo E, Rosenwald R, Ott G, Delabie J, Holcroft C, Jeffe ES, Staudt LM, Gascoyne RD. Concurrent epression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamde, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012 Oct 1;30(28):3452-9. Epub 2012 Jul 30.

9. Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL, Advani RH, Buckstein R, Rimsza LM, Connors JM, Steidl C, Gordon LI, Horning SJ, Gascoyne RD. Tumor-associated macrophages predict inferior outcomes inclassical Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood 2012 Oct 18;120(16):3280-7. doi: 10.1182/blood-2012-04-421057. Epub 2012 Sep 4.

10. Scott DW, Chan FC, Hong F, Rogic S, Tan KL, Meissner B, Ben-Neriah S, Boyle M, Kridel R, Telenius A, Woolcock BW, Farinha P, Fisher RI, Rimsza LM, Bartlett NL, Cheson BD, Shepherd LE, Advani RH, Connors JM, Kahl BS, Gordon LI, Horning SJ, Steidl C, Gascoyne RD. A gene expression-based model using formalin fixed paraffin-embedded biopsies predicts overall survival in advanced state classical Hodgkin lymphoma. J Clin Oncol 2012 Nov 26. [Epub ahead of print].

11. Meissner B, Kridel R Lim RS, Rogic S, Tse K, Scott DW, Moore R, Mungall AJ, Marra MA, Connors JM, Steidl C, Gascoyne RD. The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. Blood 2013 Apr 18;121(16):3161-4.

12. Trinh DL, Scott DW, Morin RD, Mendez-Lago M, An J, Jones SJ, Mungall AJ, Zhao Y, Schein J, Steidl C, COnnors JM, Gascoyne RD, Marra MA. Analysis of FOX01 mutations in diffuse large B-cell lymphoma. Blood 2013 May 2;121(18):3666-74.

13. Begulin W Popovic R, Teater m, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SN, Wang L, Ezponda T, Martinez-Garcia E, Zhang H, Zheng Y, Verma SK. McCabe MT, Ott HM, Van Aller GS, Kruger RG, Liu Y, McHugh CF, Scott DW, Chung YR. Kelleher N, Shaknovich R, Creasy CL, Gascoyne RD. Wong KK, Cerchietti L, Levine RL, Abdel-Wahab O, Oicht JD, Elemento O, Melnick AM. EZH2 is required for geminal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013 May 13;23(5):677-92.

14. Morin RD, Mungall K. Pleasance E, Mungall AJ, Goya R, Huff RD, Scott DW, Ding J, Roth A, Chiu R, Corbett RD, Chan FC, Mendez-Lago M, Trinh DL, Bolger-Munro M, Taylor G, Hadj Khodabakhshti A, Ben-Neriah S, Pon J, Meissner B, Woolcock B, Farnoud N, Rogic S, Lim EL, Johnson NA, Shah S, Jones S. Steidl C, Holt R, Birol I, Moore R, Connors JM, Gascoyne RD, Marra MA. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood 2013 Aug 15;122(7):1256-65.

15. Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW, Wyman S, Leser M, Shaknovich R, Chadburn A, Tabbo F, Godley LA, Gascoyne RD, BordenKL, Inghirami G, Leonard JP, Melnick A, Cerchietti L. Mechanism-based epigenetic chemosenisitization therapy of diffuse large B-cell lymphoma. Cancer Discov. 2013 Sept;3(9):1002-19.

16. Chambwe N, Kormaksson M, Geng H, De S, Michor F, Johnson NA, Morin RD, Scott DW, Godley LA, Gascoyne RD, Melnick A, Champagne F, Shaknovich R. Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood 2014 Mar 13;123(11):1699-708

17. Scott DW, Wright GW, Williams PM, Lih CJ, Walsh W, Jaffe ES, Rosenwald A, Campo E, Chan WC, Connors JM, Smeland EB, Mottok A, Braziel RM, Ott G, Delabie J, Tubbs RR, Cook JR, Weisenburger DD, Greiner TC, Glinsmann-Gibson BJ, Fu K, Staudt LM, Gascoyne RD, Rimsza LM. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 2014 Feb 20;123(8):1214-7.

18. Twa DD, Chan FC, Ben-Neriah S, Woolcock BW, Mottok A, Tan KL, Slack GW, Gunawardana J, Lim RS, McPherson AW, Kridel R, Telenius A, Scott DW, Savage KJ, Shah SP, Gascoyne RD, Steidl C. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 2014 Mar 27;123(13):2062-5.

19. Scott DW, Gascoyne RD. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer 2014 Aug;14(8):517-34.

20. Zhang S, Liu H, Chuang CL, Li X, AU M, Zhang L, Phillips ARJ, Scott DW, Cooper GJS. The pathogenic mechanism of diabetes varies with the degree of overexpression and oligomerization of human amylin in the pancreatic islet β cells. FASEB J 2014 Dec;28(12):5083-96.

21. Scott DW, Steidl C. The classical Hodgkin lymphoma tumor microenvironment: macrophages and gene expression-based modeling. Hematology Am Soc Hematol Educ Program 2014. In press.

23. Chan FC, Telenius A, Healy S, Ben-Neriah S, Mottok A, Lim R, Drake M, Hu S, Ding J, Ha G, Scott DW, Kridel R, Bashashati A, Rogic S, Johnson N, Morin RD, Rimsza LM, Sehn L, Connors JM, Marra MA, Gascoyne RD, Shah SP, Steidl C. An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup. Blood. 2015 Feb 5;125(6):959-66. doi: 10.1182/blood-2013-06-507152. Epub 2014 Nov 13.

24. Twa DD, Mottok A, Chan FC, Ben-Neriah S, Woolcock BW, Tan KL, Mungall AJ, McDonald H, Zhao Y, Lim RS, Nelson BH, Milne K, Shah SP, Morin RD, Marra MA, Scott DW, Gascoyne RD, Steidl C. Recurrent genomic rearrangements in primary testicular lymphomas. J Pathol. 2015 Jun;236(2):136-41. doi: 10.1002/path.4522. Epub 2015 Mar 26.

25. Lim EL, Trinh DL, Scott DW Chu A, Krzywinski M, Zhao Y, Robertson AG, Mungall AJ, Schein J, Boyle M, Mottok A, Ennishi D, Johnson NA, Steidl C, Connors JM, Morin RD, Gascoyne RD, Marra MA. Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients. Genome Biol. 2015 Jan 29;16:18. doi: 10.1186/s13059-014-0568-y.

26. Béguelin W, Sawh S, Chambwe N, Chan FC, Jiang Y, Choo JW, Scott DW, Chalmers A, Geng H, Tsikitas L, Tam W, Bhagat G, Gascoyne RD, Shaknovich R. IL10 receptor is a novel therapeutic target in DLBCLs. Leukemia. 2015 Aug;29(8):1684-94. doi: 10.1038/leu.2015.57. Epub 2015 Mar 3.

27. Scott DW. Cell-of-origin in difuse large B-cell lymphoma: are the assays ready for clinic? Am Soc Clin Oncol Educ Book 2015;35:e458-66. PMID: 2599210.

28. Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, Kridel R, Barry GS, Hother C, Abrisqueta P, Boyle M, Meissner B, Telenius A, Savage KJ, Sehn LH, Slack GW, Steidl C, Staudt LM, Connors JM, Rimsza LM, Gascoyne RD. Prognostic significance of diffuse large B-cell lymphoma cell of origin deteremined by digital gene expression in formalin-fixed araffin-embedded tissue biopsies. J Clin Oncol. 2015 Sep 10;33(26):2848-56. doi: 10.1200/JCO.2014.60.2383. Epub 2015 Aug 3.

29. Kridel R, Mottok A, Farinha P, Ben-Neriah S, Ennishi D, Zheng Y, Chavez EA, Shulha HP, Tan K, Chan FC, Boyle M, Meissner B, Telenius A, Sehn LH, Marra MA, Shah SP, Steidl C, Connors JM, Scott DW, Gascoyne RD. Cell of origin of transformed follicular lymphoma. Blood. 2015 Oct 29;126(18):2118-27. doi: 10.1182/blood-2015-06-649905. Epub 2015 Aug 25.

30. Ortega-Molina A, Boss IW, Canela A, Pan H, Jiang Y, Zhao C, Jiang M, Hu D, Agirre X, Niesvizky I, Lee JE, Chen HT, Ennishi D, Scott DW, Mottok A, Hother C, Liu S, Cao XJ, Tam W, Shaknovich R, Garcia BA, Gascoyne RD, Ge K, Shilatifard A, Elemento O, Nussenzweig A, Melnick AM, Wendel HG. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nat Med. 2015 Oct;21(10):1199-208. doi: 10.1038/nm.3943. Epub 2015 Sep 14.

31. Kendrick S, Tus K, Wright G, Jaffe ES, Rosenwald A, Campo E, Chan WC, Connors JM, Braziel RM, Ott G, Delabie J, Cook JR, Weisenburger DD, Greiner TC, Fu K, Staudt LM, Gascoyne RD, Scott DW, Rimsza LM. Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status. Leuk Lymphoma. 2015 Oct 5:1-4. [Epub ahead of print]

32. Mottok A, Woolcock B, Chan FC, Tong KM, Chong L, Farinha P, Telenius A, Chavez E, Ramchandani S, Drake M, Boyle M, Ben-Neriah S, Scott DW, Rimsza LM, Siebert R, Gascoyne RD, Steidl C. Genomic alterations in CIITA are frequent in primary mediastinal large B cell lymphoma and are associated with diminished MHC class II expression. Cell Rep. 2015 Nov 17;13(7):1418-31. doi: 10.1016/j.celrep.2015.10.008. Epub 2015 Nov 5.

33. Connors JM, Savage KJ. Evaluation of the risk of relapse in classical Hodgkin lymphoa at event-free survival time points and survival comparison to the general population in British Columbia. J Clin Oncol 2016 in press

34. Savage KJ, Slack GW, Mottok A, Sehn LH, Villa D, Kansara R, Kridel R, Steidl C, Ennishi D, Tan KL, Ben-Neriah S, Johnson NA, Connors JM, Farinha P, Scott DW, Gascoyne RD. The impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood. 2016 Feb 1. pii: blood-2015-10-676700. [Epub ahead of print]

35. Hapgood G, Zheng Y, Sehn L, Villa D, Klasa R, Gerrie AS, Shenkier T, Scott DW, Gascoyne RD, Slack DW, Parsons C, Morris J, Pickles T, 1. Sehn LH, Scott DW, Chbanabhai M, Berry B, Ruskova A, Berkahn L, Connors JM, Gascoyne RD. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2011Apr 10;29(11):1452-7. Epub 2011 Mar 7

36. Talhouk A, Kommoss S, Mackenzie R, Cheung M, Leung S, Chiu DS, Kalloger SE, Huntsman DG, Chen S, Intermaggio M, Gronwald J, Chan FC, Ramus SJ, Steidl C, Scott DW, Anglesio MS. Single-patient molecular testing with nonoString nCounter data using a reference-based strategy for batch effect correction. PLoS One 2016 Apr 20;11(4)e0153844.

37. Chong LC, Twa DD, Mottok A, Ben-Neriah S, Woolcock BW, Zhao Y, Savage KJ, Marra MA, Scott DW, Gascoyne RD, Morin RD, Mungal AJ, Steidl C. Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas. Blood 2016 June 7 [Epub ahead of print].

38. Kasnara R, Villa D, Gerrie AS, Klasa R, Shenkier T, Scott DW, Slack GW, Gascoyne RD, Connors JM, Sehn LH, Savage KJ. Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model. Br J Haematol 2016 Jul 22 [Epub ahead of print]

39. Kansara R, Connors JM, Savage KJ, Gerrie AS, Scott DW, Slack GW, Gascoyne RD, Sehn LH, Villa D. Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-hodgkin lymphomas. Haematologica 2016 Jun 16 [Epub ahead of print].

40. Jiang Y, Ortega-Molina A, Geng H, Ying HY, Hatzi K, Parsa S, McNally D, Wang L, Doane AS, Agirre X, Teater M, Meydan C, Li Z, Poloway D, Wang S, Ennishi D, Scott DW, Stengel KR, Kranz JE, Holson E, Sharma S, Young JW, Chu CS, Roeder RG, Shaknovich R, Hiebert SW, Gascoyne RD, Tam W, Elemento O, Wendel HG, Melnick AM. CREBBP inactivation promotes the development of HDAC3-dependent lymphomas. Cancer Discov. 2017 Jan;7(1):38-53. Epub 2016 Oct 12.

41. Hapgood G, Pickles T, Sehn LH, Villa D, Klasa R, Scott DW, Gerrie AS, Gascoyne RD, Slack GW, Parsons C, Morris JW, Connors JM, Savage KJ.Outcome of primary cutaneous anaplastic large cell lymphoma: a 20-year British Columbia Cancer Agency experience. Br J Haematol. 2017 Jan;176(2):234-240. Epub 2016 Oct 21.

42. Kridel R, Chan FC, Mottok A, Boyle M, Farinha P, Tan K, Meissner B, Bashashati A, McPherson A, Roth A, Shumansky K, Yap D, Ben-Neriah S, Rosner J, Smith MA, Nielsen C, Giné E, Telenius A, Ennishi D, Mungall A, Moore R, Morin RD, Johnson NA, Sehn LH, Tousseyn T, Dogan A, Connors JM, Scott DW, Steidl C, Marra MA, Gascoyne RD, Shah SP. Histological transformation and progrssion in follicular lymphoma: A clonal evolution study. PLoS Med. 2016 Dec 13;13(12):e1002197.

43. Scott DW, Abrisqueta P, Wright GW, Slack GW, Mottok A, Villa D, Jares P, Rauert-Wunderlich H, Royo C, Clot G, Pinyol M, Boyle M, Chan FC, Braziel RM, Chan WC, Weisenburger DD, Cook JR, Greiner TC, Fu K, Ott G, Delabie J, Smeland EB, Holte H, Jaffe ES, Steidl C, Connors JM, Gascoyne RD, Rosenwald A, Staudt LM, Campo E, Rimsza LM; Lymphoma/Leukemia Molecular Profiling Project. New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies. J Clin Oncol. 2017 May 20;35(15):1668-1677.

44. Ennishi D, Mottok A, Ben-Neriah S, Shulha HP, Farinha P, Chan FC, Meissner B, Boyle M, Hother C, Kridel R, Lai D, Saberi S, Bashashati A, Shah SP, Morin RD, Marra MA, Savage KJ, Sehn LH, Steidl C, Connors JM, Gascoyne RD, Scott DW. Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. Blood. 2017 May 18;129(20):2760-2770. Epub 2017 Mar 28.

45. Jais JP, Molina TJ, Ruminy P, Gentien D, Reyes C, Scott DW, Rimsza LM, Wright G, Gascoyne RD, Staudt LM, Haioun C, Tilly H, Gaulard P, Salles GA, Jardin F, Leroy K. Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay. Haematologica. 2017 Oct;102(10):e404-e406. Epub 2017 Jul 4.

46. Chan FC, Mottok A, Gerrie AS, Power M, Nijland M, Diepstra A, van den Berg A, Kamper P, d'Amore F, d'Amore AL, Hamilton-Dutoit S, Savage KJ, Shah SP, Connors JM, Gascoyne RD, Scott DW, Steidl C. Prognostic model to predict post-autologous stem-cell transplantation outcomes in classical Hodgkin lymphoma. J Clin Oncol. 2017 Nov 10;35(32):3722-3733. Epub 2017 Sep 12.

47. Abrisqueta P, Scott DW, Slack GW, Steidl C, Mottok A, Gascoyne RD, Connors JM, Sehn LH, Savage KJ, Gerrie AS, Villa D. Observation as the initial management strategy in patients with mantle cell lymphoma. Ann Oncol. 2017 Oct 1;28(10):2489-2495.

48. Teater M, Dominguez PM, Redmond D, Chen Z, Ennishi D, Scott DW, Cimmino L, Ghione P, Chaudhuri J, Gascoyne RD, Aifantis I, Inghirami G, Elemento O, Melnick A, Shaknovich R. AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagnesis. Nat Commun. 2018 Jan 15;9(1):222.

49. Hung SS, Meissner B, Chavez EA, Ben-Neriah S, Ennishi D, Jones MR, Shulha HP, Chan FC, Boyle M, Kridel R, Gascoyne RD, Mungall AJ, Marra MA, Scott DW, Connors JM, Steidl C. Assessment of capture and amplicon-based approaches for the development of a targeted next-generation sequencing pipeline to personalize lymphoma management. J Mol Diagn. 2018 Mar;20(2):203-214. Epub 2018 Feb 8.

50. Scott DW, King RL, Staiger AM, Ben-Neriah S, Jiang A, Horn H, Mottok A, Farinha P, Slack GW, Ennishi D, Schmitz N, Pfreundschuh M, Nowakowski GS, Kahl BS, Connors JM, Gascoyne RD, Ott G, Macon WR, Rosenwald A. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood. 2018 May 3;131(18):2060-2064

51. King RL, Nowakowski GS, Witzig TE, Scott DW, Little RF, Hong F, Gascoyne RD, Kahl BS, Macon WR. Rapid, real time pathology review for ECOC/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era. Blood Cancer J. 2018 Feb 28;8(3):27.

52. Clot G, Jares P, Giné E, Navarro A, Royo C, Pinyol M, Martín-Garcia D, Demajo S, Espinet B, Salar A, Ferrer A, Muntañola A, Aymerich M, Rauert-Wunderlich H, Jaffe ES, Connors JM, Gascoyne RD, Delabie J, López-Guillermo A, Ott G, Wright GW, Staudt LM, Rosenwald A, Scott DW, Rimsza LM, Beà S, Campo E. A gene signature that distinguishes conventional and leukemic non-nodal mantle cell lymphoma helps predict outcome. Blood. 2018 Jul 26;132(4):413-422

53. Villa D, Sehn LH, Aquino-Parsons C, Tonseth P, Scott DW, Gerrie AS, Wilson D, Bénard F, Gascoyne RD, Slack GW, Farinha P, Morris J, Pickles T, Connors JM, Savage KJ. Interim PET-directed therapy in limited stage Hodgkin lymphoma initially treated with ABVD. Haematologica. 2018 Jul 12

Dominique Trudel

1. Treurniet K, Trudel D, Sykes J, Evans AJ, Finelli A, van der Kwast T. Downgrading of biopsy based Gleason score in prostatectomy specimens. Clin Cancer Res April 2013 Jul 1;19(13):3450-61.

2. Trudel D, Zafarana F, Have CL, Bristow RH, van der Kwast T. The 4FISH-IF, a four-color dual-gene fish combined p63 immunofluorescence to evaluate NKX3. 1 and MYC status in prostate cancer. J Histochem Cytochm 2013 Jul;61(7):500-9.

3. Kron K, Trudel D, Pethe V, Briollais L, Fleshner N, van der Kwast T, Bapat B. Altered DNA methylation landscapes of ploycomb-repressed loci are associated with Gleason score and ERG oncogene expression in prostate cancer. Clin Cancer Res April 2013 Jul 1;19(13):3450-61.

4. Wagner D, Trudel D, van der Kwast T, Nonn L, Antonio Giangreco A Li D Dias A, Cardoza M, Laszlo S, Hersey K, Klotz L, Finelli A, Fleshner N. Vieth R. Randomized clinical trial of Vitamin D3 doses in prostatic vitamin D metabolite levels and Ki67 labeling in prostate cancer patients. J Clin Endocrinol Metab. 2013 Apr;98(4):1498-507.

5. Saraon P Cretu D, Musrap N, Karagiannis GS, Batruch I, Smith C, Drabovish AP, Trudel D, van der Kwast T, Morrise C, Jarvi KA, Diamandis EP. Proteomic profiling of prostate cancer cell line conditioned medium reveals a role for proteins S during the development of high grade and castrate-resistant prostate cancer. J Biol Chem 2012 Oct5;287(41):34019-31.

6. Kron K, Liu L, Trudel D, Pethe V, Trachtenberg J, Fleshner N, Bapat B, van der Kwast T. Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer. Clin Can Res 2012 18(10):2896-2904.

7. Saraon P, Trudel D, Kron K, Dmitromanolakis A, Trachtenberg J, Bapat , van der Kwast T, Jarvi K, Diamandis EP. Evaluation and prognostic significance of ACAT1 as a marker of prostate cancer progression. Prostate 2014 Apr;74(4):372-80.

8. Treurniet KM, Trudel D, Sykes J, Evans AJ, Finelli A, Van der Kwast TH. Downgrading of biopsy based Gleason score in prostatectomy specimens. J Clin Pathol. 2014 Apr;67(4):313-8.

9. Trudel D, Downes MR, Sykes J, Kron KJ, Trachtenberg J, van der Kwast TH. Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort. Eur J Cancer, 2014 Jun;50(9):1610-6.

10. Boutros PC, Fraser M, Harding NJ, de Borja R, Trudel D, Lalonde E, Meng A, Hennings-Yeomans PH, McPherson A, Sabelnykova VY, Zia A, Fox NS, Livingstone J, Shiah YJ, Wang J, Beck TA, Have CL, Chong T, Sam M, Johns J, Timms L, Buchner N, Wong A, Watson JD, Simmons TT, P'ng C, Zafarana G, Nguyen F, Luo X, Chu KC, Prokopec SD, Sykes J, Dal Pra A, Berlin A, Brown A, Chan-Seng-Yue MA, Yousif F, Denroche RE, Chong LC, Chen GM, Jung E, Fung C, Starmans MH, Chen H, Govind SK, Hawley J, D'Costa A, Pintilie M, Waggott D, Hach F, Lambin P, Muthuswamy LB, Cooper C, Eeles R, Neal D, Tetu B, Sahinalp C, Stein LD, Fleshner N, Shah SP, Collins CC, Hudson TJ, McPherson JD, van der Kwast T, Bristow RG. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet. 2015 May 25. doi: 10.1038/ng.3315. [Epub ahead of print]

11. Downes MR, Satturwar S, Trudel D, van der Kwast TH. Evaluation of ERG and PTEN protein expression in cribriform architecture prostate carcinomas. Pathol Res Pract. 2017 Jan;213(1):34-38. Epub 2016 Oct 26.

12. Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, Huang V, Shiah YJ, Yousif F, Lin X, Masella AP, Fox NS, Xie M, Prokopec SD, Berlin A, Lalonde E, Ahmed M, Trudel D, Luo X, Beck TA, Meng A, Zhang J, D'Costa A, Denroche RE, Kong H, Espiritu SM, Chua ML, Wong A, Chong T, Sam M, Johns J, Timms L, Buchner NB, Orain M, Picard V, Hovington H, Murison A, Kron K, Harding NJ, P'ng C, Houlahan KE, Chu KC, Lo B, Nguyen F, Li CH, Sun RX, de Borja R, Cooper CI, Hopkins JF, Govind SK, Fung C, Waggott D, Green J, Haider S, Chan-Seng-Yue MA, Jung E, Wang Z, Bergeron A, Dal Pra A, Lacombe L, Collins CC, Sahinalp C, Lupien M, Fleshner NE, He HH, Fradet Y, Tetu B, van der Kwast T, McPherson JD, Bristow RG, Boutros PC. Genomic hallmarks of localized, non-indolent prostate cancer. Nature. 2017 Jan 19;541(7637):359-364. Epub 2017 Jan 9.

Tomo Osako

1. Nguyen LV, Makarem M, Carles A, Moksa M, Kannan N, Pandoh P, Eirew P, Osako T, Kardel M,Cheung AM, Kennedy W, Tse K, Zeng T, Zhao Y, Humphries RK, Aparicio S, Eaves CJ, Hirst M. Clonal analysis via barcoding revelas diverse growth and differentiationof transplanted mouse and human mamary stem cells. Cell Stem Cell 2014; 14:253-63.

2. Silwel-Pandit L, Vollan HK, Chin SF, Rueda OM, McKinney S, Osako T. Quigley DA, Kristensen VN, Aparicio S, Borrensen-Dale AL, Caldas C, Langerod A. TP53 mutation spectrum in breast cancer in subtype specific and has distinct prognostic relevance. Clinc Can Res 2014; 20(3569-80.

3. Eirew P, Steif A, Khattra J, Ha G, Yap D, Farahani H, Gelmon K, Chia S, Mar C, Wan A, Laks E, Biele J, Shurmansky K, Rosner J, McPherson A, Nielsen C, Roth AJL, Lefebvre C, Bashashati A, de Souza C, Siu C, Aniba R, Brimhall J, Oloumi A, Osako T, Bruna A, Sandoval J, Algara T, Greenwood W, Leung K, Cheng H, Xue H, Wang Y, Lin D, Mungall AJ, Moore R, Zhao Y, Lorette J, Nguyen L, Huntsman D, Eaves CJ, Hansen C, Marra MA, Caldas C, Shah SP, Aparicio S. Dynamics of genomics clones in breast cancer petient xenografts at single cell resoution. Nature. 2015 Feb 19;518(7539):422-6. doi: 10.1038/nature13952. Epub 2014 Nov 26.

4. Nguyen LV, Pellacani D, Kannan N, Mararem M, Osako T, Ocx CL, Kennedy W, Beer P, Carles A, Moksa M, Babovic S, Hirst M, Aparicio S, Eaves CJ. Barcoding reveals an unexpected sequence of malingnant change by normal human mammary cells. Nature 2015 Dec 10;528(7581):267-71. (8% contribution).

5. Xu H, Di Antonio M, McKinney S, Mathew V, Ho B, O'Neil NJ, Santos ND, Silvester J, Wei V, Garcia J, Kabeer F, Lai D, Soriano P, Banáth J, Chiu DS, Yap D, Le DD, Ye FB, Zhang A, Thu K, Soong J, Lin SC, Tsai AH, Osako T, Algara T, Saunders DN, Wong J, Xian J, Bally MB, Brenton JD, Brown GW, Shah SP, Cescon D, Mak TW, Caldas C, Stirling PC, Hieter P, Balasubramanian S, Aparicio S. CX-5461 is a DNA G-quadruplex stabilized with selective lethality in BRCA1/2 deficient tumours. Nat Commun. 2017 Feb 17;8:14432

King Tan

1. Kridel R, Meissner B, Rogic S, Boyle M, Telenius A, Woolcock B, Gunawardana J, Jenkins C, Cochrane C, Ben-Neriah S, Tan K, Morin RD, Opat S, Sehn LH, Connors JM, Marra MA, Weng AP, Steidl C, Gascoyne RD. Blood 2012 Mar 1;119(9):1963-71. Epub 2011 Dec 30.

2. Scott DW, Mungall KL, Ben-Neriah S, Rogic S, Morin RD, Slack GW, Tan KL, Chan FC, Lim RS, Connors JM, Marra MA, Mungall AJ, Steidl C, Gascoyne RD. TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma. Blood 2012 May 24;119(21):4949-52. Epub 2012 Apr 11.

3. Jankova L, Robertson G, Chan C, Tan KL, Kohonen-Corish M, Fung CL, Clarke C, Lin BP, Molly M, Chapuis PH, Bokey L, Dent OF, Clarke SJ. BMC Cancer 2012 May 28;12:196. doi: 10.1186/1471-2407-12-196.

4. Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Sehn LH, Chan WC, Iqbal J, Meyer PN, Penz G, Wright G, Rimsza LM, Valentino C, Brunhoeber P, Grogan TM, Braziel RM, Cook JR, Tubbs RR, Weisenburger DD, Campo E, Rosenwald A, Ott G, Delabie J, Holcroft C, Jaffe ES, Staudt LM, Gascoyne RD. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. J Clin Oncol 2012 Oct 1;30(28):3452-9. Epub 2012 Jul 30.

5. Tan KL, Scott DW, Hong F, Kahl BS, Fischer RI, Bartlett NL, Advani RH, Buckstein R, Rimsza LM, Connors JM, Steidl C, Gordon LI, Horning SJ, Gascoyne RD. Tumor-associated macrophages predict inferior outcomes in classical Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood 2012 Oct 18;120(16):3280-7. doi: 10.1182/blood-2012-04-421057. Epub 2012 Sep 4.

6. Steidl C, Diepstra A, Lee T, Chan FC, Farinha P, Tan K, Telenius A, Barclay L, Shah SP, Connors JM, van den Berg A, Gascoyne RD. Gene expression profiling of microdissected Hodgkin Reed Sternberg cells correlates with treatment outcome in classical Hodgkin lymphomas. Blood 2012 Oct 25;120(17):3530-40. doi: 10.1182/blood-2012-06-439570. Epub 2012 Sep 5.

7. Scott DW, Chan FC, Hong F, Rogic S, Tan K, Meissner B. Farinha P, Horning SJ, Fisher RI, Bartlett NL, Shepherd LE, Connors J, de Sousa AB, Kahl BS, Gordon LI, Steidl C, Gascoyne RD. Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. J Clin Oncol 2013 Feb 20;31(6):692-700. doi: 10.1200/JCO.2012.43.4589. Epub 2012 Nov 26.

8. Kanakry JA, Li H, Gellert LL, Lemas VM, Hsieh WS, Hong F, Tan KL, Gascoyne RD, Gordon LI, Fisher RI, Bartlett NL, Stiff P, Cheson BD, Advani R, Miller TP, Kahl BS, Horning SJ, Ambinder RF. Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: Correlative analysis from a large North American Cooperative group trial. Blood. 2013 May 2;121(18):3547-53.

9. Hamilton SN, Wai ES, Tan K, Alexander C, Gascoyne RD, Connors JM. Treatment of outcomes in patients with primary cutaneous B-cell lymphoma: The BC Cancer Agency experience. Int J Radiat Oncol Biol Phys 2013 Nov 15;87(4):719-25. doi:10.1016/j.ijrobp. 2013.07.019. Epub 2013 Aug 31.

10. Bodor C, Grossmann V, Popov N, Okosun J, O’Riain C, Tan K, Marzec J, Araf S, Wang J, Lee AM, Clear A, Montoto S, Matthews J, Iqbal S, Rajnai H, Rosenwald A, Ott G, Campo E, Rimsza LM, Smeland EB, Chan WC, Braziel RM, Staudt LM, Wright G, Lister TA, Elemento O, Hills R, Gribben J, Chelala C, Matolcsy A, Kohlmann A, Haferlach T, Gascoyne RD, Fitzgibbon J. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 2013 Oct 31;122(18):3165-8. doi: 10.1182/blood-2013-04-496893. Epub 2013 Sep 19.

11. Twa DD, Chan FC, Ben-Neriah S, Woolcock BW, Mottok A, Tan KL, Slack GW, Gunawardana J, Lim RS, McPherson AW, Kridel R, Telenius A, Scott DW, Savage KJ, Shah SP, Gascoyne RD, Steidl C. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 2014 Mar 27;123(13):2062-5.

12. Perry AM, Alvarado-Bernal Y, Laurini JA, Smith LM, Slack GW, Tan KL, Sehn LH, Fu K, Aoun P, Greiner TC, Chan WC, Bierman PJ, Bociek RG, Armitage JO, Vose JM, Gascoyne RD, Weisenburger DD. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. Br J Haematol. 2014 May;165(3):382-91.

13. Gunawardana J, Chan FC, Telenius A, Woolcock B, Kridel R, Tan KL, Ben-Neriah S, Mottok A, Lim RS, Boyle M, Rogic S, Rimsza LM, Guiter C, Leroy K, Gaulard P, Haioun C, Marra MA, Savage KJ, Connors JM, Shah SP, Gascoyne RD. Steidl C. Nat Genet. 2014 Apr;46(4):329-35.

14. Twa DD, Mottok A, Chan FC, Ben-Neriah S, Woolcock BW, Tan KL, Mungall AJ, McDonald H, Zhao Y, Lim RS, Nelson BH, Milne K, Shah SP, Morin RD, Marra MA, Scott DW, Gascoyne RD, Steidl C. Recurrent genomic rearrangements in primary tetsicular lymphoma. J Pathol. 2015 Jun;236(2):136-41. doi: 10.1002/path.4522. Epub 2015 Mar 26.

15. Savage KJ, Slack GW, Mottok A, Sehn LH, Villa D, Kansara R, Kridel R, Steidl C, Ennishi D, Tan KL, Ben-Neriah S, Johnson NA, Connors JM, Farinha P, Scott DW, Gascoyne RD. The impact of dual expressionof MYC and CBL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood 2016 May 5;127(18):2182-8.

16. Kridel R, Chan FC, Mottok A, Boyle M, Farinha P, Tan K, Meissner B, Bashashati A, McPherson A, Roth A, Shumansky K, Yap D, Ben-Neriah S, Rosner J, Smith MA, Nielsen C, Giné E, Telenius A, Ennishi D, Mungall A, Moore R, Morin RD, Johnson NA, Sehn LH, Tousseyn T, Dogan A, Connors JM, Scott DW, Steidl C, Marra MA, Gascoyne RD, Shah SP. Histological transformation and progression in follicular lymphoma: a clonal evolution study. PLoS Med. 2016 Dec 13;13(12):e1002197.

17. Kendrick S, Rimsza LM, Scott DW, Slack GW, Farinha P, Tan K, Persky D, Puvvada S, Connors JM, Sehn L, Gascoyne RD, Schmelz M. Aberrant cytoplasmic exprssion of MHCII confers worse progression free survival in diffuse large B-cell lymphoma. Virchows Arch. 2017 Jan;470(1):113-117. Epub 2016 Nov 25.

18. Kridel R, Telio D, Villa D, Sehn LH, Gerrie AS, Shenkier T, Klasa R, Slack GW, Tan K, Gascoyne RD, Connors JM, Savage KJ. Diffuse large B0cell lymphoma with testicular inolvement: outcome and risk of CNS relapse in the rituximab era. Br J Haematol. 2017 Jan;176(2):210-221. Epub 2016 Oct 14.

Ghassan Allo

1. Kalloger SE, Allo G Mulligan AM, Plllett A, Aronson M, Gallinger S, Torlakovic EE, Clarke A. Use of mismatch repair immunohistochemistry and microsatellite instability testing: exploring Canadian practices. American Journal of Uro Pathology 2012;36(4):560-9.

2. Ky FI, Gilks CB, Mulligan AM, Ryan P, Allo G, Sy K, Shaw PA, Pollett A, Clarke BA. Prevalence of loss of expression of DNA mismatch repair proteins in primary epithelial ovarian tumors.

3. Anglesio M, Kommoss S, Tolcher M, Clarke B, Galletta L, Porter H, Damaraju S, Fereday S, Winterhoff B, Kalloger S, Senz J, Yang W, Steed H, Allo G, Ferguson S, Shaw P, Teoman A, Garcia J, Schoolmeester J Bakkum-Gamez J, Tinker A, Bowtell D, Huntsman D, Gilks C, McAlpine J. Molecular characterization of mucinous ovarian tumors supports a stratified treatment approach with HER2 targeting in 10% of carcinomas. J Pathol. 2013 Jan;229(1):111-20.

4. Lu FI, Gilks B, Mulligan AM, Ryan P, Allo G, Sy K, Shaw PA, Pollett A, Clarke BA. Prevalence of loss of expression of DNA mismatch repair proteins in primary epithelial ovarian tumors. International Journal of Gynecological Pathology. 2012;31(6)524-531.

5. Tinker AV, Ellard S, Welch S, Moens F, Allo G, Tsao MS, Squire J, Tu D, Eisenhauer EA, Mackay H. Phase II study of termsirolimus (CCI-779) in women with recurrent, unresectable, the NCIC Clinical Trials Group (NCIC CTG IND 199). Gynecol Oncol. 2013 Aug;130(2):269-74. doi: 10.1016/j.ygyno.2013.05.008. Epub 2013 May 11.

6. Bitanihirwe BK, Meerang M, Friess M, Soltermann A, Frischknecht L, Thies S, Felley-Bosco E, Tsao MS, Allo G, de Perrot M, Seifert B, Moch H, Stahel R, Weder W, Opitz I. PI13/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy. J Thorac Oncol. 2014 Feb;9(2):239-47.

7. Allo G, Bernardini MQ, Wu R-C Shih I-M, Kalloger S, Pollett A, Gilks CB, Clarke BA. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Mod Pathol 2014 Feb;27(2):255-61. doi: 10.1038/modpathol.2013.144. Epub 2013 Jul 26.

8. Allo G, Bandarchi B, Yanagawa N, Wang A, Shih W, Xu J, Dalby M, Nitta H, To C, Liu N, Sykes J, Tsao MS. EGFR mutation-specific immunohistochemical antibodies in lung adenocarcinoma. Histopathology 2014 May;64(6):826-39. doi: 10.1111/his.12331. Epub 2014 Jan 29.

9. Downes MR, Allo G, McCluggage WG, Sy K, Ferguson SE, Aronson M, Pollett A, Gallinger S, Bilbily E, Shaw P, Clarke BA. "Review of findings in prophylactic gynaecologic specimens in Lynch syndrome with literature review and recommendations for grossing. Histopathology 2014 Aug;65(2):228-39. Epub Apr 16

10. Tsoref D, Welch S, Lau S, Biagi J, Tonkin K, Martin LA, Ellard S, Ghatage P, Elit L, Mackay HJ, Allo G, Tsao MS, Kamel-Reid S, Eisenhauer EA, Oza AM. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol 2014 Aug 28. Pii: S0090-8258(14)1074-9. (10% contribution).

11. Stewart EL, Mascaux C, Pham NA, Sakashita S, Sykes J, Kim L, Yanagawa N, Allo G, Ishizawa K, Wang D, Zhu CQ, Li M, Ng C, Liu N, Pintilie M, Martin P, John T, Jurisica I, Leighl NB, Neel BG, Waddell TK, Shepherd FA, Liu G, Tsao MS. Clinical utility of patient-derived xenografts to determine biomarkers of prognosis and map resistance pathways in EFGR-mutant lung adenocarcinoma. J Clin Oncol 2015 Aug 1;33(22):2472-80.

12. Hai J, Sakashita S, Allo G, Ludkovski O, Ng C, Shepherd FA, Tsao MS. Inhibiting MDM2-p53 interaction suppresses tumor growth in patient-derived non-small cell lung cancer xenograft models. J Thorac Oncol 2015 Aug;10(8)1172-80.

13. Rayson D, Lupichuk S, Potvin K, Dent S, Shenkier T, Dhesy-Thind S, Ellard SL, Prady C, Salim M, Farmer P, Allo G, Tsao MS, Allan A, Ludkovski O, Bonomi M, Tu D, Hagerman L, Goodwin R, Eisenhauer E, Bradbury P. Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer. Breast Cancer Res Treat. 2016 May;157(1):109-16. doi: 10.1007/s10549-016-3812-1. Epub 2016 Apr 26.

14. Wu L, Allo G, John T, Li M, Tagawa T, Opitz I, Anraku M, Yun Z, Pintilie M, Pitcher B, Liu G, Feld R, Johnston MR, de Perrot M, Tsao MS. Patient-derived xenograft establishment from human malignant plural mesothelioma. Clin Cancer Res. 2017 Feb 15;23(4):1060.

15. Wang D, Pham NA, Tong J, Sakashita S, Allo G, Kim L, Yanagawa N, Raghavan V, Wei Y, To C, Trinh QM, Starmans MH, Chan-Seng-Yue MA, Chadwick D, Li L, Zhu CQ, Liu N, Li M, Lee S, Ignatchenko V, Strumpf D, Taylor P, Moghal N, Liu G, Boutros PC, Kislinger T, Pintilie M, Jurisica I, Shepherd FA, McPherson JD, Muthuswamy L, Moran MF, Tsao MS. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflects their primary tumors. Int J Cancer. 2017 Feb 1;140(3):662-673. doi: 10.1002/ijc.30472. Epub 2016 Nov 7.

Kyu Sang Song

1. Yoshimoto M, Ding K, Sweet JM, Ludkovski O, Trottier G, Song KS, Joshua AM, Fleshner NE, Squire JA, Evans AS. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. Mod Pathol 2013 Mar;25(3):435-47.

Hector Li-Chang

1. Wiegand KC, Sy K, Kalloger SE, Li-Chang H, Woods R, Kumar A, Streutker C, Hafezi-Bakhtiari S, Zhou C, Lim H, Huntsman DG, Clarke DG, Schaeffer DF. ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of two cohorts. Human Pathology 2014; 45(6):1258-68.

2. Sheffield BS, Garrat J, Kalloger S, Li-Chang HH, Gilks CB, Schaeffer DF. HER2 testing in gastric cancer: Interlaboratory variation in immunohistochemistry results. Archives of Pathology 2014 Nov;138(11):1495-502.

3. Osmond A, Li-Chang H, Kirsch R, Divaris D, Falck V, Liu D, Marginean C, Newell K, Parfitt J, Rudrick B, Sapp H, Smith S, Walsh J, Wasty F, Driman D. Interobserver variability in assessing high-grade dysplasia and architecture in colorectal adenomas: a multi-centre Canadian study. Journal of Clinical Pathology2014 Sep;67(9):781-6.

4. Sheffield BS, Tinker AV, Shen Y, Hwang H, Li-Chang HH, Pleasance E, Ch'ng C, Lum A, Lorette J, McConnell YJ, Sun S, Jones SJ, Gown AM, Huntsman DG, Schaeffer DF, Churg A, Yip S, Laskin J, Marra MA. Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing. PLoS One. 2015 Mar 23;10(3):e0119689. doi: 10.1371/journal.pone.0119689. eCollection 2015

5. Anglesio MS, Bashashati A, Wang YK, Senz J, Ha G, Yang W, Aniba MR, Prentice LM, Farahani H, Li Chang H, Karnezis AN, Marra MA, Yong PJ, Hirst M, Gilks B, Shah SP, Huntsman DG. Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. J Pathol. 2015 Jun;236(2):201-9. doi: 10.1002/path.4516. Epub 2015 Mar 23.

6. Li-Chang HH, Kasaian K, Ng Y, Lum A, Kong E, Lim H, Jones SJ, Huntsman DG, Schaeffer DF, Yip S. Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas. BMC Cancer. 2015 Feb 6;15:32. doi: 10.1186/s12885-015-1021-7.

7. O'Connor K, Li-Chang HH, Kalloger SE, Peixoto RD, Webber DL, Owen DA, Driman DK, Kirsch R, Serra S, Scudamore CH, Renouf DJ, Schaeffer DF. Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma. Am J Surg Pathol. 2015 Apr;39(4):472-8. doi: 10.1097/PAS.0000000000000333.

8. Hansford S, Kaurah P, Li-Chang H. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA oncol. 2015;1(1):23-32.

9. McAlpine JN, McConechy MK, Talhouk A, Li-Chang H., Leung S, Huntsman DG, Gilks CB. Detection of DNA mismatch repair (MR) deficiencies by immunohistochemistry can effectively diagnose microsatellite instability (MSI) phenotype in endometrial carcinomas. Gynecol Oncol 2015 May;137(2):306-10.

10. Sheffield BS, Tinker AV, Shen Y, Hwang H, Li-Chang H., Pleasance E, Ch’ng C, Lum A, Lorette J, McConnell YJ, Sun S, Jones SJ, Gown AM, Huntsman DG, Schaeffer DF, Churg A, Yip S, Laskin J, Marra MA. Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing. PLoS One 2015 May 23;10(3):e0119689.

11. Talhouk A, McConechy MK, Leung S, Li-Chang H., Kwon JS, Melnk N, Yang W, Senz J, Boyd N, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN. A clinicall applicable molecular-based classification for endometrial cancers. Br J Cancer 2015 Jul 14;113(2):299-310.

12. Hansford S, Kaurah P, Li-Chang H., Woo M, Senz J, Pinheiro H, Schrader KA, Schaeffer DF, Shumansky K, Zogopoulos G, Santos TA, Claro I, Carvalho J, Nielsen C, Padila S, Lum A, Talhouk A, Baker-Lange K, Richardson S, Lewis I, Lindor NM, Pennell E, MacMillan A, Fernandez B, Keller G. Lynch H, Shah SP, Guilford P, Gallinger S, Corso G, Roviello F, Caldas C, Oliveira C, Pharoah PD, Huntsman DG. JAMA Oncol 2015 Apr;1(1):23-32.

13. Riazy M, Kalloger SE, Sheffield BS, Peixoto RD, Li-Chang H., Scudamore CH, Renouf DF, Schaeffer DF. Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma. Mod Pathol 2015 Oct;28(10):1383-9.

14. O’Connor K, Cheriyan DG, Li-Chang H., Kalloger SE, Garrett J, Byrne MF, Weiss AA, Donnellan F, Schaeffer DF. Gastointestinal endoscopic ultrasound-guided fine-needle aspiration biopsy specimens: adequate diagnostic yield and accuracy can be achieved without on-site evaluation. Acta Cytol 2015;59(4):305-10.

15. Anglesio MS, Wang YK, Maassen M, Horlings HM, Bashashati A, Senz J, Mackenzie R, Grewal DS, Li-Chang H., Karnezis AN, Sheffield BS, McConechy MK, Kommoss F, Taran FA, Staebler A, Shah SP, Wallwiener D, Brucker S, Gilks CB, Kommoss S, Huntsman DG. Synchronous endometrial and ovarian carcinomas: evidence of clonality. J Natl Cancer Inst. 2016 Feb 1;108(6):djv428

16. Wang YK, Bashashati A, Anglesio MS, Cochrane DR, Grewal DS, Ha G, McPherson A, Horlings HM, Senz J, Prentice LM, Karnezis AN, Lai D, Aniba MR, Zhang AW, Shumansky K, Siu C, Wan A, McConechy MK, Li-Chang H, Tone A, Provencher D, de Ladurantaye M, Fleury H, Okamoto A, Yanagida S, Yanaihara N, Saito M, Mungall AJ, Moore R, Marra MA, Gilks CB, Mes-Masson AM, McAlpine JN, Aparicio S, Huntsman DG, Shah SP. Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. Nat Genet. 2017 Jun;49(6):856-865.

17. BenTaieb A, Li-Chang H, Huntsman D, Hamarneh G. A structured latent model for ovarian carcinoma subtyping from histopathology slides. Med Image Anal. 2017 Jul;39:194-205.

Tamara Jamaspishvili

1. Jamaspishvili T, Squire JA. Moving discoveries form cancer genomics research lab into pathology practice. In: Netto GJ, Schrijver I (ed): Genomic applications in clinical and anatomic pathology” Springer, New York 2013

2. Troyer DA, Jamaspishvili T, Wei W. Feng Z, Good J, Hawley S, Fazli L, McKenney JK, Simko J, Hurtado-Coll A, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Squire JA. A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate 2015 Aug 1;75(11):1206-15. Doi: 10.1002/pros.23003. Epub 2015 May 4.

3. Eigl BJ, North S, Winquist E, Finch D, Wood L, Sridhar SS, Powers J, Good J, Sharma M, Squire JA, Bazov J. Jamaspishvili T, Cox ME, Bradbury PA, Eisenhauer EA, Chi KN. A phase II study of the UDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND 195. Invest New Drugs, 2015 Aug;33(4):969-76. doi: 10.1007/s10637-015-0252-4. Epub 2015 May 19.

4. Lotan TL, Wei W, Ludkovski O, Morais CL, Jamaspishvili T, Hawley ST, Feng Z, Ladan Fazli, Antonio Hurtado-Coll, McKenney JK, Simko J, Carroll PR, Gleave M, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Lance R, Troyer D, Squire JA. Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison to PTEN FISH. Mod Pathol 2016 May 13.

5. Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA, Lotan TL. Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol. 2018 Apr;15(4):222-234.

6. Brimo F, Downes MR, Jamaspishvili T, Berman D, Barkan GA, Athanazio D, Abro S, Visram K, Yilmaz A, Solanki S, Hahn E, Siemens R, Kassouf W, Trpkov K. Prognostic pathological factors in radical cystosectomy after neoadjuvant chemotherapy. Histopathology. 2018 May 18.

Shingo Sakashita

1. Sakashita S, Sakashita M, Sound Tsao M. Genes and pathology of non-small cell lung carcinoma. Semin Oncol. 2014 Feb;41(1):28-39.

2. Zhang W, Wei Y, Ignatchenko V, Li L, Sakashita S, Pham NA, Taylor P, Tsao MS. Kislinger T, Moran MF. Proteomic profiles of human lung adeno and squamous cell carcinoma using super- SILAC and label-free quantification approaches. Proteomics 2014; Mar14(6):795-803.

3. Golaraei A, Cisek R, Krouglov S, Navab R, Niu C, Sakashita S, Yasufuku K, Tsao M-S, Wilson BC, Barzda V. Characterization of collagen in non-small lung carcinoma with second harmonic polarization microscopy. Biomedical Optics Express 2014,5(10):3562-3567.

4. Radulovich N, Leung L, Ibrahimov E, Navab R, Sakashita S, Zhu C-Q, Kaufman E, Lockwood WW, Thu KL, Fredyshyn Y, Moffat J, Lam WL, Tsao M-S. Coiled-coil domain containing 68 (CCDC68) demonstrates a tumor-suppressive role in pancreatic ductal adenocarcinoma. Oncogene 2014 Nov 10;0.

5. Zhang W, Sakashita S, Taylor P, Tsao MS, Moran MF. Comprehensive proteome analysis of fresh frozen and optimal cutting temperature (OCT) embedded primary non-small cell lung carcinoma by LC-MS/MS. Methods 2015 Jun 1581:50-5.

6. Cescon DW, She D, Sakashita S, Zhu CQ, Pintilie M, Shepherd FA, Tsao MS. NRF2 pathway activation and adjuvant chemotherapy benefit in lung squamous cell carcinoma. Clin Cancer Res 2015 Jun 1;21(11):2499-505.

7. Stewart EL, Mascaux C, Pham NA, Sakashita S, Sykes J, Kim L, Yanagawa N, Allo G, Ishizawa K, Wang D, Zhu CQ, Li M, Ng C, Liu N, Pintilie M, Martin P, John T, Jurisica I, Leigh NB, Neel BG, Waddell TK, Shepherd FA, Liu G, Tsao MS. Clinical utility of patient-derived xenografts to determine biomarkers of prognois and map resistance pathways in EGFR-mutant lung adenocarcinoma. J Clin Oncol. 2015 Aug 1;33(22):2472-80.

8. Hai J, Sakashita S, Allo G, Ludkovski O, Ng C, Shepherd FA, Tsao MS. Inhibiting MDM2-p53 interaction suppresses tumor growth in patient-derived non-small lung xenograft models. J Thorac Oncol 2015 Aug;10(8):1172-80.

9. Martin P, Stewart E, Pham NA, Mascaux C, Panchal D, Li M, Kim L, Sakashita S, Wang D, Sykes J, Friess T, Shepherd FA, Liu G, Tsao MS. Cetuximab inhibits T790M-mediated resistance to epidermal growth factor receptor tyrosine kinase inhi pii: S1525-7304(16)00005-X. doi: 10.1016/j.cllc.2016.01.002. [Epub ahead of printbitor in a lung adenocarcinoma patient-derived xenograft mouse model. Clinic Lung Cancer 2016 Jan 22.

10. Sacher AG, Le LW, Lara-Guerra H, Waddell TK, Sakashita S, Chen Z, Kim L, Zhang T, Kamel-Reid S, Salvarrey A, Darling G, Yasufuku K, Keshavjee S, De Perrot M, Shepherd FA, Liu G, Tsao M, Leighl NB. Oncotarget 2016 Mar 25 doi: 10.18632/oncotarget.8350. [Epub ahead of print].

11. Wang D, Pham NA, Tong J, Sakashita S, Allo G, Kim L, Yanagawa N, Raghavan V, Wei Y, To C, Trinh QM, Starmans MH, Chan-Seng-Yue MA, Chadwick D, Li L, Zhu CQ, Liu N, Li M, Lee S, Ignatchenko V, Strumpf D, Taylor P, Moghal N, Liu G, Boutros PC, Kislinger T, Pintilie M, Jurisica I, Shepherd FA, McPherson JD, Muthuswamy L, Moran MF, Tsao MS. Molecular heterogeneity of non-small cell lung carcinoma patient-drived xenografts closely reflect their primary tumors. Int J Cancer. 2017 Feb 1;140(3):662-673. Epub 2016 Nov 7.

12. Kim BR, Van de Laar E, Cabanero M, Tarumi S, Hasenoeder S, Wang D, Virtanen C, Suzuki T, Bandarchi B, Sakashita S, Pham NA, Lee S, Keshavjee S, Waddell TK, Tsao MS, Moghal N. SOX2 and P13K coperate to induce and stabilize a squamous-committed stem cell injury state during lung squamous cell carcinoma pathogenesis. PLoS Biol. 2016 Nov 23;14(11):e1002581. eCollection 2016 Nov.

13. Chia SK, Ellard SL, Mates M, Welch S, Mihalcioiu C, Miller WH Jr, Gelmon K, Lohrisch C, Kumar V, Taylor S, Hagerman L, Goodwin R, Wang T, Sakashita S, Tsao MS, Eisenhauer E, Bradbury P. A phaseI study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer. Breast Cancer Res. 2017 May 2;19(1):54.

14. Leighl NB, Tsao MS, Liu G, Tu D, Ho C, Shepherd FA, Murray N, Goffin JR, Nicholas G, Sakashita S, Chen Z, Kim L, Powers J, Seymour L, Goss G, Bradbury PA. A phase-I study of foretinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND. 196. Oncotarget. 2017 Jun 28;8(41):69651-69662. eCollection 2017 Sep 19.

15. Brana I, Pham NA, Kim L, Sakashita S, Li M, Ng C, Wang Y, Loparco P, Sierra R, Wang L, Clarke BA, Neel BG, Siu LL, Tsao MS. Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts. Oncotarget. 2017 Jul 8;8(49):84659-84670. eCollection 2017 Oct 17.

16. Jao K, Tomasini P, Kamel-Reid S, Korpanty GJ, Mascaux C, Sakashita S, Labbé C, Leighl NB, Liu G, Feld R, Bradbury PA, Hwang DM, Pintilie M, Tsao MS, Shepherd FA. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell cancer. Lung Cancer. 2018 Sep;123:22-29. Epub 2018 Jun 19

Adewunmi Adeoye

1. Isaac S Harris, Aislinn E Treloar, Satoshi Inoue, Masato Sasaki, Chiara Gorrini, Kim Chung Lee, Ka Yi Yung, Dirk Brenner, Christiane B Knobbe-Thomsen, Maureen A Cox, Adewunmi Adeoye, Jacqueline M Mason, Wanda Y Li, Kazuo Yamamoto, Andrew Wakeham, Hal K Berman, Rama Khokha, Susan J Done, Terrance J Kavanagh, Ching-Wan Lam, Tak W Mak. Glutathione and Thioredoxin Antioxidant Pathways Synergize to Drive Cancer Initiation and Progression. Cancer Cell 2015 Jan 21. Pii: S1535-1608(14)00470-X. doi: 10.1016/jccell.2014.11.019 [Epub ahead of print]

Eric Morgen

1. Liu G, Tu D, Lewis M, Cheng D, Sullivan LA, Chen Z, Morgen E, Simes J, Price TJ, Tebbutt NC, Shapiro JD, Jeffery GM, Mellor JD, Mikeska T, Virk S, Shepherd LE, Jonker DJ, O'Callaghan CJ, Zalcberg JR, Karapetis CS, Dobrovic A. Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer. Clin Cancer Res. 2016 May 15;22(10):2435-44. doi: 10.1158/1078-0432.CCR-15-0414.

2. Morgen E, Lenz H, Jonker DJ, Tu D, Milano G, Graziano F, Zalcberg J, Karapetis C, Dobrovic A, O’Callaghan CJ, Liu G. Germline Polymorphisms as Biomarkers of Tumor Response in Colorectal Cancer Patients Treated with Anti-EGFR Monoclonal Antibodies: A Systematic Review and Meta-Analysis. Pharmacogenom J. 2017 Dec;17(6):535-542. Epub 2016 Nov 29.

Tao Wang

1. Huang S, Reitze NJ, Ewing AL, McCreary S, Uihlein AH, Brower SL, Wang D, Wang T, Gabrin MJ, Keating KE, Mulligan J, Wilson C, Davison T, McKenzie S, Tsao MS, Shepherd FA, Plamadeala V. Analytical Performance of a 15-Gene Prognostic Assay for Early-Stage Non-Small-Cell Lung Carcinoma Using RNA-Stabilized Tissue. J Mol Diagn. 2015 May 7

2. Nakajima T, Geddie W, Anayama T, Ko HM, da Cunha Santos G, Boerner S, Wang T, Wang YH, Li M, Pham NA, Tsao MS, Yasufuku K. Patient-derived tumor xenograft models established from samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. Lung Cancer. 2015 Aug;89(2):110-4.

3. Wang T, Notta F, Navab R, Joseph J, Ibrahimov E, Xu J, Zhu CQ, Borgida A, Gallinger S, Tsao MS. Senescent carcinoma-associated fibroblasts upregulate IL8 to enhance prometastatic phenotypes. Mol Cancer Res. 2017 Jan;15(1):3-14.

4. Notta F, Chan-Seng-Yue M, Lemire M, Li Y, Wilson GW, Connor AA, Denroche RE, Liang SB, Brown AM, Kim JC, Wang T, Simpson JT, Beck T, Borgida A, Buchner N, Chadwick D, Hafezi-Bakhtiari S, Dick JE, Heisler L, Hollingsworth MA, Ibrahimov E, Jang GH, Johns J, Jorgensen LG, Law C, Ludkovski O, Lungu I, Ng K, Pasternack D, Petersen GM, Shlush LI, Timms L, Tsao MS, Wilson JM, Yung CK, Zogopoulos G, Bartlett JM, Alexandrov LB, Real FX, Cleary SP, Roehrl MH, McPherson JD, Stein LD, Hudson TJ, Campbell PJ, Gallinger S. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature. 2016 Oct 20;538(7625):378-382.

5. Notta F, Chan-Seng-Yue M, Lemire M, Li Y, Wilson GW, Connor AA, Denroche RE, Liang SB, Brown AM, Kim JC, Wang T, Simpson JT, Beck T, Borgida A, Buchner N, Chadwick D, Hafezi-Bakhtiari S, Dick JE, Heisler L, Hollingsworth MA, Ibrahimov E, Jang GH, Johns J, Jorgensen LG, Law C, Ludkovski O, Lungu I, Ng K, Pasternack D, Petersen GM, Shlush LI, Timms L, Tsao MS, Wilson JM, Yung CK, Zogopoulos G, Bartlett JM, Alexandrov LB, Real FX, Cleary SP, Roehrl MH, McPherson JD, Stein LD, Hudson TJ, Campbell PJ, Gallinger S. Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature. 2017 Feb 2;542(7639):124.

6. Hai J, Zhu CQ, Wang T, Organ SL, Shepherd FA, Tsao MS. TRIM14 is a putative tumor suppressor and regulator of innate immune response in non-small cell lung cancer. Sci Rep. 2017 Jan 6;7:39692.

7. Chia SK, Ellard SL, Mates M, Welch S, Mihalcioiu C, Miller WH Jr, Gelmon K, Lohrisch C, Kumar V, Taylor S, Hagerman L, Goodwin R, Wang T, Sakashita S, Tsao MS, Eisenhauer E, Bradbury P. A phase-I study of lapatinib in combination with foretinib, a C-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. Breast Cancer Res. 2017 May 2;19(1):54. doi: 10.1186/s13058-017-0836-3.

8. Wang T, Moon JY, Wu Y, Amos CI, Hung RJ, Tardon A, Andrew A, Chen C, Christiani DC, Albanes D, Heijden EHFMV, Duell E, Rennert G, Goodman G, Liu G, Mckay JD, Yuan JM, Field JK, Manjer J, Grankvist K, Kiemeney LA, Marchand LL, Teare MD, Schabath MB, Johansson M, Aldrich MC, Davies M, Johansson M, Tsao MS, Caporaso N, Lazarus P, Lam S, Bojesen SE, Arnold S, Wu X, Zong X, Hong YC, Ho GYF. Plelotropy of genetic variants on obesity and smoking phenotypes: Results from the oncoarray project of the International Lung Cancer Consortium. PLoS One. 2017 Sep 28;12(9):e0185660.

Zhi Qiang Wang

1. Wang ZQ, Milne K, Webb JR, Watson PH. CD74 and intratumoral immune response in breast cancer. Oncotarget 2016 Apr 6 doi 10.18632/oncotarget.8610. [Epub ahead of print]

2. Wang ZQ, Milne K, Derocher H, Webb JR, Nelson BH, Watson PH. CD103 and intratumoral immune response in breast cancer. Clin Cancer Res 2016 Jun 7 pii: clincanres.0732.2016. [Epub ahead of print] PMID: 27267849.

Natalia Guggisberg

1. Kornaga EN, Klimowicz AC, Guggisberg N, Ogilvie T, Morris DG, Webster M, Magliocco AM. A systemic comparison of three commercial estrogen receptor assays in a single clinical outcome breast cancer cohort. Mod Pathol 2016 Aug;29(8):799-809. Epub 2016 Apr 29.

Michael Cabanero

1. Cabanero M, Tsao M-S. Taking action on actionable mutations: a French initiative on universality in precision cancer care. Translational Cancer Research June 2016;5(1).

2. Cabanero M, Tsao MS. Circulating DNA in non-small cell lung cancer: A Review. Current Oncology. Curr Oncol 2018 Jun;25(Suppl 1):S38-S44. Doi 10.3747/co.25.3761. Epub 2018 Jun 13.

3. Labbé C, Cabanero M, Korpanty GJ, et. al. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Lung Cancer. 2017 Sep;111:23-29.

4. Ly D, Zhu CQ, Cabanero M, Tsao MS, Zhang L. Role for High-Affinity IgE Receptor in Prognosis of Lung Adenocarcinoma Patients. Cancer Immunol Res. 2017 Sep;5(9):821-829.

5. Cabanero M, Sangha R, Sheffield B, Sukhai M, Pakkal M, Kamel-Reid S, Karsan A, Ionescu D, Juergens RA, Butts C, Tsao MS. Management of EGFR Mutated NSCLC: Practical Implications from a Clinical and Pathology Perspective. Current Oncology, 24(2), 111-119.

6. Kim BR, Van de Laar E, Cabanero M, Tarumi S, Hasenoeder S, Wang D, Virtanen C, Suzuki T, Bandarchi B, Sakashita S, Pham NA, Lee S, Keshavjee S, Waddell TK, Tsao MS, Moghal N. SOX2 and PI3K cooperate to induce and stabilize a squamous-committed stem cell injury-state during lung squamous cell carcinoma pathogenesis. PLOS Biology. 2016 Nov 23;14(11):e1002581.

Anthony Karnezis

1. Ramos P, Karnezis AN, Craig DW, Sekulic A, Russell ML, Hendricks WP, Cornerveaux JJ, Barrett MT, Shumansky K, Yang Y, Shah SP, Prentice LM, Marra MA, Kefer J, Zismann VL, McEachron TA, Sathia B, Prat J, D’Angelo E, Clarke BA, Pressey JG, Farley JH, Anthony SP, Roden RB, Cunliffe HE, Huntsman DG, Trent JM. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat Genet 2014 May;46(5):427-9.

2. Anglesio MS, Bashashati A, Wang YK, Senz J, Ha G, Yang W, Aniba MR, Prentice LM, Farahani H, Li Chang H, Karnezis AN, Marra MA, Yong PJ, Hirst M, Gilks B, Shah SP, Huntsman DG. Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. J Pathol 2015 Jun;236(2):201-9.

3. Mackenzie R, Kommoss S, Winterhoff BJ, Kipp BR, Garcia JJ, Voss J, Halling K, Karnezis AN, Senz J, Yang W, Prigge ES, Reuschenbach M, Doeberitz MV, Gilks BC, Huntsman DG, Bakkum-Gamez J, McAlpine JN, Anglesio MS. Targeted deep sequencing of mucinous ovarian tumors revelas multiple overlapping RAS-pathwaactivating mutations in borderline and cancerous neoplasms. BMC Cancer 2015 May 19;15:415.

4. Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, Yang W, Senz J, Boyd N, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 2015 Jul 14;113(2):299-310.

5. Ramos P, Karnezis AN, Hendricks W, Wang Y, Tembe W, Zismann V, Legendre C, Liang WS, Russell ML, Craig DW, Farley JH, Monk BJ, Anthony SP, Sekulic A, Cunliffe HE, Huntsman DG, Trent JM. Loss of the tumor suppressor SMARCA4 is small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). Orphanet J Rare Diseases 2015;10:32.

6. Karnezis AN, Wang Y, Ramos P, Hendricks WP, Oliva E, D’Angelo E, Prat J, Nucci MR, Nielsen TO, Chow C, Leung S, Kommoss F, Kommoss S, Silva A, Ronnett BM, Rabban JT, Bowtell DD, Weissman BE, Trent JM, Gilks CB, Huntsman DG. Dual loss of SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. J Pathol 2016 Feb;238(3):389-400.

7. Anglesio MS, Wang YK, Maassen M, Horlings HM, Bashashati A, Senz J, MacKenzie R, Grewal DS, Li-Chang H, Karnezis AN, Sheffield BS, McConechy MK, Kommoss F, Taran FA, Staebler A, Shah SP, Wallwiener D, Brucker S, Gilks CB, Kommoss S, Huntsman DG. Synchronous endometrial and ovarian carcinomas: evidence of clonality. J Nat Cancer Inst 2016 Feb 1;108(6).

8. Witkowski L, Goudie C, Ramos P, Boshari T, Brunet JS, Karnezis AN, Longy M, Knost JA, Saloustros E, McCluggage WG, Stewart CJ, Hendricks WP, Cunliffe H, Huntsman DG, Pautier P, Levine DA, Trant JM, Berchuck A, Hasselblatt M, Foulkes WD. The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. Gynecol Oncol 2016 Jun;141(3):454-60.

9. Clarke BA, Witkowski L, Ton Nu TN, Shaw PA, Gilks CB, Huntsman D, Karnezis AN, Sebire N, Lamovec J, Roth LM, Stewart CJ, Hasselblatt M, Foulkes WD, McCluggage WG. Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small-cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics. Histopathology 2016 Apr 21. [Epub ahead of print].

10. Hoang LN, Lee YS, Karnezis AN, Tessier-Cloutier B, Almandani N, Coatham M, Gilks CB, Soslw RA, Stewart CJ, Kobel M, Lee CH. Immunophenotypic features of dedifferentiated endometrial carcinoma – insights from BRG1/INI1-deficient tumours. Histopathology Apr 22 [Epub ahead of print].

11. McPherson A, Roth A, Laks E, Masud T, Bashashati A, Zhang AW, Ha G, Biele J, Yap D, Wan A, Prentice LM, Khattra J, Smith MA, Nielsen CB, Mullaly SC, Kalloger S, Karnezis AN, Shumansky K, Siu C, Rosner J, Chan HL, Ho J, Melnyk N, Senz J, Yang W, Moore R, Mungall AJ, Marra MA, Bouchard-Côté A, Gilks CB, Huntsman DG, McAlpine JN, Aparicio S, Shah SP. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat Genet 2016 Jul;48(7):758-67.

12. Cheng A*, Karnezis AN*, Jordan S, Singh N, McAlpine J, Gilks CB. Comparison of routine morphological assessment and p16 immunostaining for subclassification of vulvar squamous cell carcinoma into HPV-associated and HPV-independent cases. Int J Gynecol Pathol 2016;35:385-393.

13. Karnezis AN*, Huang LN*, Coatham M, Rayn S, Almadani N, Coutier B, Irving J, Meng B, Li X, Chow C, McAlpine J, Kuo K-T, Djordjevic B, Soslow RA, Huntsman DG, Gilks CB, Kobel M, Lee C-H. Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas. Modern Pathol 2016;29:302-314.

14. Coatham M, Li X, Meng B, Karnezis AN, Hoang L, Tessier-Cloutier B, Gilks CB, Huntsman D, Soslow R, Stewart C, Postovit L, Köbel M, Lee CH. Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas. Modern Pathol 2016, Dec;29(12):1586-1593.

15. Wu R, Zhai Y, Karnezis AN, Garcia P, Naseem A, Hu TC, Fearon ER, Cho KR. Impact of oviductal vesus ovarian epithelial cell of origin on ovarian endometrioid carcinoma phenotype in the mouse. J Pathol 2016; Nov;140(3)

16. Hughes CS, McConechy MK, Cochrane DR, Nazeran T, Karnezis AN, Huntsman DG, Morin GB. Quantitative profiling of signale formalin fixed tumour sections: proteomics for translational research. Sci Rep. 2016 Oct 7;6:34949.

17. Karnezis AN, Cho KR, Gilks CB, Pearce CL, Huntsman DG. The disparate origins of ovarian cancers: pathogenesis and prevention strategies. Nat Rev Cancer. 2017 Jan;17(1):65-74. Epub 2016 Nov 25. Review.

18. Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, Boyd N, Pike J, Anglesio M, Kwon JS, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN. Confirmation of ProMisE: A simple, genomic-based clinical classifier for endometrial cancer. Cancer. 2017 Mar 1;123(5):802-813. Epub 2017 Jan 6.

19. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, Dennis J, Pirie A, Riggan MJ, Chornokur G, Earp MA, Lyra PC Jr, Lee JM, Coetzee S, Beesley J, McGuffog L, Soucy P, Dicks E, Lee A, Barrowdale D, Lecarpentier J, Leslie G, Aalfs CM, Aben KKH, Adams M, Adlard J, Andrulis IL, Anton-Culver H, Antonenkova N; AOCS study group, Aravantinos G, Arnold N, Arun BK, Arver B, Azzollini J, Balmaña J, Banerjee SN, Barjhoux L, Barkardottir RB, Bean Y, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Birrer MJ, Bjorge L, Black A, Blankstein K, Blok MJ, Bodelon C, Bogdanova N, Bojesen A, Bonanni B, Borg Å, Bradbury AR, Brenton JD, Brewer C, Brinton L, Broberg P, Brooks-Wilson A, Bruinsma F, Brunet J, Buecher B, Butzow R, Buys SS, Caldes T, Caligo MA, Campbell I, Cannioto R, Carney ME, Cescon T, Chan SB, Chang-Claude J, Chanock S, Chen XQ, Chiew YE, Chiquette J, Chung WK, Claes KBM, Conner T, Cook LS, Cook J, Cramer DW, Cunningham JM, D'Aloisio AA, Daly MB, Damiola F, Damirovna SD, Dansonka-Mieszkowska A, Dao F, Davidson R, DeFazio A, Delnatte C, Doheny KF, Diez O, Ding YC, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Dossus L, Duran M, Dürst M, Dworniczak B, Eccles D, Edwards T, Eeles R, Eilber U, Ejlertsen B, Ekici AB, Ellis S, Elvira M; EMBRACE Study, Eng KH, Engel C, Evans DG, Fasching PA, Ferguson S, Ferrer SF, Flanagan JM, Fogarty ZC, Fortner RT, Fostira F, Foulkes WD, Fountzilas G, Fridley BL, Friebel TM, Friedman E, Frost D, Ganz PA, Garber J, García MJ, Garcia-Barberan V, Gehrig A; GEMO Study Collaborators, Gentry-Maharaj A, Gerdes AM, Giles GG, Glasspool R, Glendon G, Godwin AK, Goldgar DE, Goranova T, Gore M, Greene MH, Gronwald J, Gruber S, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TVO, Harrington PA, Harris HR, Hauke J; HEBON Study, Hein A, Henderson A, Hildebrandt MAT, Hillemanns P, Hodgson S, Høgdall CK, Høgdall E, Hogervorst FBL, Holland H, Hooning MJ, Hosking K, Huang RY, Hulick PJ, Hung J, Hunter DJ, Huntsman DG, Huzarski T, Imyanitov EN, Isaacs C, Iversen ES, Izatt L, Izquierdo A, Jakubowska A, James P, Janavicius R, Jernetz M, Jensen A, Jensen UB, John EM, Johnatty S, Jones ME, Kannisto P, Karlan BY, Karnezis A, Kast K; KConFab Investigators, Kennedy CJ, Khusnutdinova E, Kiemeney LA, Kiiski JI, Kim SW, Kjaer SK, Köbel M, Kopperud RK, Kruse TA, Kupryjanczyk J, Kwong A, Laitman Y, Lambrechts D, Larrañaga N, Larson MC, Lazaro C, Le ND, Le Marchand L, Lee JW, Lele SB, Leminen A, Leroux D, Lester J, Lesueur F, Levine DA, Liang D, Liebrich C, Lilyquist J, Lipworth L, Lissowska J, Lu KH, Lubinński J, Luccarini C, Lundvall L, Mai PL, Mendoza-Fandiño G, Manoukian S, Massuger LFAG, May T, Mazoyer S, McAlpine JN, McGuire V, McLaughlin JR, McNeish I, Meijers-Heijboer H, Meindl A, Menon U, Mensenkamp AR, Merritt MA, Milne RL, Mitchell G, Modugno F, Moes-Sosnowska J, Moffitt M, Montagna M, Moysich KB, Mulligan AM, Musinsky J, Nathanson KL, Nedergaard L, Ness RB, Neuhausen SL, Nevanlinna H, Niederacher D, Nussbaum RL, Odunsi K, Olah E, Olopade OI, Olsson H, Olswold C, O'Malley DM, Ong KR, Onland-Moret NC; OPAL study group, Orr N, Orsulic S, Osorio A, Palli D, Papi L, Park-Simon TW, Paul J, Pearce CL, Pedersen IS, Peeters PHM, Peissel B, Peixoto A, Pejovic T, Pelttari LM, Permuth JB, Peterlongo P, Pezzani L, Pfeiler G, Phillips KA, Piedmonte M, Pike MC, Piskorz AM, Poblete SR, Pocza T, Poole EM, Poppe B, Porteous ME, Prieur F, Prokofyeva D, Pugh E, Pujana MA, Pujol P, Radice P, Rantala J, Rappaport-Fuerhauser C, Rennert G, Rhiem K, Rice P, Richardson A, Robson M, Rodriguez GC, Rodríguez-Antona C, Romm J, Rookus MA, Rossing MA, Rothstein JH, Rudolph A, Runnebaum IB, Salvesen HB, Sandler DP, Schoemaker MJ, Senter L, Setiawan VW, Severi G, Sharma P, Shelford T, Siddiqui N, Side LE, Sieh W, Singer CF, Sobol H, Song H, Southey MC, Spurdle AB, Stadler Z, Steinemann D, Stoppa-Lyonnet D, Sucheston-Campbell LE, Sukiennicki G, Sutphen R, Sutter C, Swerdlow AJ, Szabo CI, Szafron L, Tan YY, Taylor JA, Tea MK, Teixeira MR, Teo SH, Terry KL, Thompson PJ, Thomsen LCV, Thull DL, Tihomirova L, Tinker AV, Tischkowitz M, Tognazzo S, Toland AE, Tone A, Trabert B, Travis RC, Trichopoulou A, Tung N, Tworoger SS, van Altena AM, Van Den Berg D, van der Hout AH, van der Luijt RB, Van Heetvelde M, Van Nieuwenhuysen E, van Rensburg EJ, Vanderstichele A, Varon-Mateeva R, Vega A, Edwards DV, Vergote I, Vierkant RA, Vijai J, Vratimos A, Walker L, Walsh C, Wand D, Wang-Gohrke S, Wappenschmidt B, Webb PM, Weinberg CR, Weitzel JN, Wentzensen N, Whittemore AS, Wijnen JT, Wilkens LR, Wolk A, Woo M, Wu X, Wu AH, Yang H, Yannoukakos D, Ziogas A, Zorn KK, Narod SA, Easton DF, Amos CI, Schildkraut JM, Ramus SJ, Ottini L, Goodman MT, Park SK, Kelemen LE, Risch HA, Thomassen M, Offit K, Simard J, Schmutzler RK, Hazelett D, Monteiro AN, Couch FJ, Berchuck A, Chenevix-Trench G, Goode EL, Sellers TA, Gayther SA, Antoniou AC, Pharoah PDP. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017 May;49(5):680-691. Epub 2017 Mar 27.

20. Wang YK, Bashashati A, Anglesio MS, Cochrane DR, Grewal DS, Ha G, McPherson A, Horlings HM, Senz J, Prentice LM, Karnezis AN, Lai D, Aniba MR, Zhang AW, Shumansky K, Siu C, Wan A, McConechy MK, Li-Chang H, Tone A, Provencher D, de Ladurantaye M, Fleury H, Okamoto A, Yanagida S, Yanaihara N, Saito M, Mungall AJ, Moore R, Marra MA, Gilks CB, Mes-Masson AM, McAlpine JN, Aparicio S, Huntsman DG, Shah SP. Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. Nat Genet. 2017 Jun;49(6):856-865. Epub 2017 Apr 24.

21. Wang Y, Chen SY, Karnezis AN, Colborne S, Santos ND, Lang JD, Hendricks WP, Orlando KA, Yap D, Kommoss F, Bally MB, Morin GB, Trent JM, Weissman BE, Huntsman DG. The histone methyltransferase EZH2 is therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type. J Pathol. 2017 Jul;242(3):371-383. Epub 2017 Jun 2.

22. Cochrane DR, Tessier-Cloutier B, Lawrence KM, Nazeran T, Karnezis AN, Salamanca C, Cheng AS, McAlpine JN, Hoang LN, Gilks CB, Huntsman DG. Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin? J Pathol. 2017 Sep;243(1):26-36. Epub 2017 Aug 7.

23. Karnezis AN, Leung S, Magrill J, McConechy MK, Yang W, Chow C, Kobel M, Lee CH, Huntsman DG, Talhouk A, Kommoss F, Gilks CB, McAlpine JN. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. J Pathol Clin Res. 2017 Oct 14;3(4):279-293.

24. Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, Britton H, Kommoss F, Grevenkamp F, Karnezis A, Yang W, Lum A, Krämer B, Taran F, Staebler A, Lax S, Brucker SY, Huntsman DG, Gilks CB, McAlpine JN, Talhouk A. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018 May 1;29(5):1180-1188.

25. Lang JD, Hendricks WPD, Orlando KA, Yin H, Kiefer J, Ramos P, Sharma R, Pirrotte P, Raupach EA, Sereduk C, Tang N, Liang WS, Washington M, Facista SJ, Zismann VL, Cousins EM, Major MB, Wang Y, Karnezis AN, Sekulic A, Hass R, Vanderhyden BC, Nair P, Weissman BE, Huntsman DG, Trent JM. Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) through multikinase inhibition. Clin Cancer Res. 2018 Apr 15;24(8):1932-1943. Epub 2018 Feb 9.

26. Wang Y, Karnezis AN, Magrill J, Tessier-Cloutier B, Lum A, Senz J, Gilks CB, McCluggage WG, Huntsman DG, Kommoss F. DICER1 hot-spot mutations in ovarian gyndroblastoma. Histopathology. 2018 Aug;73(2):306-313. Epub 2018 Jun 5.

27. Kuwahara Y, Kennedy LM, Karnezis AN, Mora-Blanco EL, Rogers AB, Fletcher CD, Huntsman DG, Roberts CWM, Rathmell WK, Weissman BE. High frequency of ovarian cyst development in Vhl2B/+;Snf5+/- Mice. Am J Pathol. 2018 Jul;188(7):1510-1516. Epub 2018 Apr 22.

28. Zhang AW, McPherson A, Milne K, Kroeger DR, Hamilton PT, Miranda A, Funnell T, Little N, de Souza CPE, Laan S, LeDoux S, Cochrane DR, Lim JLP, Yang W, Roth A, Smith MA, Ho J, Tse K, Zeng T, Shlafman I, Mayo MR, Moore R, Failmezger H, Heindl A, Wang YK, Bashashati A, Grewal DS, Brown SD, Lai D, Wan ANC, Nielsen CB, Huebner C, Tessier-Cloutier B, Anglesio MS, Bouchard-Côté A, Yuan Y, Wasserman WW, Gilks CB, Karnezis AN, Aparicio S, McAlpine JN, Huntsman DG, Holt RA, Nelson BH, Shah SP. Interfaces of malignant and immunologic clonal dynamics in ovarian cancer. Cell. 2018 Jun 14;173(7):1755-1769.e22. Epub 2018 May 10.

29. Kommoss FK, Karnezis AN, Kommoss F, Talhouk A, Taran FA, Staebler A, Gilks CB, Huntsman DG, Krämer B, Brucker SY, McAlpine JN, Kommoss S. L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. Br J Cancer. 2018 Jul 27. [Epub ahead of print]

30. Magrill J, Karnezis AN, Tessier-Cloutier B, Talhouk A, Kommoss S, Cochrane D, Chow C, Cheng A, Soslow R, Hauptmann S, du Bois A, Pfisterer J, Gilks CB, Huntsman DG, Kommoss F. Tubo-ovarian transitional cell carcinoma and high-grade serous carcinoma show subtly different immunohistochemistry profiles. Int J Gynecol Pathol. 2018 Jul 27. [Epub ahead of print]

Hirotsugu Notsuda

1. Notsuda H, Bradbury PA, Tsao MS. HER2 transmembrane domain mutations: rare new target for non-small cell lung cancer therapy. J Thorac Oncol 2017 Mar;12(3):422-424.

Basile Tessier-Cloutier

1. Karnezis A, Wang Y, Keul J, Tessier-Cloutier B, Magrill J, Kommoss S, Senz J, Yang W, Proctor L, Schmidt D, Gilks CB, Huntsman D. Kommoss F. DICER1 and FOXL2 mutation status correlates with clinicopathologic features in ovarian Sertoli-Leydig cell tumours. Modern Pathology [Accepted]

2. Anglesio MS, Papadopoulos N, Ayhan A, Nazeran TM, Noë M, Horlings HM, Lum A, Jones S, Senz J, Seckin T, Ho J, Wu RC, Lac V, Ogawa H, Tessier-Cloutier B, Alhassan R, Wang A, Wang Y, Cohen JD, Wong F, Hasanovic A, Orr N, Zhang M, Popoli M, McMahon W, Wood LD, Mattox A, Allaire C, Segars J, Williams C, Tomasetti C, Boyd N, Kinzler KW, Gilks CB, Diaz L, Wang TL, Vogelstein B, Yong PJ, Huntsman DG, Shih IM. Cancer-associated mutations in endometriosis without cancer. N Engl J Med. 2017 May 11;376(19):1835-1848. PMID: 28489996

3. Cochrane DR, Tessier-Cloutier B, Lawrence KM, Nazeran T, Karnezis AN, Salamanca C, Cheng AS, McAlpine JN, Hoang LN, Gilks CB, Huntsman DG. Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin? J Pathol. 2017 Sep;243(1):26-36. PMID: 28678427

4. Waters AM, Ozkan-Dagliyan I, Vaseva AV, Fer N, Strathern LA, Hobbs GA, Tessier-Cloutier B, Gillette WK, Bagni R, Whiteley GR, Hartley JL, McCormick F, Cox AD, Houghton PJ, Huntsman DG, Philips MR, Der CJ. Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies.  Sci Signal. 2017 Sep 26;10(498).

5. Xia Z, Cochrane DR, Anglesio MS, Wang YK, Nazeran T, Tessier-Cloutier B, McConechy MK, Senz J, Lum A, Bashashati A, Shah SP, Huntsman DG. LINE-1 retrotransposon-mediated DNA transductions in endometriosis associated ovarian cancers. Gynecol Oncol. 2017 Dec;147(3):642-647. PMID: 29032825

6. Wang Y, Karnezis AN, Magrill J, Tessier-Cloutier B, Lum A, Senz J, Gilks CB, McCluggage WG, Huntsman DG, Kommoss F. DICER1 hotspot mutations in ovarian gynandroblastoma. Histopathology. 2018 Apr 16.  

7. Prentice LM, Miller RR, Knaggs J, Mazloomian A, Aguirre Hernandez R, Franchini P, Parsa K, Tessier-Cloutier B, Lapuk A, Huntsman D, Schaeffer DF, Sheffield BS. Formalin fixation increases deamination mutation signature but should not lead to false positive mutations in clinical practice.  PLoS One. 2018 Apr 26;13(4).

8. Zhang AW, McPherson A, Milne K, Kroeger DR, Hamilton PT, Miranda A, Funnell T, Little N, Camila de Souza PE, Laan S, LeDoux S, Cochrane DR, Lim JLP, Yang W, Roth A, Smith MA, Ho J, Tse K, Zeng T, Shlafman I, Mayo MR, Moore R, Heindl FHA, Wang YK, Bashashati A, Grewal DS, Brown SD, Lai D, Wan ANC, Nielsen CB, Huebner C, Tessier-Cloutier B, Anglesio MS, Bouchard-Côté A, Yuan Y, Wasserman WW, Gilks CB, Karnezis AN, Aparicio S, McAlpine JN, Huntsman DG, Holt RA, Nelson BH, Shah SP. Interfaces of malignant and immunologic clonal dynamics in ovarian cancer. Cell. 2018 May 7.

Last Updated ( Feb 27, 2015)